Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
chrysin
chrysin interacts weakly with the I-kappa-B kinase epsilon binding site and inhibits the enzyme at doses higher than 0.06 mM
(1R,4R)-4-(2-amino-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-cyclohexanol
-
(4-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)phenyl)acetic acid
-
IC50 for the IKKbeta is 0.0022 mM
(E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol
the compound directly binds to the ATP binding site of the enzyme with a strong binding affinity
-
(E)-4-[3-(5-(adamant-1-yl)-2-(but-1-oxy)-4-(2-methoxyethoxymethoxy)-phenyl)-3-oxoprop-1-en-1-yl]benzoic acid
shows highest inhibition of IKKbeta and highest induction of apoptosis in Jurkat cells
(E)-4-[3-(5-(adamant-1-yl)-2-(hexyl-1-oxy)-4-(2-methoxyethoxymethoxy)phenyl)-3-oxoprop-1-en-1-yl]benzoic acid
exhibits improved anti-IKKbeta and growth inhibitory activities and has lost its RAR-dependent transactivation function
(E)-4-[3-(5-(adamant-1-yl)-2-ethoxy-4-(2-methoxyethoxymethoxy)phenyl)-3-oxoprop-1-en-1-yl]benzoic acid
-
(E)-4-[3-(5-(adamant-1-yl)-4-(2-methoxyethoxymethoxy)-2-(pentyl-1-oxy)phenyl)-3-oxoprop-1-en-1-yl]benzoic acid
-
(E)-4-[3-(5-(adamant-1-yl)-4-(2-methoxyethoxymethoxy)-2-(prop-2-en-1-oxy)phenyl)-3-oxoprop-1-en-1-yl]benzoic acid
-
(E)-4-[3-(5-(adamant-1-yl)-4-(2-methoxyethoxymethoxy)-2-(prop-2-yn-1-oxy)phenyl)-3-oxoprop-1-en-1-yl]benzoic acid
shows highest inhibition of IKKbeta and highest induction of apoptosis in Jurkat cells
(E)-4-[3-(5-(adamant-1-yl)-4-(2-methoxyethoxymethoxy)-2-phenylmethoxy-phenyl)-3-oxoprop-1-en-1-yl]benzoic acid
exhibits improved anti-IKKbeta and growth inhibitory activities and has lost its RAR-dependent transactivation function
(E)-4-[3-(5-adamant-1-yl-4-(2-methoxyethoxymethoxy)-2-(prop-1-oxy)-phenyl)-3-oxoprop-1-en-1-yl]benzoic acid
-
(R)-2-amino-4-(2-(hydroximethyl)pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
(R)-2-amino-4-(3-hydroxypyrrolidin-1-yl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
-
(S)-2-amino-4-(2-(hydroximethyl)pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
1-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-sulfonamide
-
1-(4-chlorophenyl)-4-ureido-1H-pyrazole-3-carboxamide
i.e. SC-108
1-(6-chloro-9H-beta-carbolin-8-yl)-3-methylurea
-
inhibits IKK with IC50 of 0.02 mM
1-(benzo[d][1,3]dioxol-5-yl)-8-(3-chloroisonicotinamido)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
i.e. PHA-379
1-(benzo[d][1,3]dioxol-5-yl)-8-(5-chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)-4,5-dihydro-1H-benzo-[g]indazole-3-carboxamide
i.e. PHA-250
1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol
NCI0288748, 65% inhibition at 0.1 mM
1-[3-[7-(piperidin-4-yloxy)isoquinolin-6-yl]phenyl]methanamine
-
-
1-[4-(1-hydroxynaphthalen-2-yl)-6-imino-3-methyl-6,7-dihydropyrazolo[3,4-d][1,3]thiazin-1(4H)-yl]-2-phenylethan-1-one
NCI0657381, 76% inhibition at 0.1 mM
1-[4-[7-(piperidin-4-yloxy)isoquinolin-6-yl]phenyl]methanamine
-
-
1-[4-[7-(piperidin-4-yloxy)isoquinolin-6-yl]phenyl]methanesulfonamide
-
-
15d-prostaglandin J2
-
strongly inhibits IKK
17-acetoxyjolkinolide B
17-AJB is isolated from a traditional Chinese medicinal herb Euphorbia fischeriana Steud. 17-AJB interacts with IKK directly and keeps IKK in its phosphorylated form irreversibly, inactivating its kinase activity, leading to its failure to activate NF-kappaB. The effect of 17-AJB on IKK is specific. It has no effect on other kinases such as p38, p44/42, and JNK. 17-AJB induces apoptosis in tumor cells
2,4-diamino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-benzenesulfonamide
-
2-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide
-
2-(4-fluorophenyl)-8-methyl-N-[2-(piperidin-1-yl)ethyl]-8H-imidazo[4,5-d][1,3]thiazolo[5,4-b]pyridin-5-amine
-
-
2-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)benzoic acid
-
IC50 for the IKK complex is above 0.1 mM
2-amino-4-((1R,2S,3R,4S)-2,3,4-trihydroxycyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-((1R,4R)-4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-((1R,4R)-4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide
-
2-amino-4-((1RS,2SR,3RS)-2,3-dihydroxycyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-((cyclopropylmethyl)amino)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
-
2-amino-4-(2-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]- pyrimidine-5-carbonitrile
-
2-amino-4-(2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-(2-hydroxyethylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-(2-hydroxyphenyl)-77H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-(2-morpholinoethylamino)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
-
2-amino-4-(3-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
-
2-amino-4-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-(3-hydroxypropylamino)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
-
2-amino-4-(3-hydroyphenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-(4-(2-hydroxyethyl)piperazin-1-yl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
-
2-amino-4-(4-(methylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
-
2-amino-4-(4-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-(4-hydroxymethyl)phenyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
-
2-amino-4-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimdine-5-carbonitrile
-
2-amino-4-(4-methylpiperazin-1-yl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
-
2-amino-4-(4-phenylpiperazin-1-yl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
-
2-amino-4-(benzylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-(cyclohexyl(2-hydroxyethyl)amino)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
-
2-amino-4-(cyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-(cyclohexylmethylamino)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
-
2-amino-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-(piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-morpholino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-4-phenyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
-
2-amino-6-(2-hydroxy-6-isobutoxyphenyl)-4-(piperidin-3-yl)nicotinonitrile
i.e. PHA-535E
2-benzamido-pyrimidines
-
diverse derivatives, synthesis and inhibitory potential determination, overview
2-hydroxy-N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]acetamide
-
2-methanesulfonyl-4-methyl-7-methylamino-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
-
-
2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7yl)pyridin-2-yl)methyl)acetamide
-
BMS-066, inhibitor of IKKbeta
2-[[bis(2-hydroxyethyl)amino]methyl]-4-(2-methylbutan-2-yl)phenol
NCI0079692, 59% inhibition at 0.1 mM
3-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimdin-4-yl)benzamide
-
3-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-benzenesulfonamide
-
3-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)benzoic acid
-
IC50 for the IKKbeta is 0.001 mM
3-amino-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-4-(1-benzofuran-2-yl)-6-methylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-4-(2-methoxyethoxy)thieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-4-(4-chlorophenyl)-6-methylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-4-(4-hydroxyphenyl)-6-methylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-4-ethoxythieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-4-furan-2-yl-6-methylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-4-methoxythieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-4-methyl-6-morpholin-4-ylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-4-methyl-6-piperazin-1-ylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-4-methyl-6-piperidin-1-ylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-4-propoxythieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(1,4-diazepan-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(2-aminoethoxy)-4-methylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(2-hydroxyethoxy)-4-methylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(3-aminoazepan-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(3-aminopropoxy)-4-methylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(3-hydroxypiperidin-1-yl)-4-methylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(3-hydroxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(3-hydroxypropoxy)-4-methylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(3-oxo-1,4-diazepan-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(3-oxopiperazin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(4-aminopiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(4-carbamoylpiperazin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(4-carbamoylpiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(4-hydroxy-3,3-dimethylpiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(4-hydroxypiperidin-1-yl)-4-methylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(4-hydroxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(4-methoxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-(4-methylpiperazin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-methyl-4-(2-methylpropyl)thieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-methyl-4-(4-methylphenyl)thieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-methyl-4-phenylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-methyl-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-methyl-4-pyridin-2-ylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-methyl-4-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-methyl-4-[4-(methylsulfonyl)phenyl]thieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-methylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-piperazin-1-yl-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-[(2-hydroxyethyl)amino]-4-methylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-[(3R)-3-aminopyrrolidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-[(3R)-3-hydroxypyrrolidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-[(3S)-3-aminopyrrolidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-[(3S)-3-hydroxypyrrolidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-[4-(dimethylamino)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-[4-(methylamino)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-amino-6-[4-[(methylsulfonyl)amino]piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide
-
-
3-methoxy-N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]propanamide
-
3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzonitrile
-
3-[7-(benzyloxy)isoquinolin-6-yl]benzenesulfonamide
-
-
3-[7-(piperidin-4-yloxy)isoquinolin-6-yl]benzenesulfonamide
-
-
4'-amino-4-chloro-4''-sulfamoyl-1,1':3',1''-terphenyl-5'-carboxamide
-
-
4-((2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-benzenesulfonamide
-
4-((2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-benzoic acid
-
4-(1-benzothiophen-2-yl)-N-[3-chloro-4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
-
IC50 for the IKK complex is 250 nM
4-(1-benzothiophen-2-yl)-N-[3-methoxy-4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
-
IC50 for the IKK complex is 150 nM
4-(1-benzothiophen-2-yl)-N-[4-(pyrrolidin-1-ylcarbonyl)phenyl]pyrimidin-2-amine
-
IC50 for the IKK complex is 0.0085 mM, cellular profile
4-(1-benzothiophen-2-yl)-N-[4-([4-(dimethyl-amino)piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
-
IC50 for the IKK complex is 80 nM, cellular profile
4-(1-benzothiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
-
IC50 for the IKK complex is 70 nM, cellular profile
4-(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline
-
BMS-345541, inhibitor of IKKbeta
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimdin-4-yl)benzamide
-
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-benzenesulfonamide
-
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(p-tolyl)-benzenesulfonamide
-
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methylbenzenesulfonamide
-
4-(2-amino-7H-pyrrol[2,3-d]pyrimidin-4-yl)benzenesulfonamide
-
4-(5-(3-acetamino-3-methylbutyl)thiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
-
IC50 for the IKK complex is 800 nM
4-(5-(3-amino-3-ethylpentyl)thiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
-
IC50 for the IKK complex is 30 nM
4-(5-(3-amino-3-methyl-but-1-ynyl)thiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
-
IC50 for the IKK complex is 200 nM
4-(5-(3-amino-3-methyl-butyl)thiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
-
IC50 for the IKK complex is 40 nM
4-(5-(3-hydroxy-3-methylbutyl)thiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amin
-
IC50 for the IKK complex is 50 nM, cellular profile
4-(5-(3-methoxypropyl)thiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
-
IC50 for the IKK complex is 100 nM, cellular profile
4-(5-(4-hydroxybutyl)thiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
-
IC50 for the IKK complex is 40 nM, cellular profile
4-(5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzenesulfonamide
-
4-(7-[[1-(ethylsulfonyl)piperidin-4-yl]oxy]isoquinolin-6-yl)benzenesulfonamide
-
-
4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzenesulfonamide
-
4-(piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
-
4-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)benzoic acid
-
IC50 for the IKK complex is 0.018 mM, cellular profile
4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine
-
4-methyl-7-methylamino-2-(azepan-1-yl)-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
-
-
4-methyl-7-methylamino-2-(methylthio)-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
-
-
4-methyl-7-methylamino-2-benzylamino-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
-
-
4-methyl-7-methylamino-2-cyclopentylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
-
-
4-methyl-7-methylamino-2-diethylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
-
-
4-methyl-7-methylamino-2-ethylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
-
-
4-methyl-7-methylamino-2-hydroxyethylamino-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
-
-
4-methyl-7-methylamino-2-methylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
-
-
4-methyl-7-methylamino-2-methylamino-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
-
-
4-methyl-7-methylamino-2-piperidine-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
-
-
4-methyl-7-methylamino-2-thienylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
-
-
4-methyl-7-methylamino-2-[1,2,3,6-tetrahydropyridine]-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
-
-
4-[6-[(2-hydroxyethyl)amino]-7-methyl-7,8-dihydro-2H,6H-[1,3]dioxolo[4,5-g][1]benzopyran-8-yl]-2,6-dimethoxyphenol
NCI0671177, 68% inhibition at 0.1 mM
4-[7-(benzyloxy)isoquinolin-6-yl]benzenesulfonamide
-
-
4-[7-(piperidin-3-ylmethoxy)isoquinolin-6-yl]benzenesulfonamide
-
-
4-[7-(piperidin-3-yloxy)isoquinolin-6-yl]benzenesulfonamide
-
-
4-[7-(piperidin-4-ylmethoxy)isoquinolin-6-yl]benzenesulfonamide
-
-
4-[7-(piperidin-4-yloxy)isoquinolin-6-yl]benzenesulfonamide
-
-
4-[7-[(1-acetylpiperidin-4-yl)oxy]isoquinolin-6-yl]benzenesulfonamide
-
-
4-[N'-(4,6-dimethylpyrimidin-2-yl)carbamimidamido]-N-(phenylcarbamoyl)benzene-1-sulfonamide
NCI0107328, 94% inhibition at 0.1 mM
5,6-dibromo-beta-carboline
-
inhibits IKK with IC50 of 600 nM
5-((3-fluorophenyl)ethynyl)-2-ureidothiophene-3-carboxamide
i.e. PHA-966
5-(4-fluorophenyl)-2-ureidothiophene-3-carboxamide
i.e. SC-440
5-amino-2,30-bithiophene-4-carboxamide
i.e. SC-514
5-Aminosalicylate
-
weak inhibition of IKK-2
5-bromo-6-chloro-beta-carboline
-
inhibits IKK with IC50 of 600 nM
5-bromo-6-cyano-beta-carboline
-
inhibits IKK with IC50 of 0.0011 mM
5-bromo-6-fluoro-beta-carboline
-
inhibits IKK with IC50 of 0.002 mM
5-bromo-6-methoxy-beta-carboline
-
nonspecific inhibitor of IKK, inhibits IKK with IC50 of 0.004 mM
5-bromo-6-trifluoromethyl-beta-carboline
-
inhibits IKK with IC50 of 0.0011 mM
5-bromo-beta-carboline
-
inhibits IKK with IC50 of 0.015 mM
6,6-dimethyl-1-[3-[3-(3-nitrophenoxy)propoxy]phenyl]-1,3,5-triazinane-2,4-diimine
NCI0111727, 75% inhibition at 0.1 mM
6,8-dichloro-7-(cyclohexylmethoxy)-9H-beta-carboline
-
inhibits IKK with IC50 of 0.003 mM
6,8-dichloro-7-ethoxy-9H-beta-carboline
-
inhibits IKK with IC50 of 140 nM
6,8-dichloro-7-methoxy-9H-beta-carboline
-
inhibits IKK with IC50 of 170 nM
6,8-dichloro-9H-beta-carbolin-7-yl morpholine-4-carboxylate
-
inhibits IKK with IC50 of 0.0032 mM
6,8-dichloro-beta-carboline
-
inhibits IKK with IC50 of 200 nM
6-bromo-7-(piperidin-4-yloxy)isoquinoline
-
-
6-bromo-7-[[1-(ethylsulfonyl)piperidin-4-yl]oxy]isoquinoline
-
-
6-phenyl-7-(piperidin-3-ylmethoxy)isoquinoline
-
-
6-phenyl-7-(piperidin-3-yloxy)isoquinoline
-
-
6-phenyl-7-(piperidin-4-ylmethoxy)isoquinoline
-
-
6-phenyl-7-(piperidin-4-yloxy)isoquinoline
-
-
6-phenyl-7-(pyridin-3-ylmethoxy)isoquinoline
-
-
6-phenyl-7-(pyridin-4-ylmethoxy)isoquinoline
-
-
7-(2-fluorophenyl)-N,1-dimethyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
-
7-(3-fluorophenyl)-N,1-dimethyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
-
7-(3-methoxyphenyl)-N,1-dimethyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
-
7-(3-[[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino]propyl)-1,3-dimethyl-8-(morpholin-4-yl)-3,7-dihydro-1H-purine-2,6-dione
NCI0293897, 55% inhibition at 0.1 mM
7-(4-fluorophenyl)-N,1-dimethyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
-
7-(OCH2CH(CH2CH2))-6,8-dichloro-beta-carboline
-
inhibits IKK with IC50 of 80 nM
7-(piperidin-4-yloxy)isoquinoline
-
-
7-hydroxy-6,8-dichloro-beta-carboline
-
inhibits IKK with IC50 of 0.011 mM
7-[(1-acetylpiperidin-4-yl)oxy]-6-bromoisoquinoline
-
-
7-[(1-acetylpiperidin-4-yl)oxy]-6-phenylisoquinoline
-
-
7-[3-(aminomethyl)phenyl]-N,1-dimethyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
-
7-[[1-(ethylsulfonyl)piperidin-4-yl]methoxy]-6-phenylisoquinoline
-
-
7-[[1-(ethylsulfonyl)piperidin-4-yl]oxy]-6-phenylisoquinoline
-
-
8-(5-chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
PHA-408, ATP-competitive, selective IKK-2 inhibitor
8-amino-6-chloro-beta-carboline
-
inhibits IKK with IC50 of 0.0013 mM
8-dimethylamino-6-chloro-beta-carboline
-
inhibits IKK with IC50 of 0.0018 mM
8-methyl-2-(4-fluorophenyl)-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-amine
-
-
8-methylamino-6-chloro-beta-carboline
-
inhibits IKK with IC50 of 0.0018 mM
8-nitro-6-chloro-beta-carboline
-
inhibits IKK with IC50 of 0.004 mM
acetamide,N-[2-[[2-(4-fluorophenyl)-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-yl]amino]ethyl]
-
-
Acetylsalicylate
-
weak inhibition of IKK-2
Acetylsalicylic acid
-
nonspecific for IKK, anti-inflammatory
antirheumatic gold compound
-
inhibition of IKKbeta
-
arsenic trioxide
-
nonspecific for IKK, acts on a cystein ersidue in the activation loop
arsenite
-
inhibition of IKKbeta
Berberine
an isoquinoline alkaloid derived from a plant used traditionally in Chinese and Ayurvedic medicine inhibits IKK activity. Addition of DTT to the kinase reaction reverses the berberine-mediated inhibition of IKK activity
BMS-345541
-
specific for IKK-2, binds at an allosteric site
COMPOUND A
leads to a significant reduction of Panc-1 cell and MiaPaCa-2 cell growth
curcumin
-
weak inhibition of IKK-2
cyclopentenone prostaglandins
cyclopentenone prostanoids
-
inhibition of IKK and thus inhibition of NFkappaB-mediated HSV-1-induced HIV-1 replication
cyclopentone prostaglandines
-
inhibition of IKK-2
ethanol,N-[2-[[2-(4-fluorophenyl)-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-yl]amino]ethyl]
-
-
evodiamine
-
alkaloid extracted from Evodia rutaecarpa fruits exhibiting antiproliferative, antimetastatic, and apoptotic activities, inhibits IKKalpha activity, suppresses IKKalpha phosphorylation and degradation, and specifically blocks NF-kappaB activation by IKK and other agents, translocation, and activity, overview
IMD-0354
-
specific IKKbeta inhibition
LY294002
phosphorylation of IKKalphaT23 is inhibited both by LY294002 and wortmannin, but phosphorylation of Ser176/Ser180 is not
lysyl-N-(4-methoxynaphthalen-2-yl)alaninamide
NCI0339925, 93% inhibition at 0.1 mM
methyl (6-chloro-9H-beta-carbolin-8-yl)carbamate
-
inhibits IKK with IC50 of 700 nM
methyl 1-(3-amino-2-carbamoyl-4-propylthieno[2,3-b]pyridin-6-yl)piperidine-4-carboxylate
-
-
MX781
0.02 mM inhibit IKKbeta by 65% in the presence of an ATP concentration corresponding to its Km value
N,1-dimethyl-7-phenyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
-
N,1-dimethyl-7-phenyl-1H-pyrazolo[5,1-b]purin-4-amine
-
-
N,3,8-trimethyl-2-phenyl-3,8-dihydrodiimidazo[4,5-b:4',5'-d]pyridin-5-amine
-
N,8-dimethyl-2-phenyl-8H-imidazo[4,5-d][1,3]oxazolo[5,4-b]pyridin-5-amine
-
N,8-dimethyl-2-phenyl-8H-imidazo[4,5-d][1,3]thiazolo[5,4-b]pyridin-5-amine
-
N,N-dimethyl-3-[(4-[[(6-phenylisoquinolin-7-yl)oxy]methyl]piperidin-1-yl)sulfonyl]propan-1-amine
-
-
N-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine
-
-
N-(2-aminoethyl)-4-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)benzamide
-
IC50 for the IKK complex is 0.0044 mM
N-(2-dimethyl-aminoethyl)-4-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)benzamide
-
IC50 for the IKK complex is 300 nM, cellular profile
N-(2-pyrrolidin-1-yl-ethyl)-4-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)benzamide
-
IC50 for the IKK complex is 500 nM
N-(3,5-bis-trifluoromethylphenyl)-5-chloro-2-hydroxybenzamide
-
-
N-(3-methyl-butyl)-4-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)benzamide
-
IC50 for the IKKbeta is above 0.1 mM
N-(3-[2-imino-6-methyl-3-[(3-nitrophenyl)methyl]-4-oxo-1,2,3,4-tetrahydropyrimidin-5-yl]propyl)-4-methylbenzene-1-sulfonamide
NCI0211135, complete inhibition at 0.1 mM
N-(4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)-methanesulfonamide
-
N-(6-chloro-9H-beta-carbolin-8-yl)-2-(pyridin-2-yl)acetamide
-
inhibits IKK with IC50 of 0.003 mM
N-(6-chloro-9H-beta-carbolin-8-yl)-2-methoxybenzamide
-
inhibits IKK with IC50 of 0.02 mM
N-(6-chloro-9H-beta-carbolin-8-yl)-3-methoxybenzamide
-
inhibits IKK with IC50 of 600 nM
N-(6-chloro-9H-beta-carbolin-8-yl)-4-hydroxybutanamide
-
inhibits IKK with IC50 of 0.02 mM
N-(6-chloro-9H-beta-carbolin-8-yl)-4-methoxybenzamide
-
inhibits IKK with IC50 of 0.0013 mM
N-(6-chloro-9H-beta-carbolin-8-yl)acetamide
-
inhibits IKK with IC50 of 600 nM
N-(6-chloro-9H-beta-carbolin-8-yl)benzamide
-
inhibits IKK with IC50 of 700 nM
N-(6-chloro-9H-beta-carbolin-8-yl)benzenesulfonamide
-
inhibits IKK with IC50 of 0.02 mM
N-(6-chloro-9H-beta-carbolin-8-yl)methanesulfonamide
-
inhibits IKK with IC50 of 0.0083 mM
N-(6-chloro-9H-beta-carbolin-8-yl)morpholine-4-carboxamide
-
inhibits IKK with IC50 of 0.02 mM
N-(6-chloro-9H-beta-carbolin-8-yl)pyridine-2-carboxamide
-
inhibits IKK with IC50 of 0.001 mM
N-(6-chloro-9H-beta-carbolin-8-yl)pyridine-4-carboxamide
-
inhibits IKK with IC50 of 300 nM
N-(8-methyl-2-phenylimidazo[1,2-a]thieno[3,2-e]pyrazin-5-yl)ethane-1,2-diamine
-
-
N-acetylcysteine
inhibits phosphorylation of IkappaBalpha
N-benzyl-6-chloro-9H-beta-carbolin-8-amine
-
inhibits IKK with IC50 of 0.02 mM
N-ethyl-2-(4-fluorophenyl)-N-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-amine
-
-
N-methyl-2-(4-fluorophenyl)-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-amine
-
-
N-tosyl-L-phenylalanine chloromethyl ketone
-
-
N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]-1,2,3-thiadiazole-4-carboxamide
-
N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]acetamide
-
N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]butanediamide
-
N-[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorobenzyl]acetamide
-
-
N-[[2-fluoro-5-[8-methyl-5-methylamino-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]acetamide
-
-
N-[[2-fluoro-5-[8-methyl-5-methylamino-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]methanesulfonamide
-
-
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]-1,2,3-thiadiazole-5-amide
-
-
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]acetamide
-
-
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]isoxazole-5-amide
-
-
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]methanesulfonamide
-
-
N1-(1,8-dimethylimidazo-[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine
i.e. PHA-068E
N2,N2-dimethyl-N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]glycinamide
-
N2-(2-chlorophenyl)-N-[6-[(2-chlorophenyl)sulfamoyl]-2-methyl-4-oxoquinazolin-3(4H)-yl]glycinamide
NCI0687760, 89% inhibition at 0.1 mM
N4-cyclohexyl-5-(trifluoromethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
N4-cyclohexyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
nimbolide
-
nimbolide inhibits TNF-alpha-induced p65 nuclear translocation and phosphorylation. Nimbolide binds to and inhibits IKK activation. It suppresses NF-betaB activation by inhibition of IkappaBbeta kinase, wild-type not IKKbeta mutant C179A, leading to suppression of IkappaBalpha phosphorylation and degradation, nuclear translocation, DNA binding, and gene transcription
PHA-408
a selective IKK-2 inhibitor, shows time-dependent binding to the enzyme
prostaglandin 2alpha
-
inhibits IKK
prostaglandin A1
-
strongly inhibits IKK
Prostaglandin A2
-
strongly inhibits IKK
prostaglandin E1
-
inhibits IKK
prostaglandin E2
-
inhibits IKK
protein HSCARG
-
or NMRAL1, NmrA-like family domain-containing protein 1, inhibits the phosphorylation of IKKbeta
-
PS-1145
-
i.e. 8-(NHC(O)-3'-pyridyl)-6-chloro-beta-carboline, inhibits IKK with IC50 of 100 nM in vitro, blocks phosphorylation of IkappaBalpha and subsequent activation of NFkappaB in vivo
PS1145
-
inhibits IKK, blocks TNFalpha activation by IKK in vivo
Rapamycin
suppresses IKK activity potentailly through dissociation of raptor from the mTOR complex
ring finger protein 8
-
upon TNFalpha stimulation, ring finger protein 8 binds to the catalytic subunits of the enzyme complex, resulting in inhibition of IkappaB kinase alpha/beta phosphorylation and subsequent nuclear factor-kappaB activation
-
RNAi
-
specific IKKbeta inhibition
-
S1627
-
specific for the IKK complex, inhibits purified IKK in vitro with IC50 of 0.02 mM, inhibits IKK and NFkappaB nuclear translocation in vivo in umbilical vein endothelial cells and in rats, overview
-
salicylate
-
weak inhibition of IKK-2
sulindac sulfide
-
nonspecific for IKK, anti-inflammatory
trans-resveratrol
-
nonspecific for IKK, anti-inflammatory
vaccina virus virulence factor B14
-
interacts and inhibits IKKcomplex. Interaction between vaccina virus virulence factor B14 and IKK complex requires IKKbeta but not IKKalpha
-
vaccinia virus virulence factor B14
-
interacts and inhibits IKKcomplex. Interaction between B14 and IKK complex requires IKKbeta but not IKKalpha
-
Wortmannin
phosphorylation of IKKalphaT23 is inhibited both by LY294002 and wortmannin, but phosphorylation of Ser176/Ser180 is not
YopJ
-
effector protein YopJ from Yersinia pestis inhibits MAPK kinase and IKK activation by acetylating the conserved serine and threonine residues in the activation loop of the kinase. Furthermore, YopJ inhibits Tax-mediated IkappaB phosphorylation
-
AS602868
-
-
AS602868
-
IKKbeta inhibitor
AS602868
-
inhibitor of IKK-beta
cyclopentenone prostaglandins
-
nonspecific for IKK, anti-inflammatory
cyclopentenone prostaglandins
-
inhibition of IKKbeta
sulfasalazine
-
nonspecific for IKK, anti-inflammatory
sulfasalazine
-
weak inhibition of IKK-2
additional information
-
CREB-binding protein-bound NEMO/IKKgamma inhibits IKKalpha and p65 transcriptional activities
-
additional information
-
evodiamine analogue rutaecarpine does not inhibit IKK and NF-kappaB activation
-
additional information
-
prolyl hydroxylase-1 negatively regulates IKKbeta, hydroxylation represses IKKbeta activity by altering protein expression or by preventing its activation through phosphorylation on S177/S181
-
additional information
-
simvastatin inhibits the TNFalpha-induced activation of IkappaB kinase and activation of NF-kappaB in vitro and in vivo, simvastatin highly affects the whole NF-kappaB-dependent pathway of signaling, overview
-
additional information
structure-based design of IKK-2 inhibitors based on induced-fit docking into the homology model, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acquired Immunodeficiency Syndrome
In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2.
Acute Kidney Injury
Ischemic preconditioning attenuates renal ischemia-reperfusion injury by inhibiting activation of IKKbeta and inflammatory response.
Acute Lung Injury
[Potential molecular mechanism of multiple organ dysfunction syndrome induced by hemorrhage and endotoxin]
Adenocarcinoma
Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate.
Adenocarcinoma
GADD45alpha is highly expressed in pancreatic ductal adenocarcinoma cells and required for tumor cell viability.
Adenocarcinoma
Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers.
Adenocarcinoma
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
Adenocarcinoma
Transfer of IkappaBalpha gene increase the sensitivity of paclitaxel mediated with caspase 3 activation in human lung cancer cell.
Adenocarcinoma of Lung
Loss of IKKbeta activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis.
Adenoma
Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer.
Adenoma
Expression of apurinic/apyrimidinic endonuclease-1 (APE-1) in H. pylori-associated gastritis, gastric adenoma, and gastric cancer.
Adenomyosis
Immunoreactivity of progesterone receptor isoform B, nuclear factor kappaB, and IkappaBalpha in adenomyosis.
Adenoviridae Infections
Amelioration of glucose tolerance by hepatic inhibition of nuclear factor kappaB in db/db mice.
Agammaglobulinemia
Autosomal-dominant primary immunodeficiencies.
Alzheimer Disease
SSH1 impedes SQSTM1/p62 flux and MAPT/Tau clearance independent of CFL (cofilin) activation.
Amyotrophic Lateral Sclerosis
A novel TBK1 mutation in a family with diverse frontotemporal dementia spectrum disorders.
Amyotrophic Lateral Sclerosis
ALS-associated TBK1 variant p.G175S is defective in phosphorylation of p62 and impacts TBK1-mediated signalling and TDP-43 autophagic degradation.
Amyotrophic Lateral Sclerosis
Association of the New Variant Tyr424Asp at TBK1 Gene with Amyotrophic Lateral Sclerosis and Cognitive Decline.
Amyotrophic Lateral Sclerosis
Autophagy and ALS: mechanistic insights and therapeutic implications.
Amyotrophic Lateral Sclerosis
Beyond ALS and FTD: the phenotypic spectrum of TBK1 mutations includes PSP-like and cerebellar phenotypes.
Amyotrophic Lateral Sclerosis
Coexistence of variants in TBK1 and in other ALS-related genes elucidates an oligogenic model of pathogenesis in sporadic ALS.
Amyotrophic Lateral Sclerosis
Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort.
Amyotrophic Lateral Sclerosis
Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Genetic and functional analysis of TBK1 variants in Korean patients with sporadic amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Haploinsufficiency of TANK-binding kinase 1 prepones age-associated neuroinflammatory changes without causing motor neuron degeneration in aged mice.
Amyotrophic Lateral Sclerosis
Rare TBK1 variants in patients with frontotemporal dementia and amyotrophic lateral sclerosis in a Chinese cohort.
Amyotrophic Lateral Sclerosis
Screening of the TBK1 gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin.
Amyotrophic Lateral Sclerosis
TBK1 is associated with ALS and ALS-FTD in Sardinian patients.
Amyotrophic Lateral Sclerosis
TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis.
Amyotrophic Lateral Sclerosis
TBK1 mutations in Italian patients with amyotrophic lateral sclerosis: genetic and functional characterisation.
Amyotrophic Lateral Sclerosis
Tuning Apoptosis and Neuroinflammation: TBK1 Restrains RIPK1.
Amyotrophic Lateral Sclerosis
UBQLN2 Promotes the Production of Type I Interferon via the TBK1-IRF3 Pathway.
Amyotrophic Lateral Sclerosis
[A Pair of Siblings with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis and a Novel Thr462Lysfs Mutation in the TBK1 Gene].
Anaphylaxis
Phosphorylation of SNAP-23 by IkappaB kinase 2 regulates mast cell degranulation.
Anthrax
Anthrax lethal toxin enhances IkappaB kinase activation and differentially regulates pro-inflammatory genes in human endothelium.
Arthritis
Amelioration of arthritis by intraarticular dominant negative Ikk beta gene therapy using adeno-associated virus type 5.
Arthritis
Amelioration of Arthritis by Intraarticular Dominant Negative IKKbeta Gene Therapy Using Adeno-Associated Virus Type 5.
Arthritis
IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis.
Arthritis
Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation.
Arthritis
NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint.
Arthritis
Periodic, Partial Inhibition of IKK{beta}-Mediated Signaling Yields Therapeutic Benefit in Preclinical Models of Rheumatoid Arthritis.
Arthritis
Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta.
Arthritis
The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis.
Arthritis
Therapeutic effects of a TBK1 kinase inhibitor in germinal center-driven, autoantibody-mediated inflammatory arthritis.
Arthritis
Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis.
Arthritis, Experimental
Amelioration of arthritis by intraarticular dominant negative Ikk beta gene therapy using adeno-associated virus type 5.
Arthritis, Experimental
Amelioration of Arthritis by Intraarticular Dominant Negative IKKbeta Gene Therapy Using Adeno-Associated Virus Type 5.
Arthritis, Experimental
Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation.
Arthritis, Experimental
Collagen and aggrecan degradation is blocked in interleukin-1-treated cartilage explants by an inhibitor of IkappaB kinase through suppression of metalloproteinase expression.
Arthritis, Experimental
Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation.
Arthritis, Experimental
Periodic, Partial Inhibition of IKK{beta}-Mediated Signaling Yields Therapeutic Benefit in Preclinical Models of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Antiviral gene expression in rheumatoid arthritis: role of IKKepsilon and interferon regulatory factor 3.
Arthritis, Rheumatoid
Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation.
Arthritis, Rheumatoid
Expression and regulation of inducible IkappaB kinase (IKK-i) in human fibroblast-like synoviocytes.
Arthritis, Rheumatoid
Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy.
Arthritis, Rheumatoid
IkappaBalpha promoter polymorphisms in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis.
Arthritis, Rheumatoid
Inhibitor IkappaBalpha promoter functional polymorphisms in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation.
Arthritis, Rheumatoid
Melittin inhibits inflammatory target gene expression and mediator generation via interaction with IkappaB kinase.
Arthritis, Rheumatoid
Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome.
Arthritis, Rheumatoid
Selective regulation of cytokine induction by adenoviral gene transfer of IkappaBalpha into human macrophages: lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is nuclear factor-kappaB independent.
Asthma
Adenovirus-mediated overexpression of novel mutated IkappaBalpha inhibits nuclear factor kappaB activation in endothelial cells.
Asthma
Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure-activity relationship.
Asthma
Amlexanox ameliorates acetaminophen-induced acute liver injury by reducing oxidative stress in mice.
Asthma
Anti-inflammatory inhibitors of IkappaB kinase in asthma and COPD.
Asthma
Arsenic trioxide, a potent inhibitor of NF-kappaB, abrogates allergen-induced airway hyperresponsiveness and inflammation.
Asthma
IkappaB kinase beta inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma.
Asthma
Oxidants induce a corticosteroid-insensitive phosphorylation of histone 3 at serine 10 in monocytes.
Asthma
Selective blockade of NF-kappaB by novel mutated IkappaBalpha suppresses CD3/CD28-induced activation of memory CD4+ T cells in asthma.
Asthma
The signaling adapter p62 is an important mediator of T helper 2 cell function and allergic airway inflammation.
Asthma
[Studies on the effect of Ginkgo biloba extracts on NF-kappaB pathway]
Astrocytoma
Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma.
Astrocytoma
Nuclear factor kappaB activation by muscarinic receptors in astroglial cells: effect of ethanol.
Ataxia
Effect of ovarian hormones on survival genes in laser captured serotonin neurons from macaques.
Ataxia
Persistent Activation of NF-?B in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage.
Ataxia Telangiectasia
ATM-dependent nuclear accumulation of IKK-alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin.
Ataxia Telangiectasia
Molecular Linkage Between the Kinase ATM and NF-{kappa}B Signaling in Response to Genotoxic Stimuli.
Ataxia Telangiectasia
Nickel carcinogenesis mechanism: cell cycle dysregulation.
Atherosclerosis
Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis.
Atherosclerosis
Inhibition of cytokine-induced IkappaB kinase activation as a mechanism contributing to the anti-atherogenic activity of tilianin in hyperlipidemic mice.
Atherosclerosis
Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice.
Atherosclerosis
Potential utility of natural polyphenols for reversing fat-induced insulin resistance.
Atherosclerosis
Roles of an IkappaB kinase-related pathway in human cytomegalovirus-infected vascular smooth muscle cells: a molecular link in pathogen-induced proatherosclerotic conditions.
Autoimmune Diseases
A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development.
Autoimmune Diseases
IKKbeta inhibitors identification part I: homology model assisted structure based virtual screening.
Autoimmune Diseases
Recent progress in small molecule TBK1 inhibitors: a patent review (2015- 2020).
Autoimmune Diseases
TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery.
Bacterial Infections
Coordinate regulation of IkappaB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-kappaB-inducing kinase.
Bacterial Infections
Drosophila peptidoglycan recognition protein LC (PGRP-LC) acts as a signal-transducing innate immune receptor.
Bacterial Infections
NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha.
Bacterial Infections
TBK1 protects vacuolar integrity during intracellular bacterial infection.
Bacterial Infections
Tumor suppressor Foxo3a is involved in the regulation of lipopolysaccharide-induced interleukin-8 in intestinal HT-29 cells.
Barrett Esophagus
Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma.
Bone Resorption
Control of osteoclast activity and bone loss by IKK subunits: new targets for therapy.
Bone Resorption
IKK{beta} as a target for treatment of inflammation induced bone loss.
Brain Injuries
alpha-melanocyte-stimulating hormone inhibits NF-kappaB activation and IkappaBalpha degradation in human glioma cells and in experimental brain inflammation.
Brain Injuries, Traumatic
NF-kappaB and IkappaBalpha expression following traumatic brain injury to the immature rat brain.
Brain Ischemia
Antioxidants attenuate reperfusion injury after global brain ischemia through inhibiting nuclear factor-kappa B activity in rats.
Brain Ischemia
Modulation of IkappaB kinase autophosphorylation and activity following brain ischemia.
Brain Ischemia
Oxidative stress increases phosphorylation of IkappaB kinase-alpha by enhancing NF-kappaB-inducing kinase after transient focal cerebral ischemia.
Brain Ischemia
Oxidative stress transiently decreases the IKK complex (IKKalpha, beta, and gamma), an upstream component of NF-kappaB signaling, after transient focal cerebral ischemia in mice.
Brain Neoplasms
IkappaBalpha degradation is not a requirement for the X-ray-induced activation of nuclear factor kappaB in normal rat astrocytes and human brain tumour cells.
Breast Neoplasms
A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition.
Breast Neoplasms
All roads lead to IKKepsilon.
Breast Neoplasms
Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-?B: implication in breast cancer metastasis.
Breast Neoplasms
Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.
Breast Neoplasms
Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer.
Breast Neoplasms
Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation.
Breast Neoplasms
Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha.
Breast Neoplasms
IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines.
Breast Neoplasms
IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells.
Breast Neoplasms
IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a.
Breast Neoplasms
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway.
Breast Neoplasms
IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer.
Breast Neoplasms
Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells.
Breast Neoplasms
Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factor-kappaB pathway.
Breast Neoplasms
Inhibition of IkappaB kinase-beta and anticancer activities of novel chalcone adamantyl arotinoids.
Breast Neoplasms
Integrative genomic approaches identify IKBKE as a breast cancer oncogene.
Breast Neoplasms
Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance.
Breast Neoplasms
Marasmius oreades substances block NF-kappaB activity through interference with IKK activation pathway.
Breast Neoplasms
Maximal adamantyl-substituted retinoid-related molecule-induced apoptosis requires NF-kappaB noncanonical and canonical pathway activation.
Breast Neoplasms
Negative regulation of transactivation function but not DNA binding of NF-kappaB and AP-1 by IkappaBbeta1 in breast cancer cells.
Breast Neoplasms
Nitric oxide-mediated inhibition of NFkappaB regulates hyperthermia-induced apoptosis.
Breast Neoplasms
Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.
Breast Neoplasms
Nuclear factor-kappaB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo.
Breast Neoplasms
Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone.
Breast Neoplasms
Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide.
Breast Neoplasms
Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.
Breast Neoplasms
Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms.
Breast Neoplasms
Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer.
Breast Neoplasms
shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer.
Breast Neoplasms
Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKbeta.
Breast Neoplasms
SUMOylation-dependent localization of IKKepsilon in PML nuclear bodies is essential for protection against DNA-damage-triggered cell death.
Breast Neoplasms
Targeting the NF-kappaB pathway in estrogen receptor negative MDA-MB-231 breast cancer cells using small inhibitory RNAs.
Breast Neoplasms
The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells.
Breast Neoplasms
The IKK/NF-?B signaling pathway requires Morgana to drive breast cancer metastasis.
Breast Neoplasms
TNFalpha induces HIF-1alpha expression through activation of IKKbeta.
Breast Neoplasms
Tyrosine kinase p56lck regulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of IkappaBalpha following hypoxia/reoxygenation.
Breast Neoplasms
ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth.
Breast Neoplasms
[The nuclear factor kappa B activation: the key step of cell proliferation in estrogen receptor-negative breast cancer cells]
Bronchitis, Chronic
[Mangiferin protects rats against chronic bronchitis via regulating NF-kappaB (P65) and IkappaBalpha expression in mononuclear cells].
Burkitt Lymphoma
Differential effects of tumor necrosis factor-alpha and CD40L on NF-kappaB inhibitory proteins IkappaBalpha, beta and epsilon and on the induction of the Jun amino-terminal kinase pathway in Ramos Burkitt lymphoma cells.
calpain-3 deficiency
Pathophysiology of limb girdle muscular dystrophy type 2A: hypothesis and new insights into the IkappaBalpha/NF-kappaB survival pathway in skeletal muscle.
Carcinogenesis
A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas.
Carcinogenesis
A modified version of galectin-9 suppresses cell growth and induces apoptosis of human T-cell leukemia virus type I-infected T-cell lines.
Carcinogenesis
A review on the role of TANK-binding kinase 1 signaling in cancer.
Carcinogenesis
Assessment of TANK-binding kinase 1 as a therapeutic target in cancer.
Carcinogenesis
Attribution of NF-?B Activity to CHUK/IKK?-Involved Carcinogenesis.
Carcinogenesis
Binding of manumycin A inhibits IkappaB kinase beta activity.
Carcinogenesis
Critical role of IkappaB kinase alpha in embryonic skin development and skin carcinogenesis.
Carcinogenesis
Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers.
Carcinogenesis
Effectiveness of IkappaB kinase inhibitors in murine colitis-associated tumorigenesis.
Carcinogenesis
Eugenol inhibits cell proliferation via NF-kappaB suppression in a rat model of gastric carcinogenesis induced by MNNG.
Carcinogenesis
Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.
Carcinogenesis
Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis.
Carcinogenesis
IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells.
Carcinogenesis
IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a.
Carcinogenesis
IKKalpha, a critical regulator of epidermal differentiation and a suppressor of skin cancer.
Carcinogenesis
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.
Carcinogenesis
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.
Carcinogenesis
Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers.
Carcinogenesis
Inhibitor of kappaB Kinase Beta Regulates Gastric Carcinogenesis via Interleukin-1alpha Expression.
Carcinogenesis
Innate immunity meets with cellular stress at the IKK complex: Regulation of the IKK complex by HSP70 and HSP90.
Carcinogenesis
KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta.
Carcinogenesis
Loss of p53 enhances catalytic activity of IKKbeta through O-linked beta-N-acetyl glucosamine modification.
Carcinogenesis
Mutant IkappaBalpha suppresses hypoxia-induced VEGF expression through downregulation of HIF-1alpha and COX-2 in human glioma cells.
Carcinogenesis
Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.
Carcinogenesis
Piceatannol, a catechol-type polyphenol, inhibits phorbol ester-induced NF-{kappa}B activation and cyclooxygenase-2 expression in human breast epithelial cells: cysteine 179 of IKK{beta} as a potential target.
Carcinogenesis
Reduction in IkappaB kinase alpha expression promotes the development of skin papillomas and carcinomas.
Carcinogenesis
Reduction of IKKalpha expression promotes chronic ultraviolet B exposure-induced skin inflammation and carcinogenesis.
Carcinogenesis
Role of IkappaB kinase in tumorigenesis.
Carcinogenesis
The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
Carcinogenesis
[Expression of nuclear transcription factor kappaB in hamster buccal pouch carcinogenesis]
Carcinoma
A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas.
Carcinoma
Aberrant expression of interferon regulatory factor 3 in human lung cancer.
Carcinoma
Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells.
Carcinoma
Adriamycin activates NF-kappaB in human lung carcinoma cells by IkappaBalpha degradation.
Carcinoma
Cepharanthin-enhanced radiosensitivity through the inhibition of radiation-induced nuclear factor-kappaB activity in human oral squamous cell carcinoma cells.
Carcinoma
Chemosensitivity of human pancreatic carcinoma cells is enhanced by IkappaBalpha super-repressor.
Carcinoma
Critical role of IkappaB kinase alpha in embryonic skin development and skin carcinogenesis.
Carcinoma
Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1.
Carcinoma
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.
Carcinoma
Effects of IkappaB kinase alpha on the differentiation of squamous carcinoma cells.
Carcinoma
Effects of marine sponge extracts on mitogen-activated protein kinase (MAPK/ERK(1,2)) activity in SW-13 human adrenal carcinoma cells.
Carcinoma
Enhanced IkappaB kinase activity is responsible for the augmented activity of NF-kappaB in human head and neck carcinoma cells.
Carcinoma
Epigenetic inactivation of IkappaB Kinase-alpha in oral carcinomas and tumor progression.
Carcinoma
Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo.
Carcinoma
Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma.
Carcinoma
High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity.
Carcinoma
Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling.
Carcinoma
IKKalpha enhances human keratinocyte differentiation and determines the histological variant of epidermal squamous cell carcinomas.
Carcinoma
IKKalpha is a critical coregulator of a Smad4-independent TGFbeta-Smad2/3 signaling pathway that controls keratinocyte differentiation.
Carcinoma
IKKalpha is required to maintain skin homeostasis and prevent skin cancer.
Carcinoma
IKKalpha shields 14-3-3sigma, a G(2)/M cell cycle checkpoint gene, from hypermethylation, preventing its silencing.
Carcinoma
Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalpha.
Carcinoma
Increase in IkappaB kinase alpha expression suppresses the tumor progression and improves the prognosis for nasopharyngeal carcinoma.
Carcinoma
Inhibition of IkappaB kinase-beta and anticancer activities of novel chalcone adamantyl arotinoids.
Carcinoma
Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter.
Carcinoma
NF-kappaB signalling proteins p50/p105, p52/p100, RelA, and IKKepsilon are over-expressed in oesophageal squamous cell carcinomas.
Carcinoma
Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis.
Carcinoma
Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53.
Carcinoma
Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Carcinoma
Reduction in IkappaB kinase alpha expression promotes the development of skin papillomas and carcinomas.
Carcinoma
Reduction of IKKalpha expression promotes chronic ultraviolet B exposure-induced skin inflammation and carcinogenesis.
Carcinoma
TANK-binding kinase 1 is a mediator of platelet-induced EMT in mammary carcinoma cells.
Carcinoma
The anti-inflammatory and anti-cancer properties of epigallocatechin-3-gallate are mediated by folate cycle disruption, adenosine release and NF-kappaB suppression.
Carcinoma
The tumor suppressor activity of IKKalpha in stratified epithelia is exerted in part via the TGF-beta antiproliferative pathway.
Carcinoma
The ubiquitin-proteasome pathway and enhanced activity of NF-kappaB in gastric carcinoma.
Carcinoma in Situ
Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers.
Carcinoma, Ehrlich Tumor
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Carcinoma, Hepatocellular
Binding of manumycin A inhibits IkappaB kinase beta activity.
Carcinoma, Hepatocellular
Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8.
Carcinoma, Hepatocellular
Common inhibitory serine sites phosphorylated by IRS-1 kinases, triggered by insulin and inducers of insulin resistance.
Carcinoma, Hepatocellular
Freeze-dried grape powder attenuates mitochondria- and oxidative stress-mediated apoptosis in liver cells.
Carcinoma, Hepatocellular
Hepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAIL-dependent liver damage.
Carcinoma, Hepatocellular
High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer.
Carcinoma, Hepatocellular
IkappaBalpha gene therapy in tumor necrosis factor-alpha- and chemotherapy-mediated apoptosis of hepatocellular carcinomas.
Carcinoma, Hepatocellular
Inhibition of CK2 activity by TGF-beta1 promotes IkappaB-alpha protein stabilization and apoptosis of immortalized hepatocytes.
Carcinoma, Hepatocellular
Interferon alpha inhibits the nuclear factor kappa B activation triggered by X gene product of hepatitis B virus in human hepatoma cells.
Carcinoma, Hepatocellular
Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK/p38 and inhibiting IkappaBalpha kinase-NFkappaB.
Carcinoma, Hepatocellular
NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis.
Carcinoma, Hepatocellular
Regulation of alpha-fetoprotein by nuclear factor-kappaB protects hepatocytes from tumor necrosis factor-alpha cytotoxicity during fetal liver development and hepatic oncogenesis.
Carcinoma, Hepatocellular
Roles of Akt/PKB and IKK complex in constitutive induction of NF-kappaB in hepatocellular carcinomas of transforming growth factor alpha/c-myc transgenic mice.
Carcinoma, Hepatocellular
TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration.
Carcinoma, Hepatocellular
The ORF2 glycoprotein of hepatitis E virus inhibits cellular NF-kappaB activity by blocking ubiquitination mediated proteasomal degradation of IkappaBalpha in human hepatoma cells.
Carcinoma, Hepatocellular
TNF-alpha-induced sphingosine 1-phosphate inhibits apoptosis through a phosphatidylinositol 3-kinase/Akt pathway in human hepatocytes.
Carcinoma, Hepatocellular
[Enhancement of HepG2 cell radiosensitivity by mutant IkappaBalpha gene transfection.]
Carcinoma, Non-Small-Cell Lung
Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1.
Carcinoma, Non-Small-Cell Lung
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.
Carcinoma, Non-Small-Cell Lung
Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Carcinoma, Ovarian Epithelial
Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.
Carcinoma, Renal Cell
Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalpha.
Carcinoma, Squamous Cell
A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas.
Carcinoma, Squamous Cell
Aberrant expression of interferon regulatory factor 3 in human lung cancer.
Carcinoma, Squamous Cell
Critical role of IkappaB kinase alpha in embryonic skin development and skin carcinogenesis.
Carcinoma, Squamous Cell
Effects of IkappaB kinase alpha on the differentiation of squamous carcinoma cells.
Carcinoma, Squamous Cell
Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo.
Carcinoma, Squamous Cell
High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity.
Carcinoma, Squamous Cell
Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling.
Carcinoma, Squamous Cell
IKKalpha enhances human keratinocyte differentiation and determines the histological variant of epidermal squamous cell carcinomas.
Carcinoma, Squamous Cell
IKKalpha is a critical coregulator of a Smad4-independent TGFbeta-Smad2/3 signaling pathway that controls keratinocyte differentiation.
Carcinoma, Squamous Cell
IKKalpha shields 14-3-3sigma, a G(2)/M cell cycle checkpoint gene, from hypermethylation, preventing its silencing.
Carcinoma, Squamous Cell
NF-kappaB signalling proteins p50/p105, p52/p100, RelA, and IKKepsilon are over-expressed in oesophageal squamous cell carcinomas.
Carcinoma, Squamous Cell
Potentiation of tumor necrosis factor-mediated apoptosis of oral squamous cell carcinoma cells by adenovirus-mediated gene transfer of NF-kappaB inhibitor.
Carcinoma, Squamous Cell
Reduction in IkappaB kinase alpha expression promotes the development of skin papillomas and carcinomas.
Carcinoma, Squamous Cell
Reduction of IKKalpha expression promotes chronic ultraviolet B exposure-induced skin inflammation and carcinogenesis.
Carcinoma, Squamous Cell
The tumor suppressor activity of IKKalpha in stratified epithelia is exerted in part via the TGF-beta antiproliferative pathway.
Carcinosarcoma
Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo.
Cardiomegaly
Astragaloside IV protects against the pathological cardiac hypertrophy in mice.
Cardiomegaly
Suppressor of IKK? is an essential negative regulator of pathological cardiac hypertrophy.
Chlamydia Infections
Cleavage of p65/RelA of the NF-kappaB pathway by Chlamydia.
Chondrosarcoma
Effective adenoviral transfer of IkappaBalpha into human fibroblasts and chondrosarcoma cells reveals that the induction of matrix metalloproteinases and proinflammatory cytokines is nuclear factor-kappaB dependent.
Classical Swine Fever
Classical swine fever virus non-structural protein 4B binds tank-binding kinase 1.
Classical Swine Fever
The Npro product of classical swine fever virus interacts with IkappaBalpha, the NF-kappaB inhibitor.
Coinfection
Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappaB.
Coinfection
Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways.
Coinfection
Functional characterization of a purified, recombinant NF-kappaB/IkappaB complex.
Colitis
Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide.
Colitis
An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice.
Colitis
Attenuation of NF-?B in Intestinal Epithelial Cells Is Sufficient to Mitigate the Bone Loss Comorbidity of Experimental Mouse Colitis.
Colitis
Cutting edge: The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis.
Colitis
Epithelial cell I kappa B-kinase beta has an important protective role in Clostridium difficile toxin A-induced mucosal injury.
Colitis
Nuclear factor-kappa B in intestinal protection and destruction.
Colitis
Opposing functions of IKKbeta during acute and chronic intestinal inflammation.
Colitis
Plant sterol guggulsterone inhibits nuclear factor-kappaB signaling in intestinal epithelial cells by blocking IkappaB kinase and ameliorates acute murine colitis.
Colitis, Ulcerative
Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis.
Colitis, Ulcerative
Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis.
Colitis, Ulcerative
[Effect of Kuijieling decoction on proteins expression of IKK-alpha in colonic mucosa of ulcerative colitis model rats]
Colitis-Associated Neoplasms
Effectiveness of IkappaB kinase inhibitors in murine colitis-associated tumorigenesis.
Colitis-Associated Neoplasms
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.
Colonic Neoplasms
A ginseng saponin metabolite suppresses tumor necrosis factor-alpha-promoted metastasis by suppressing nuclear factor-kappaB signaling in murine colon cancer cells.
Colonic Neoplasms
Activation of NF-kappaB determines the sensitivity of human colon cancer cells to TNFalpha-induced apoptosis.
Colonic Neoplasms
Antiproliferative crude soy saponin extract modulates the expression of IkappaBalpha, protein kinase C, and cyclooxygenase-2 in human colon cancer cells.
Colonic Neoplasms
Evaluation of the expression of transcriptional factor NF-kappaB induced by phytic acid in colon cancer cells.
Colonic Neoplasms
Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells.
Colonic Neoplasms
Mapping of the critical region of mitogene-inducible gene-6 for NF-kappaB activation.
Colonic Neoplasms
Sulindac inhibits activation of the NF-kappaB pathway.
Colonic Neoplasms
Sustained activation of protein kinase C downregulates nuclear factor-kappaB signaling by dissociation of IKK-gamma and Hsp90 complex in human colonic epithelial cells.
Colonic Neoplasms
The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis.
Colonic Neoplasms
[The role of NF-kappaB in colon cancer].
Colorectal Neoplasms
A small molecule, (E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) phenol suppresses tumor growth via inhibition of IkappaB kinase ? in colorectal cancer
Colorectal Neoplasms
Association between activation of atypical NF-kappaB1 p105 signaling pathway and nuclear beta-catenin accumulation in colorectal carcinoma.
Colorectal Neoplasms
Evaluation of the expression of transcriptional factor NF-kappaB induced by phytic acid in colon cancer cells.
Colorectal Neoplasms
Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue.
Colorectal Neoplasms
Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation.
Colorectal Neoplasms
Prolyl Hydroxylase-3 Is Downregulated in Colorectal Cancer Cells and Inhibits IKKbeta, Independent of Hydroxylase Activity.
Colorectal Neoplasms
Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
Colorectal Neoplasms
The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB.
Colorectal Neoplasms
Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells.
Communicable Diseases
Role of IkappaBalpha and IkappaBbeta in the biphasic nuclear translocation of NF-kappaB in TNFalpha-stimulated astrocytes and in neuroblastoma cells.
Corneal Ulcer
Inhibition by a selective IkappaB kinase-2 inhibitor of interleukin-1-induced collagen degradation by corneal fibroblasts in three-dimensional culture.
Coronary Occlusion
Cardioprotection involves activation of NF-kappa B via PKC-dependent tyrosine and serine phosphorylation of I kappa B-alpha.
Cowpox
Cowpox virus and other members of the orthopoxvirus genus interfere with the regulation of NF-kappaB activation.
Cowpox
Modified vaccinia virus Ankara can activate NF-kappaB transcription factors through a double-stranded RNA-activated protein kinase (PKR)-dependent pathway during the early phase of virus replication.
Crohn Disease
Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease.
Crohn Disease
Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis.
Cystic Fibrosis
Anti-inflammatory gene therapy directed at the airway epithelium.
Cystic Fibrosis
Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-beta kinase pathway.
Cystic Fibrosis
High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the I kappa B kinase alpha pathway in response to extracellular NaCl content.
Cystic Fibrosis
Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice.
Dementia
Gene mutations in a Han Chinese Alzheimer's disease cohort.
Dementia
Ik2/TBK1 and Hook/Dynein, an adaptor complex for early endosome transport, are genetic modifiers of FTD-associated mutant CHMP2B toxicity in Drosophila.
Dementia
TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis.
Dementia
[A Pair of Siblings with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis and a Novel Thr462Lysfs Mutation in the TBK1 Gene].
Dermatitis
IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice.
Dermatitis
IKKbeta Leads to an Inflammatory Skin Disease Resembling Interface Dermatitis.
Diabetes Mellitus
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.
Diabetes Mellitus
Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta.
Diabetes Mellitus, Type 1
Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB.
Diabetes Mellitus, Type 1
Inhibition of TBK1/IKK? Promotes Regeneration of Pancreatic ?-cells.
Diabetes Mellitus, Type 1
NF-kappa B prevents beta cell death and autoimmune diabetes in NOD mice.
Diabetes Mellitus, Type 2
Adiponectin suppresses IkappaB kinase activation induced by tumor necrosis factor-alpha or high glucose in endothelial cells: role of cAMP and AMP kinase signaling.
Diabetes Mellitus, Type 2
Feed-forward Signaling of TNF{alpha} and NF{kappa}B via IKK{beta} Pathway contributes to Insulin Resistance and Coronary Arteriolar Dysfunction in Type 2 Diabetic Mice.
Diabetes Mellitus, Type 2
Genetic variability in insulin action inhibitor Ikkbeta (IKBKB) does not play a major role in the development of type 2 diabetes.
Diabetes Mellitus, Type 2
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.
Diabetes Mellitus, Type 2
Potential utility of natural polyphenols for reversing fat-induced insulin resistance.
Diabetes Mellitus, Type 2
Prevention of fat-induced insulin resistance by salicylate.
Diabetes Mellitus, Type 2
Reduced Skeletal Muscle Inhibitor of {kappa}B{beta} Content Is Associated With Insulin Resistance in Subjects With Type 2 Diabetes: Reversal by Exercise Training.
Diabetes Mellitus, Type 2
Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta.
Down Syndrome
Down syndrome candidate region 1 increases the stability of the IkappaBalpha protein: implications for its anti-inflammatory effects.
Dysautonomia, Familial
ELP3 localises to mitochondria and actin-rich domains at edges of HeLa cells.
Dysautonomia, Familial
Episodic somnolence in an infant with Riley-Day syndrome.
Dysautonomia, Familial
Genomic organization and chromosomal localization of the mouse IKBKAP gene.
Dysautonomia, Familial
IKBKAP mRNA in peripheral blood leukocytes: a molecular marker of gene expression and splicing in familial dysautonomia.
Dysautonomia, Familial
Potential role of tubulin acetylation and microtubule-based protein trafficking in familial dysautonomia.
Dysautonomia, Familial
Specific correction of a splice defect in brain by nutritional supplementation.
Dysautonomia, Familial
Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia.
Ectodermal Dysplasia
A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency.
Ectodermal Dysplasia
Anhidrotic ectodermal dysplasia and immunodeficiency: the role of NEMO.
Ectodermal Dysplasia
Autosomal-dominant primary immunodeficiencies.
Ectodermal Dysplasia
Growth hormone and insulin-like growth factor I insensitivity of fibroblasts isolated from a patient with an I{kappa}B{alpha} mutation.
Ectodermal Dysplasia
Heterozygous N-terminal deletion of IkappaBalpha results in functional nuclear factor kappaB haploinsufficiency, ectodermal dysplasia, and immune deficiency.
Ectodermal Dysplasia
IKKalpha is a p63 transcriptional target involved in the pathogenesis of ectodermal dysplasias.
Ectodermal Dysplasia
Immune deficiency caused by impaired expression of nuclear factor-kappaB essential modifier (NEMO) because of a mutation in the 5' untranslated region of the NEMO gene.
Ectodermal Dysplasia
Inherited disorders of NF-kappaB-mediated immunity in man.
Encephalitis
alpha-melanocyte-stimulating hormone inhibits NF-kappaB activation and IkappaBalpha degradation in human glioma cells and in experimental brain inflammation.
Encephalomyelitis
Neuronal I kappa B kinase beta protects mice from autoimmune encephalomyelitis by mediating neuroprotective and immunosuppressive effects in the central nervous system.
Encephalomyelitis, Autoimmune, Experimental
Neuronal I kappa B kinase beta protects mice from autoimmune encephalomyelitis by mediating neuroprotective and immunosuppressive effects in the central nervous system.
Endometrial Neoplasms
Expression of inflammatory cytokines by adipose tissue from patients with endometrial cancer.
Endometriosis
Immunohistochemical study of the ubiquitin-nuclear factor-kB pathway in the endometrium of the baboon (Papio anubis) with and without endometriosis.
Endometriosis
Nuclear factor kappaB pathway and interleukin-6 are affected in eutopic endometrium of women with endometriosis.
Endotoxemia
4-O-Methylgallic acid suppresses inflammation-associated gene expression by inhibition of redox-based NF-kappaB activation.
Endotoxemia
Neuronal activity and transcription of proinflammatory cytokines, IkappaBalpha, and iNOS in the mouse brain during acute endotoxemia and chronic infection with Trypanosoma brucei brucei.
Endotoxemia
Pleiotropic functions of TNF-alpha determine distinct IKKbeta-dependent hepatocellular fates in response to LPS.
Endotoxemia
Role of NFkappaB in the mortality of sepsis.
Endotoxemia
[Sophoridine inhibits NF-kappaB signaling pathway activation in kidney tissue of endotoxemia mice].
Eosinophilia
Arsenic trioxide, a potent inhibitor of NF-kappaB, abrogates allergen-induced airway hyperresponsiveness and inflammation.
Eosinophilia
Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma.
Epilepsy
NF-kappaB activity and iNOS expression in monocytes from internal jugular blood of migraine without aura patients during attacks.
Erectile Dysfunction
IkappaB kinase 2 inhibition corrects defective nitrergic erectile mechanisms in diabetic mouse corpus cavernosum.
Escherichia coli Infections
Escherichia coli up-regulates proinflammatory cytokine expression in granulocyte/macrophage lineages of CD34 stem cells via p50 homodimeric NF-kappaB.
Escherichia coli Infections
Induction of proinflammatory mediators requires activation of the TRAF, NIK, IKK and NF-kappaB signal transduction pathway in astrocytes infected with Escherichia coli.
Esophageal Neoplasms
Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-kappaB.
Exanthema
I kappa B alpha promoter polymorphisms in patients with systemic lupus erythematosus.
Eye Infections
An off-target effect of BX795 blocks herpes simplex virus type 1 infection of the eye.
Fatty Liver
Animal models of steatohepatitis.
Fibrosarcoma
Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin.
Fibrosarcoma
Lymphotoxin-beta receptor activation by lymphotoxin-alpha(1)beta(2) and LIGHT promotes tumor growth in an NFkappaB-dependent manner.
Frontotemporal Dementia
A novel TBK1 mutation in a family with diverse frontotemporal dementia spectrum disorders.
Frontotemporal Dementia
Association of the TBK1 mutation p.Ile334Thr with frontotemporal dementia and literature review.
Frontotemporal Dementia
Autophagy and ALS: mechanistic insights and therapeutic implications.
Frontotemporal Dementia
Beyond ALS and FTD: the phenotypic spectrum of TBK1 mutations includes PSP-like and cerebellar phenotypes.
Frontotemporal Dementia
Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort.
Frontotemporal Dementia
Haploinsufficiency of TANK-binding kinase 1 prepones age-associated neuroinflammatory changes without causing motor neuron degeneration in aged mice.
Frontotemporal Dementia
Rare TBK1 variants in patients with frontotemporal dementia and amyotrophic lateral sclerosis in a Chinese cohort.
Frontotemporal Dementia
TBK1 is associated with ALS and ALS-FTD in Sardinian patients.
Frontotemporal Dementia
TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis.
Frontotemporal Dementia
The clinical, neuroanatomical, and neuropathologic phenotype of TBK1-associated frontotemporal dementia: A longitudinal case report.
Frontotemporal Dementia
Tuning Apoptosis and Neuroinflammation: TBK1 Restrains RIPK1.
Frontotemporal Dementia
Variable clinical phenotype in TBK1 mutations: case report of a novel mutation causing primary progressive aphasia and review of the literature.
Frontotemporal Dementia
[A Pair of Siblings with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis and a Novel Thr462Lysfs Mutation in the TBK1 Gene].
Frontotemporal Lobar Degeneration
ALS-associated TBK1 variant p.G175S is defective in phosphorylation of p62 and impacts TBK1-mediated signalling and TDP-43 autophagic degradation.
Frontotemporal Lobar Degeneration
SSH1 impedes SQSTM1/p62 flux and MAPT/Tau clearance independent of CFL (cofilin) activation.
Gastritis
Activation of IkappaB kinase and NF-kappaB is essential for Helicobacter pylori-induced chronic gastritis in Mongolian gerbils.
Gastritis
Helicobacter pylori Induces I{kappa}B Kinase {alpha} Nuclear Translocation and Chemokine Production in Gastric Epithelial Cells.
Genetic Diseases, Inborn
ELP3 localises to mitochondria and actin-rich domains at edges of HeLa cells.
Genetic Diseases, Inborn
Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia.
Glaucoma
Genomic Organization of TBK1 Copy Number Variations in Glaucoma Patients.
Glaucoma
Suppression of IkappaBalpha increases the expression of matrix metalloproteinase-2 in human ciliary muscle cells.
Glaucoma
Transgenic TBK1 mice have features of normal tension glaucoma.
Glioblastoma
Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase.
Glioblastoma
Identification of a novel pro-apopotic function of NF-kappaB in the DNA damage response.
Glioblastoma
Multiple forms of protein kinase from normal human brain and glioblastoma.
Glioblastoma
The regulating role of mutant IkappaBalpha in expression of TIMP-2 and MMP-9 in human glioblastoma multiform.
Glioma
Adenovirus-mediated gene transduction of IkappaB or IkappaB plus Bax gene drastically enhances tumor necrosis factor (TNF)-induced apoptosis in human gliomas.
Glioma
alpha-melanocyte-stimulating hormone inhibits NF-kappaB activation and IkappaBalpha degradation in human glioma cells and in experimental brain inflammation.
Glioma
Manganese potentiates lipopolysaccharide-induced expression of NOS2 in C6 glioma cells through mitochondrial-dependent activation of nuclear factor kappaB.
Glioma
Mutant IkappaBalpha suppresses hypoxia-induced VEGF expression through downregulation of HIF-1alpha and COX-2 in human glioma cells.
Glioma
Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas.
Glioma
Protein kinase translocation following beta-adrenergic receptor activation in C6 glioma cells.
Glioma
Transient nuclear factor kappaB (NF-kappaB) activation stimulated by interleukin-1beta may be partly dependent on proteasome activity, but not phosphorylation and ubiquitination of the IkappaBalpha molecule, in C6 glioma cells. Regulation of NF-kappaB linked to chemokine production.
Glomerulosclerosis, Focal Segmental
Increased nuclear factor-kappaB and angiotensinogen gene expression in posttransplant recurrent focal segmental glomerulosclerosis.
Glucose Intolerance
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity.
Granulosa Cell Tumor
Characterization of the Inhibitor of KappaB Kinase (IKK) Complex in Granulosa Cell Tumors of the Ovary and Granulosa Cell Tumor-Derived Cell Lines.
Head and Neck Neoplasms
Curcumin Treatment Suppresses IKK{beta} Kinase Activity of Salivary Cells of Patients with Head and Neck Cancer: A Pilot Study.
Hematologic Neoplasms
Mutational analysis of IkappaBalpha in hematologic malignancies.
Hematologic Neoplasms
Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression.
Hemorrhagic Fevers, Viral
Viral immune surveillance: Toward a TH17/TH9 gate to the central nervous system.
Hepatitis
Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta.
Hepatitis
NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis.
Hepatitis B
Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha.
Hepatitis B
IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C.
Hepatitis B
Stimulation of DDX3 expression by ginsenoside Rg3 through the Akt/p53 pathway activates the innate immune response via TBK1/IKK?/IRF3 signalling.
Hepatitis B
Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB.
Hepatitis C
Hepatitis C virus core protein induces malignant transformation of biliary epithelial cells by activating nuclear factor-kappaB pathway.
Hepatitis C
Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta.
Hepatitis C
Hepatitis C virus nonstructural 5B protein regulates tumor necrosis factor alpha signaling through effects on cellular IkappaB kinase.
Hepatitis C
Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkappaBalpha and its degradation by calpain protease.
Hepatitis C
Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon.
Hepatitis E
The ORF2 glycoprotein of hepatitis E virus inhibits cellular NF-kappaB activity by blocking ubiquitination mediated proteasomal degradation of IkappaBalpha in human hepatoma cells.
Herpes Simplex
Activation of NF-kappaB in cells productively infected with HSV-1 depends on activated protein kinase R and plays no apparent role in blocking apoptosis.
Herpes Simplex
Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase.
Herpes Simplex
Herpes Simplex Virus 1 Inhibits TANK-Binding Kinase 1 through Formation of the Us11-Hsp90 Complex.
Herpes Simplex
Herpes simplex virus disrupts NF-kappaB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes.
Herpes Simplex
HSV-1 ICP27 suppresses NF-kappaB activity by stabilizing IkappaBalpha.
HIV Infections
Disruption of MAP kinase activation and nuclear factor binding to the IL-12 p40 promoter in HIV-infected myeloid cells.
HIV Infections
Ikappakappa mediates NF-kappaB activation in human immunodeficiency virus-infected cells.
Hodgkin Disease
Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.
Hodgkin Disease
Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma.
Hodgkin Disease
Germline mutations and polymorphisms in the NFKBIA gene in Hodgkin lymphoma.
Hodgkin Disease
Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.
Hodgkin Disease
Mutational analysis of IkappaBalpha in hematologic malignancies.
Hodgkin Disease
Mutations in the genes coding for the NF-{kappa}B regulating factors I{kappa}B{alpha} and A20 are uncommon in nodular lymphocyte-predominant Hodgkin lymphoma.
Hodgkin Disease
Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha.
Hodgkin Disease
Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells.
Hodgkin Disease
[Preliminary analysis of mutations in exon 5 of IkappaBalpha gene in Hodgkin lymphoma]
Hyperalgesia
Specific Inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats.
Hyperalgesia
TANK-binding kinase 1 (TBK1) modulates inflammatory hyperalgesia by regulating MAP kinases and NF-?B dependent genes.
Hyperlipidemias
Diet-induced obesity and acute hyperlipidemia reduce IkappaBalpha levels in rat skeletal muscle in a fiber-type dependent manner.
Hypersensitivity
Cepharanthin-enhanced radiosensitivity through the inhibition of radiation-induced nuclear factor-kappaB activity in human oral squamous cell carcinoma cells.
Hypersensitivity
Defective feedback regulation of NF-kappaB underlies Sjogren's syndrome in mice with mutated kappaB enhancers of the IkappaBalpha promoter.
Hypotension
Activation of the cholinergic anti-inflammatory pathway reduces NF-kappab activation, blunts TNF-alpha production, and protects againts splanchic artery occlusion shock.
Hypotension
Efferent vagal fibre stimulation blunts nuclear factor-kappaB activation and protects against hypovolemic hemorrhagic shock.
Hypotension
Trehalose: a biophysics approach to modulate the inflammatory response during endotoxic shock.
ikappab kinase deficiency
Activation of both nuclear factor of activated T cells and inhibitor of nuclear factor-kappa B kinase beta-subunit-/nuclear factor-kappa B is critical for cyclooxygenase-2 induction by benzo[a]pyrene in human bronchial epithelial cells.
ikappab kinase deficiency
Deficiency in Ikkbeta gene enhances arsenic-induced gadd45alpha expression.
ikappab kinase deficiency
IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice.
ikappab kinase deficiency
Inhibition of NF-kappaB stabilizes gadd45alpha mRNA.
ikappab kinase deficiency
Inhibitor of nuclear factor kappaB kinase deficiency enhances oxidative stress and prolongs c-Jun NH2-terminal kinase activation induced by arsenic.
ikappab kinase deficiency
NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha.
ikappab kinase deficiency
Opposing functions of IKKbeta during acute and chronic intestinal inflammation.
ikappab kinase deficiency
Relationship between IkappaBalpha deficiency, NFkappaB activity and interleukin-8 production in CF human airway epithelial cells.
ikappab kinase deficiency
Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta.
Infections
A parapoxviral virion protein targets the retinoblastoma protein to inhibit NF-?B signaling.
Infections
A role for I{kappa}B kinase 2 in bipolar spindle assembly.
Infections
Activation of NF-kappa B via the Ikappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells.
Infections
Activation of NF-kappaB following detachment delays apoptosis in intestinal epithelial cells.
Infections
Activation of NF-kappaB promotes the transition of large, CD43+ pre-B cells to small, CD43- pre-B cells.
Infections
Activation of non-canonical NF-{kappa}B signaling by the oncoprotein TIO.
Infections
Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity.
Infections
Activation of the NF-kappaB pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter.
Infections
Activation of the virus-induced IKK/NF-kappaB signalling axis is critical for the replication of human cytomegalovirus in quiescent cells.
Infections
An antiinflammatory role for IKKbeta through the inhibition of "classical" macrophage activation.
Infections
An off-target effect of BX795 blocks herpes simplex virus type 1 infection of the eye.
Infections
Antiviral gene expression in rheumatoid arthritis: role of IKKepsilon and interferon regulatory factor 3.
Infections
Apoptosis of dedifferentiated hepatoma cells is independent of NF-kappaB activation in response to LPS.
Infections
Autosomal-dominant primary immunodeficiencies.
Infections
Bacterial Muramyl Dipeptide (MDP) Restricts Human Cytomegalovirus Replication via an IFN-?-Dependent Pathway.
Infections
Bile salts induce resistance to apoptosis through NF-kappaB-mediated XIAP expression.
Infections
Ca(2+) /calmodulin-dependent kinase II contributes to inhibitor of nuclear factor-kappa B kinase complex activation in Helicobacter pylori infection.
Infections
Chemosensitivity of human pancreatic carcinoma cells is enhanced by IkappaBalpha super-repressor.
Infections
Chronic human immunodeficiency virus type 1 infection of myeloid cells disrupts the autoregulatory control of the NF-kappaB/Rel pathway via enhanced IkappaBalpha degradation.
Infections
Co-regulation of NF-kappaB and inflammasome-mediated inflammatory responses by myxoma virus pyrin domain-containing protein m013.
Infections
Conditional deletion of IkappaB-kinase-beta accelerates helicobacter-dependent gastric apoptosis, proliferation, and preneoplasia.
Infections
Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma.
Infections
Control of the NF-kappaB inhibitor IkappaBalpha in pathogen infection.
Infections
Cowpox virus and other members of the orthopoxvirus genus interfere with the regulation of NF-kappaB activation.
Infections
CRISPR/Cas9-Mediated Chicken TBK1 Gene Knockout and Its Essential Role in STING-Mediated IFN-? Induction in Chicken Cells.
Infections
Ctenopharyngodon idella TBK1 activates innate immune response via IRF7.
Infections
Cytokine upregulation of proteinase-activated-receptors 2 and 4 expression mediated by p38 MAP kinase and inhibitory kappa B kinase beta in human endothelial cells.
Infections
Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines.
Infections
Efficient replication by herpes simplex virus type 1 involves activation of the IkappaB kinase-IkappaB-p65 pathway.
Infections
Enhanced proteolysis of IkappaBalpha and IkappaBbeta proteins in astrocytes by Moloney murine leukemia virus (MoMuLV)-ts1 infection: a potential mechanism of NF-kappaB activation.
Infections
Enhancement of lipopolysaccharide-stimulated JNK activity in rat aortic smooth muscle cells by pharmacological and adenovirus-mediated inhibition of inhibitory kappa B kinase signalling.
Infections
Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis.
Infections
Escherichia coli up-regulates proinflammatory cytokine expression in granulocyte/macrophage lineages of CD34 stem cells via p50 homodimeric NF-kappaB.
Infections
H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells.
Infections
Helicobacter pylori Induces I{kappa}B Kinase {alpha} Nuclear Translocation and Chemokine Production in Gastric Epithelial Cells.
Infections
Helicobacter pylori infection activates NF-kappaB signaling pathway to induce iNOS and protect human gastric epithelial cells from apoptosis.
Infections
Helicobacter pylori-induced modification of the histone H3 phosphorylation status in gastric epithelial cells reflects its impact on cell cycle regulation.
Infections
Herpes simplex virus type 1 ICP27-dependent activation of NF-kappaB.
Infections
Host and parasite-derived IKK activities direct distinct temporal phases of NF-{kappa}B activation and target gene expression following Toxoplasma gondii infection.
Infections
Human cytomegalovirus stimulates cellular IKK2 activity and requires the enzyme for productive replication.
Infections
Human polynucleotide phosphorylase (hPNPaseold-35): a potential link between aging and inflammation.
Infections
I kappa B kinase alpha (IKK?) activity is required for functional maturation of dendritic cells and acquired immunity to infection.
Infections
Identification of a signaling cascade for interleukin-8 production by Helicobacter pylori in human gastric epithelial cells.
Infections
Identification of NF-kappaB-dependent gene networks in respiratory syncytial virus-infected cells.
Infections
IkappaB kinase is a critical regulator of chemokine expression and lung inflammation in respiratory syncytial virus infection.
Infections
Ikkepsilon regulates viral-induced interferon regulatory factor-3 activation via a redox-sensitive pathway.
Infections
In vivo and in vitro phosphorylation of DNA-dependent RNA polymerase of Escherichia coli by bacteriophage-T7-induced protein kinase.
Infections
Incomplete regulation of NF-kappaB by IkappaBalpha during respiratory syncytial virus infection in A549 cells.
Infections
Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IkappaBalpha overexpression.
Infections
Induction of proinflammatory mediators requires activation of the TRAF, NIK, IKK and NF-kappaB signal transduction pathway in astrocytes infected with Escherichia coli.
Infections
Inhibition of lipopolysaccharide-induced macrophage IL-12 production by Leishmania mexicana amastigotes: the role of cysteine peptidases and the NF-kappaB signaling pathway.
Infections
Inhibition of the NF-kappaB pathway by varicella-zoster virus in vitro and in human epidermal cells in vivo.
Infections
InsP3R-SEC5 interaction on phagosomes modulates innate immunity to Candida albicans by promoting cytosolic Ca2+ elevation and TBK1 activity.
Infections
Interleukin-4 and interleukin-10 modulate nuclear factor kappaB activity and nitric oxide synthase-2 expression in Theiler's virus-infected brain astrocytes.
Infections
Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy.
Infections
Listeria monocytogenes infection of P388D1 macrophages results in a biphasic NF-kappaB (RelA/p50) activation induced by lipoteichoic acid and bacterial phospholipases and mediated by IkappaBalpha and IkappaBbeta degradation.
Infections
MEKK3 and TAK1 synergize to activate IKK complex in Helicobacter pylori infection.
Infections
Molecular cloning of IKKbeta from the mandarin fish Siniperca chuatsi and its up-regulation in cells by ISKNV infection.
Infections
Murine gamma-herpesvirus 68 hijacks MAVS and IKKbeta to initiate lytic replication.
Infections
Mycoplasma ovipneumoniae induces inflammatory response in sheep airway epithelial cells via a MyD88-dependent TLR signaling pathway.
Infections
NF-?B activation coordinated by IKK? and IKK? enables latent infection of Kaposi's sarcoma-associated herpesvirus.
Infections
NF-kappa B hyperactivation has differential effects on the APC function of nonobese diabetic mouse macrophages.
Infections
NF-kappa B is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria.
Infections
NF-kappaB activation during Rickettsia rickettsii infection of endothelial cells involves the activation of catalytic IkappaB kinases IKKalpha and IKKbeta and phosphorylation-proteolysis of the inhibitor protein IkappaBalpha.
Infections
NF-kappaB is required for apoptosis prevention during herpes simplex virus type 1 infection.
Infections
NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha.
Infections
NF-kappaB: linking inflammation and immunity to cancer development and progression.
Infections
NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis.
Infections
Nod1 is an essential signal transducer in intestinal epithelial cells infected with bacteria that avoid recognition by toll-like receptors.
Infections
Nuclear factor kappa B is involved in lipopolysaccharide-stimulated induction of interferon regulatory factor-1 and GAS/GAF DNA-binding in human umbilical vein endothelial cells.
Infections
Nuclear factor-kappaB mediates Kupffer cell apoptosis through transcriptional activation of Fas/FasL.
Infections
Oncolytic activity of Sindbis virus in human oral squamous carcinoma cells.
Infections
Persistent activation of RelA by respiratory syncytial virus involves protein kinase C, underphosphorylated IkappaBbeta, and sequestration of protein phosphatase 2A by the viral phosphoprotein.
Infections
Porcine arterivirus activates the NF-kappaB pathway through IkappaB degradation.
Infections
Porcine epidemic diarrhea virus inhibits dsRNA-induced interferon-? production in porcine intestinal epithelial cells by blockade of the RIG-I-mediated pathway.
Infections
Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an Ikappa B repressor.
Infections
Protein kinase C-zeta is critical in pancreatitis-induced apoptosis of Kupffer cells.
Infections
Protein kinase of bacteriophage T7. 1. Purification.
Infections
Protein kinase R, IkappaB kinase-beta and NF-kappaB are required for human rhinovirus induced pro-inflammatory cytokine production in bronchial epithelial cells.
Infections
Regulatory serine residues mediate phosphorylation-dependent and phosphorylation-independent activation of interferon regulatory factor 7.
Infections
Requirements for the induction of interleukin-6 by herpes simplex virus-infected leukocytes.
Infections
Respiratory syncytial virus inhibits lung epithelial Na+ channels by up-regulating inducible nitric-oxide synthase.
Infections
Roles of an IkappaB kinase-related pathway in human cytomegalovirus-infected vascular smooth muscle cells: a molecular link in pathogen-induced proatherosclerotic conditions.
Infections
Rotavirus NSP1 inhibits NFkappaB activation by inducing proteasome-dependent degradation of beta-TrCP: a novel mechanism of IFN antagonism.
Infections
Selective inhibition of inhibitory kappa B kinase-beta abrogates induction of nitric oxide synthase in lipopolysaccharide-stimulated rat aortic smooth muscle cells.
Infections
Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death.
Infections
Simultaneous inhibition of Rac1 and IKK pathways sensitizes lung cancer cells to TNFalpha-mediated apoptosis.
Infections
Specific deficiency in nuclear factor-kappaB activation in neurons of the central nervous system.
Infections
Targeting Autophagic Regulation of NFkappaB in HTLV-I Transformed Cells by Geldanamycin: Implications for Therapeutic Interventions.
Infections
TBC1D9 regulates TBK1 activation through Ca2+ signaling in selective autophagy.
Infections
Temporal pattern of NFkappaB activation influences apoptotic cell fate in a stimuli-dependent fashion.
Infections
The Cytomegalovirus Tegument Protein UL35 Antagonizes Pattern Recognition Receptor-Mediated Type I IFN Transcription.
Infections
The major component of IkappaBalpha proteolysis occurs independently of the proteasome pathway in respiratory syncytial virus-infected pulmonary epithelial cells.
Infections
The Npro product of classical swine fever virus interacts with IkappaBalpha, the NF-kappaB inhibitor.
Infections
The protein kinase IKKepsilon can inhibit HCV expression independently of IFN and its own expression is downregulated in HCV-infected livers.
Infections
The role of IKK? in Venezuelan equine encephalitis virus infection.
Infections
The role of the IKK complex in viral infections.
Infections
The small GTP-binding protein Rac1 induces cardiac myocyte hypertrophy through the activation of apoptosis signal-regulating kinase 1 and nuclear factor-kappa B.
Infections
Triggering of DC migration by dengue virus stimulation of COX-2-dependent signaling cascades in vitro highlights the significance of these cascades beyond inflammation.
Infections
Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells.
Infections
Venezuelan Equine Encephalitis Virus nsP3 Phosphorylation Can Be Mediated by IKK? Kinase Activity and Abrogation of Phosphorylation Inhibits Negative-Strand Synthesis.
Infections
Vitamin D Alleviates Rotavirus Infection through a Microrna-155-5p Mediated Regulation of the TBK1/IRF3 Signaling Pathway In Vivo and In Vitro.
Infections
Zebrafish FGFR3 is a negative regulator of RLR pathway to decrease IFN expression.
Inflammatory Bowel Diseases
An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice.
Inflammatory Breast Neoplasms
Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade.
Influenza, Human
HERP Binds TBK1 To Activate Innate Immunity and Repress Virus Replication in Response to Endoplasmic Reticulum Stress.
Influenza, Human
Influenza virus-induced NF-kappaB-dependent gene expression is mediated by overexpression of viral proteins and involves oxidative radicals and activation of IkappaB kinase.
Influenza, Human
The IkappaB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells.
Insulin Resistance
A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance.
Insulin Resistance
Amelioration of glucose tolerance by hepatic inhibition of nuclear factor kappaB in db/db mice.
Insulin Resistance
An EGFR Tyrosine-Kinase Inhibitor (PD153035) Improves Glucose Tolerance and Insulin Action in High-Fat Diet-Fed Mice.
Insulin Resistance
Animal models of steatohepatitis.
Insulin Resistance
Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice.
Insulin Resistance
Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta.
Insulin Resistance
Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation.
Insulin Resistance
Common inhibitory serine sites phosphorylated by IRS-1 kinases, triggered by insulin and inducers of insulin resistance.
Insulin Resistance
Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance.
Insulin Resistance
Fatty acid-induced insulin resistance in L6 myotubes is prevented by inhibition of activation and nuclear localization of nuclear factor kappa B.
Insulin Resistance
Feed-forward Signaling of TNF{alpha} and NF{kappa}B via IKK{beta} Pathway contributes to Insulin Resistance and Coronary Arteriolar Dysfunction in Type 2 Diabetic Mice.
Insulin Resistance
Heat treatment improves glucose tolerance and prevents skeletal muscle insulin resistance in rats fed a high-fat diet.
Insulin Resistance
High-fat diet induces Ikkbeta and reduces insulin sensitivity in rats with low running capacity.
Insulin Resistance
HSP72 protects against obesity-induced insulin resistance.
Insulin Resistance
Hypertension and insulin resistance are not directly related in obese dogs.
Insulin Resistance
Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet.
Insulin Resistance
IKK-beta links inflammation to obesity-induced insulin resistance.
Insulin Resistance
IKKbeta suppression of TSC1 function links the mTOR pathway with insulin resistance.
Insulin Resistance
Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance.
Insulin Resistance
IRS-1 regulation in health and disease.
Insulin Resistance
Is NF-kappaB a culprit in type 2 diabetes?
Insulin Resistance
JNK1 and IKK{beta}: molecular links between obesity and metabolic dysfunction.
Insulin Resistance
L-glutamine supplementation induces insulin resistance in adipose tissue and improves insulin signalling in liver and muscle of rats with diet-induced obesity.
Insulin Resistance
Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB.
Insulin Resistance
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.
Insulin Resistance
Mechanism for improved insulin sensitivity after gastric bypass surgery.
Insulin Resistance
Molecular mechanism of interactions between Chrysin and I-kappa-B kinase epsilon (IKKe)/Tank Binding Kinase-1(TBK1): Cell based assay and insilico molecular docking studies.
Insulin Resistance
Oxidized LDL impair adipocyte response to insulin by activating serine/threonine kinases.
Insulin Resistance
Potential utility of natural polyphenols for reversing fat-induced insulin resistance.
Insulin Resistance
Prevention of fat-induced insulin resistance by salicylate.
Insulin Resistance
Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease.
Insulin Resistance
Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta.
Insulin Resistance
Review article: diabetes and atherosclerosis--running on a common road.
Insulin Resistance
Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo.
Insulin Resistance
Salicylic acid reverses phorbol 12-myristate-13-acetate (PMA)- and tumor necrosis factor alpha (TNFalpha)-induced insulin receptor substrate 1 (IRS1) serine 307 phosphorylation and insulin resistance in human embryonic kidney 293 (HEK293) cells.
Insulin Resistance
Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome.
Insulin Resistance
siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle.
Insulin Resistance
TANK-binding kinase 1 mediates phosphorylation of insulin receptor at serine residue 994: a potential link between inflammation and insulin resistance.
Insulin Resistance
The obese healthy paradox: is inflammation the answer?
Insulin Resistance
The protein kinase IKKepsilon regulates energy balance in obese mice.
Insulin Resistance
Variant in the 3' Region of the IkappaBalpha Gene Associated With Insulin Resistance in Hispanic Americans: The IRAS Family Study.
Insulin Resistance
[Effects of berberine on serum levels of inflammatory factors and inflammatory signaling pathway in obese mice induced by high fat diet]
Klatskin Tumor
Effect of mutated IkappaBalpha transfection on multidrug resistance in hilar cholangiocarcinoma cell lines.
Latent Infection
Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway.
Latent Infection
Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta.
Latent Infection
New Mechanism by Which Human Cytomegalovirus MicroRNAs Negate the Proinflammatory Response to Infection.
Latent Infection
NF-?B activation coordinated by IKK? and IKK? enables latent infection of Kaposi's sarcoma-associated herpesvirus.
Leukemia
1alpha,25-dihydroxyvitamin D3 stimulates phosphorylation of IkappaBalpha and synergizes with TPA to induce nuclear translocation of NFkappaB during monocytic differentiation of NB4 leukemia cells.
Leukemia
An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism.
Leukemia
Critical roles of I?B kinase subunits in mast cell degranulation.
Leukemia
Distinct IkappaB kinase regulation in adult T cell leukemia and HTLV-I-transformed cells.
Leukemia
Enhanced proteolysis of IkappaBalpha and IkappaBbeta proteins in astrocytes by Moloney murine leukemia virus (MoMuLV)-ts1 infection: a potential mechanism of NF-kappaB activation.
Leukemia
IKKgamma mediates the interaction of cellular IkappaB kinases with the tax transforming protein of human T cell leukemia virus type 1.
Leukemia
Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells.
Leukemia
Inhibition of NF-kappaB by mutant IkappaBalpha enhances TNF-alpha-induced apoptosis in HL-60 cells by controlling bcl-xL expression.
Leukemia
Maximal adamantyl-substituted retinoid-related molecule-induced apoptosis requires NF-kappaB noncanonical and canonical pathway activation.
Leukemia
Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells.
Leukemia
Mutational analysis of IkappaBalpha in hematologic malignancies.
Leukemia
Role of adapter function in oncoprotein-mediated activation of NF-kappaB. Human T-cell leukemia virus type I Tax interacts directly with IkappaB kinase gamma.
Leukemia
Siva-1 Promotes K-48 Polyubiquitination of TRAF2 and Inhibits TCR-Mediated Activation of NF-kappaB.
Leukemia
Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.
Leukemia, Erythroblastic, Acute
NF-kappaB transcription factors are involved in normal erythropoiesis.
Leukemia, Hairy Cell
Mutational analysis of IkappaBalpha in hematologic malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541.
Leukemia, Lymphocytic, Chronic, B-Cell
Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mutational analysis of IkappaBalpha in hematologic malignancies.
Leukemia, Myeloid
Mutational analysis of IkappaBalpha in hematologic malignancies.
Leukemia, Myeloid, Acute
Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.
Leukemia, Myeloid, Acute
Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts.
Leukemia, Myeloid, Acute
Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia.
Leukemia, T-Cell
Activation of IKKalpha and IKKbeta through their fusion with HTLV-I tax protein.
Leukemia, T-Cell
Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions.
Leukemia, T-Cell
Distinct IkappaB kinase regulation in adult T cell leukemia and HTLV-I-transformed cells.
Leukemia, T-Cell
Downregulation of active IKK beta by Ro52-mediated autophagy.
Leukemia, T-Cell
Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins.
Leukemia, T-Cell
Human T-cell leukemia virus type 1 Tax induction of NF-kappaB involves activation of the IkappaB kinase alpha (IKKalpha) and IKKbeta cellular kinases.
Leukemia, T-Cell
IKKgamma mediates the interaction of cellular IkappaB kinases with the tax transforming protein of human T cell leukemia virus type 1.
Leukemia, T-Cell
IKKgamma serves as a docking subunit of the IkappaB kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus Tax protein.
Leukemia, T-Cell
In vitro activation of the IkappaB kinase complex by human T-cell leukemia virus type-1 Tax.
Leukemia, T-Cell
NF-kappaB-inducing kinase and IkappaB kinase participate in human T-cell leukemia virus I Tax-mediated NF-kappaB activation.
Leukemia, T-Cell
Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha.
Leukemia, T-Cell
Role of adapter function in oncoprotein-mediated activation of NF-kappaB. Human T-cell leukemia virus type I Tax interacts directly with IkappaB kinase gamma.
Leukemia, T-Cell
Stimulation of IKK-gamma oligomerization by the human T-cell leukemia virus oncoprotein Tax.
Leukemia, T-Cell
Targeting Autophagic Regulation of NFkappaB in HTLV-I Transformed Cells by Geldanamycin: Implications for Therapeutic Interventions.
Leukemia, T-Cell
The human T-cell leukemia virus type-1 Tax protein regulates the activity of the IkappaB kinase complex.
Leukemia, T-Cell
The tax oncoprotein of human T-cell leukemia virus type 1 associates with and persistently activates IkappaB kinases containing IKKalpha and IKKbeta.
Leukemia-Lymphoma, Adult T-Cell
Induction of cell death in adult T-cell leukemia cells by a novel IkappaB kinase inhibitor.
Leukemia-Lymphoma, Adult T-Cell
Mutational analysis of IkappaBalpha in hematologic malignancies.
Leukemia-Lymphoma, Adult T-Cell
Targeting Autophagic Regulation of NFkappaB in HTLV-I Transformed Cells by Geldanamycin: Implications for Therapeutic Interventions.
Leukemia-Lymphoma, Adult T-Cell
Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells.
Leukopenia
Activation of the cholinergic anti-inflammatory pathway reduces NF-kappab activation, blunts TNF-alpha production, and protects againts splanchic artery occlusion shock.
Liver Cirrhosis
Angiotensin II Activates IkappaB Kinase Phosphorylation of RelA at Ser(536) to Promote Myofibroblast Survival and Liver Fibrosis.
Liver Cirrhosis
Dual TBK1/IKK? inhibitor amlexanox attenuates the severity of hepatotoxin-induced liver fibrosis and biliary fibrosis in mice.
Liver Diseases
Lipotoxicity reduces DDX58/Rig-1 expression and activity leading to impaired autophagy and cell death.
Liver Failure
Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality.
Liver Failure
p38alpha MAPK inhibits JNK activation and collaborates with IkappaB kinase 2 to prevent endotoxin-induced liver failure.
Liver Neoplasms
High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer.
Liver Neoplasms
Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro and in vivo.
Liver Neoplasms
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.
Low Tension Glaucoma
Genomic Organization of TBK1 Copy Number Variations in Glaucoma Patients.
Lung Diseases
Glutaredoxin 1 regulates cigarette smoke-mediated lung inflammation through differential modulation of I{kappa}B kinases in mice: impact on histone acetylation.
Lung Diseases
Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation.
Lung Injury
Duration and Intensity of NF-{kappa}B Activity Determine the Severity of Endotoxin-Induced Acute Lung Injury.
Lung Injury
Enhanced heat shock protein 70 expression alters proteasomal degradation of IkappaB kinase in experimental acute respiratory distress syndrome.
Lung Injury
[Effects of nuclear factor-kappaB on ventilator induced lung biotrauma by higher tidal volume and its interaction with pro-inflammatory cytokines]
Lung Neoplasms
Blockage of NF-kappaB by IKKbeta- or RelA-siRNA rather than the NF-kappaB super-suppressor IkappaBalpha mutant potentiates adriamycin-induced cytotoxicity in lung cancer cells.
Lung Neoplasms
Blocking TBK1 alleviated radiation-induced pulmonary fibrosis and epithelial-mesenchymal transition through Akt-Erk inactivation.
Lung Neoplasms
Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells.
Lung Neoplasms
Gallic acid suppresses lipopolysaccharide-induced nuclear factor-kappaB signaling by preventing RelA acetylation in A549 lung cancer cells.
Lung Neoplasms
Gene transfer of inhibitor kappaB in human lung cancer cell line NCI-H460 inhibits tumorigenesis and angiogenesis in vivo.
Lung Neoplasms
IkappaBalpha gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-alpha-mediated cell death.
Lung Neoplasms
Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells.
Lung Neoplasms
Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis.
Lung Neoplasms
TBK1 kinase addiction in lung cancer cells is mediated via autophagy of Tax1bp1/Ndp52 and non-canonical NF-?B signalling.
Lung Neoplasms
Transfer of IkappaBalpha gene increase the sensitivity of paclitaxel mediated with caspase 3 activation in human lung cancer cell.
Lung Neoplasms
Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation.
Lung Neoplasms
Using RNA Interference in Lung Cancer Cells to Target the IKK-NF-?B Pathway.
Lung Neoplasms
[Inhibition of NF-kappaB through IkappaBalpha transfection affects invasion of human lung cancer cell line A549]
Lupus Erythematosus, Systemic
I kappa B alpha promoter polymorphisms in patients with systemic lupus erythematosus.
Lyme Disease
Systematic analysis highlights the key role of TLR2/NF-kappaB/MAP kinase signaling for IL-8 induction by macrophage-like THP-1 cells under influence of Borrelia burgdorferi lysates.
Lymphadenopathy
Inhibition of NF-kappaB in T cells blocks lymphoproliferation and partially rescues autoimmune disease in gld/gld mice.
Lymphoma
Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.
Lymphoma
Activation of NF-kappaB by hepatitis B virus X protein through an IkappaB kinase-independent mechanism.
Lymphoma
Altered regulation of cyclic AMP-dependent protein kinase in a mouse lymphoma cell line.
Lymphoma
Characterization of TAE684 as a potent LRRK2 kinase inhibitor.
Lymphoma
Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen.
Lymphoma
I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.
Lymphoma
Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma.
Lymphoma
IkappaBalpha overexpression delays tumor formation in v-rel transgenic mice.
Lymphoma
Interleukin-13-induced type II polarization of inflammatory macrophages is mediated through suppression of nuclear factor-kappaB and preservation of IkappaBalpha in a T cell lymphoma.
Lymphoma
KSHV vFLIP binds to IKK-gamma to activate IKK.
Lymphoma
Mutational analysis of IkappaBalpha in hematologic malignancies.
Lymphoma
Oncogenic activation of NF-kappaB.
Lymphoma
Protein phosphorylation as a key mechanism for the regulation of BCL-3 activity.
Lymphoma
Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level.
Lymphoma
Subunit interaction in cyclic AMP-dependent protein kinase of mutant lymphoma cells.
Lymphoma
The synthetic epoxyquinoids jesterone dimer and epoxyquinone A monomer induce apoptosis and inhibit REL (human c-Rel) DNA binding in an IkappaBalpha-deficient diffuse large B-cell lymphoma cell line.
Lymphoma
TRIM41 is required to innate antiviral response by polyubiquitinating BCL10 and recruiting NEMO.
Lymphoma, B-Cell
A cell-based assay for IkappaBalpha stabilization using a two-color dual luciferase-based sensor.
Lymphoma, B-Cell
Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.
Lymphoma, B-Cell
Mutational analysis of the IkappaBalpha gene in activated B cell-like diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
Lymphoma, Large B-Cell, Diffuse
A cell-based assay for IkappaBalpha stabilization using a two-color dual luciferase-based sensor.
Lymphoma, Large B-Cell, Diffuse
Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.
Lymphoma, Large B-Cell, Diffuse
Mutational analysis of the IkappaBalpha gene in activated B cell-like diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
Lymphoma, Mantle-Cell
Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level.
Lymphoma, Primary Effusion
KSHV vFLIP binds to IKK-gamma to activate IKK.
Lymphoma, T-Cell
Activation of NF-kappaB by hepatitis B virus X protein through an IkappaB kinase-independent mechanism.
Lymphoma, T-Cell
Interleukin-13-induced type II polarization of inflammatory macrophages is mediated through suppression of nuclear factor-kappaB and preservation of IkappaBalpha in a T cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents.
Malaria
FOSL1 Inhibits Type I Interferon Responses to Malaria and Viral Infections by Blocking TBK1 and TRAF3/TRIF Interactions.
Measles
Measles virus V protein is a decoy substrate for IkappaB kinase alpha and prevents Toll-like receptor 7/9-mediated interferon induction.
Melanoma
BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways.
Melanoma
Conditional ablation of Ikkb inhibits melanoma tumor development in mice.
Melanoma
Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells.
Melanoma
Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
Melanoma
DEAF1 Is a Pellino1-interacting Protein Required for Interferon Production by Sendai Virus and Double-stranded RNA.
Melanoma
Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription.
Melanoma
Fish MITA Serves as a Mediator for Distinct Fish IFN Gene Activation Dependent on IRF3 or IRF7.
Melanoma
Influenza A Virus PA Antagonizes Interferon-? by Interacting with Interferon Regulatory Factor 3.
Melanoma
KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment.
Melanoma
Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity.
Melanoma
mda-9/Syntenin regulates the metastatic phenotype in human melanoma cells by activating nuclear factor-kappaB.
Melanoma
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Melanoma
N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of kappaB kinase beta expression.
Melanoma
NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Melanoma
Responses of the Toll-like receptor and melanoma differentiation-associated protein 5 signaling pathways to avian infectious bronchitis virus infection in chicks.
Melanoma
Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth.
Melanoma
The IKK?-dependent non-canonical pathway of NF-?B activation is constitutively active and modulates progression-related functions in a subset of human melanomas.
Melanoma
The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells.
Melanoma
The protein kinase IKKepsilon contributes to tumour growth and tumour pain in a melanoma model.
Melanoma
The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells.
Memory Disorders
Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort.
Memory Disorders
The IkappaB kinase regulates chromatin structure during reconsolidation of conditioned fear memories.
Metabolic Diseases
IKKepsilon: a bridge between obesity and inflammation.
Metabolic Diseases
TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery.
Metabolic Syndrome
Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome.
Microcephaly
Combination of linkage mapping and microarray-expression analysis identifies NF-kappaB signaling defect as a cause of autosomal-recessive mental retardation.
Migraine Disorders
NF-kappaB activity and iNOS expression in monocytes from internal jugular blood of migraine without aura patients during attacks.
Migraine Disorders
Nuclear factor-kappaB as a molecular target for migraine therapy.
Motor Neuron Disease
Association of the TBK1 mutation p.Ile334Thr with frontotemporal dementia and literature review.
Motor Neuron Disease
Variable clinical phenotype in TBK1 mutations: case report of a novel mutation causing primary progressive aphasia and review of the literature.
Mouth Neoplasms
Potentiation of tumor necrosis factor-mediated apoptosis of oral squamous cell carcinoma cells by adenovirus-mediated gene transfer of NF-kappaB inhibitor.
Multiple Myeloma
Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis.
Multiple Myeloma
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
Multiple Myeloma
Evidence for a phosphorylation-independent role for Ser 32 and 36 in proteasome inhibitor-resistant (PIR) IkappaBalpha degradation in B cells.
Multiple Myeloma
Growth inhibition of multiple myeloma cells by a novel IkappaB kinase inhibitor.
Multiple Myeloma
Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma.
Multiple Myeloma
Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.
Multiple Myeloma
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Multiple Myeloma
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
Multiple Sclerosis
Neuronal I kappa B kinase beta protects mice from autoimmune encephalomyelitis by mediating neuroprotective and immunosuppressive effects in the central nervous system.
Murine Acquired Immunodeficiency Syndrome
Activation of the ubiquitin proteolytic system in murine acquired immunodeficiency syndrome affects IkappaBalpha turnover.
Muscle Cramp
NF-kappaB-Dependent Induction of Cathelicidin-Related Antimicrobial Peptide in Murine Mast Cells by Lipopolysaccharide.
Muscular Atrophy
Inhibition of IkappaB kinase alpha (IKK?) or IKKbeta (IKK?) plus forkhead box O (Foxo) abolishes skeletal muscle atrophy.
Muscular Atrophy
Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action.
Muscular Atrophy
Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy.
Muscular Atrophy
The IkappaB kinases IKKalpha and IKKbeta are necessary and sufficient for skeletal muscle atrophy.
Muscular Atrophy
The Proteasome Inhibitor MG132 Reduces Immobilization-Induced Skeletal Muscle Atrophy in Mice.
Muscular Disorders, Atrophic
The IkappaB kinases IKKalpha and IKKbeta are necessary and sufficient for skeletal muscle atrophy.
Muscular Dystrophies, Limb-Girdle
Beta-defensin overexpression induces progressive muscle degeneration in mice.
Myelodysplastic Syndromes
Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.
Myelodysplastic Syndromes
Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia.
Myelodysplastic Syndromes
Mutational analysis of IkappaBalpha in hematologic malignancies.
Myocardial Ischemia
Early activation of IKKbeta during in vivo myocardial ischemia.
Myocardial Ischemia
Early activation of transcription factor NF-kappaB during ischemia in perfused rat heart.
Myocardial Reperfusion Injury
Sesquiterpene lactone parthenolide, an inhibitor of IkappaB kinase complex and nuclear factor-kappaB, exerts beneficial effects in myocardial reperfusion injury.
Myocardial Reperfusion Injury
Sesquiterpene lactone parthenolide, an inhibitor of IkappaB kinase complex and nuclear factor-kappaB, exerts beneficial effects in myocardial reperfusion injury. Shock 17(2):127-134, 2002.
Myocarditis
Attenuation of NF-kappaB signalling in rat cardiomyocytes at birth restricts the induction of inflammatory genes.
Nasopharyngeal Carcinoma
Ikappa B kinase alpha involvement in the development of nasopharyngeal carcinoma through a NF-?B-independent and ERK-dependent pathway.
Nasopharyngeal Carcinoma
Increase in IkappaB kinase alpha expression suppresses the tumor progression and improves the prognosis for nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
[IkappaB alpha mRNA expression and its DNA sequence in nasopharyngeal carcinoma cell lines]
Neoplasm Metastasis
A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas.
Neoplasm Metastasis
A ginseng saponin metabolite suppresses tumor necrosis factor-alpha-promoted metastasis by suppressing nuclear factor-kappaB signaling in murine colon cancer cells.
Neoplasm Metastasis
Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis.
Neoplasm Metastasis
Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-?B: implication in breast cancer metastasis.
Neoplasm Metastasis
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer.
Neoplasm Metastasis
High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer.
Neoplasm Metastasis
Ikappa B kinasebeta/nuclear factor-kappaB activation controls the development of liver metastasis by way of interleukin-6 expression.
Neoplasm Metastasis
IKK? inibition by a glucosamine derivative enhances Maspin expression in osteosarcoma cell line.
Neoplasm Metastasis
IKKalpha at the crossroads of inflammation and metastasis.
Neoplasm Metastasis
Loss of IKKbeta activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis.
Neoplasm Metastasis
miR-146a suppresses invasion of pancreatic cancer cells.
Neoplasm Metastasis
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin.
Neoplasm Metastasis
Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells.
Neoplasm Metastasis
Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo.
Neoplasm Metastasis
Reduction in IkappaB kinase alpha expression promotes the development of skin papillomas and carcinomas.
Neoplasm Metastasis
The Specific IKK?/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-?B and MAP Kinase Pathways.
Neoplasms
17-Acetoxyjolkinolide B irreversibly inhibits IkappaB kinase and induces apoptosis of tumor cells.
Neoplasms
25-Hydroxycholesterol, 7beta-hydroxycholesterol and 7-ketocholesterol upregulate interleukin-8 expression independently of Toll-like receptor 1, 2, 4 or 6 signalling in human macrophages.
Neoplasms
5-Fluorouracil suppression of NF-KappaB is mediated by the inhibition of IKappab kinase activity in human salivary gland cancer cells.
Neoplasms
A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas.
Neoplasms
A novel function of InIB from Listeria monocytogenes: activation of NF-kappaB in J774 macrophages.
Neoplasms
A novel ubiquitin-like domain in IkappaB kinase beta is required for functional activity of the kinase.
Neoplasms
A novel Zinc finger protein, ZCCHC11, interacts with TIFA and modulates TLR signaling.
Neoplasms
A review on the role of TANK-binding kinase 1 signaling in cancer.
Neoplasms
A role for NF-kappaB essential modifier/IkappaB kinase-gamma (NEMO/IKKgamma) ubiquitination in the activation of the IkappaB kinase complex by tumor necrosis factor-alpha.
Neoplasms
A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells.
Neoplasms
A small molecule, (E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) phenol suppresses tumor growth via inhibition of IkappaB kinase ? in colorectal cancer
Neoplasms
A20 inhibits NF-kappaB activation in endothelial cells without sensitizing to tumor necrosis factor-mediated apoptosis.
Neoplasms
Activation of NF-kappaB by extracellular S100A4: analysis of signal transduction mechanisms and identification of target genes.
Neoplasms
Activation of NF-kappaB by hepatitis B virus X protein through an IkappaB kinase-independent mechanism.
Neoplasms
Activation of NF-{kappa}B Signaling by Inhibitor of NF-{kappa}B Kinase {beta} Increases Aggressiveness of Ovarian Cancer.
Neoplasms
Activation of nuclear factor kappaB and Bcl-x survival gene expression by nerve growth factor requires tyrosine phosphorylation of IkappaBalpha.
Neoplasms
Activation of nuclear factor-kappaB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529.
Neoplasms
Activation of phosphatidylinositol 3-kinase and c-Jun-N-terminal kinase cascades enhances NF-kappaB-dependent gene transcription in BCG-stimulated macrophages through promotion of p65/p300 binding.
Neoplasms
Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin.
Neoplasms
Activation of the cholinergic anti-inflammatory pathway reduces NF-kappab activation, blunts TNF-alpha production, and protects againts splanchic artery occlusion shock.
Neoplasms
Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions.
Neoplasms
Activation of the Ikappa B kinases by RIP via IKKgamma /NEMO-mediated oligomerization.
Neoplasms
Adenovirus-mediated inhibitor kappaB gene transfer improves the chemosensitivity to anticancer drugs in human lung cancer in vitro and in vivo.
Neoplasms
Adiponectin suppresses IkappaB kinase activation induced by tumor necrosis factor-alpha or high glucose in endothelial cells: role of cAMP and AMP kinase signaling.
Neoplasms
African swine fever virus IAP-like protein induces the activation of nuclear factor kappa B.
Neoplasms
AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin.
Neoplasms
All roads lead to mTOR: integrating inflammation and tumor angiogenesis.
Neoplasms
An antiinflammatory role for IKKbeta through the inhibition of "classical" macrophage activation.
Neoplasms
An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4.
Neoplasms
Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway.
Neoplasms
Angiotensin II upregulates Toll-like receptor 4 and enhances lipopolysaccharide-induced CD40 expression in rat peritoneal mesothelial cells.
Neoplasms
Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice.
Neoplasms
Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model.
Neoplasms
Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.
Neoplasms
Antiproliferative, cytotoxic and hemolytic activities of a triterpene glycoside from Psolus patagonicus and its desulfated analog.
Neoplasms
Antiviral gene expression in rheumatoid arthritis: role of IKKepsilon and interferon regulatory factor 3.
Neoplasms
Arachidonic acid influences proinflammatory gene induction by stabilizing the inhibitor-kappaBalpha/nuclear factor-kappaB (NF-kappaB) complex, thus suppressing the nuclear translocation of NF-kappaB.
Neoplasms
Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer.
Neoplasms
Assessment of TANK-binding kinase 1 as a therapeutic target in cancer.
Neoplasms
Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation.
Neoplasms
Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival.
Neoplasms
Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha.
Neoplasms
B-cell translocation gene 2 mediates crosstalk between PI3K/Akt1 and NFkappaB pathways which enhances transcription of MnSOD by accelerating IkappaBalpha degradation in normal and cancer cells.
Neoplasms
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer.
Neoplasms
Bcl-2 activates the transcription factor NFkappaB through the degradation of the cytoplasmic inhibitor IkappaBalpha.
Neoplasms
Bcl-2 intersects the NFkappaB signalling pathway and suppresses apoptosis in ventricular myocytes.
Neoplasms
betaTrCP-mediated proteolysis of NF-kappaB1 p105 requires phosphorylation of p105 serines 927 and 932.
Neoplasms
Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.
Neoplasms
Blocking caspase-3-mediated proteolysis of IKKbeta suppresses TNF-alpha-induced apoptosis.
Neoplasms
Bortezomib induces canonical NF-{kappa}B activation in multiple myeloma cells.
Neoplasms
Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity.
Neoplasms
Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells.
Neoplasms
Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue.
Neoplasms
c-Src-dependent tyrosine phosphorylation of IKKbeta is involved in tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 expression.
Neoplasms
Calagualine inhibits nuclear transcription factors-kappaB activated by various inflammatory and tumor promoting agents.
Neoplasms
Cantharidin-induced acute hepatotoxicity: the role of TNF-?, IKK-?, Bcl-2, Bax and caspase3.
Neoplasms
Capsaicin, a Component of Red Peppers, Inhibits the Growth of Androgen-Independent, p53 Mutant Prostate Cancer Cells.
Neoplasms
CARMA3 is Crucial for EGFR-Induced Activation of NF-{kappa}B and Tumor Progression.
Neoplasms
Caspase cleavage product lacking amino-terminus of IkappaBalpha sensitizes resistant cells to TNF-alpha and TRAIL-induced apoptosis.
Neoplasms
Caspase-mediated cleavage of hematopoietic progenitor kinase 1 (HPK1) converts an activator of NFkappaB into an inhibitor of NFkappaB.
Neoplasms
Characterization of a profile of the anthocyanins isolated from Vitis coignetiae Pulliat and their anti-invasive activity on HT-29 human colon cancer cells.
Neoplasms
Characterization of NFkappaB activation by detection of green fluorescent protein-tagged IkappaB degradation in living cells.
Neoplasms
Characterization of protein tyrosine kinase activity in murine Leydig tumor cells.
Neoplasms
Characterization of the Inhibitor of KappaB Kinase (IKK) Complex in Granulosa Cell Tumors of the Ovary and Granulosa Cell Tumor-Derived Cell Lines.
Neoplasms
Chondroitin-4-sulphate reduced oxidative injury in caerulein-induced pancreatitis in mice: the involvement of NF-kappaB translocation and apoptosis activation.
Neoplasms
Clinical implications of inflammatory cytokines in the cochlea: a technical note.
Neoplasms
Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma.
Neoplasms
Cloning and characterization of a homologue of the alpha inhibitor of NF-kappaB in Rainbow trout (Oncorhynchus mykiss).
Neoplasms
Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen.
Neoplasms
Conditional ablation of Ikkb inhibits melanoma tumor development in mice.
Neoplasms
Conjugated linoleic acid promotes human adipocyte insulin resistance through NFkappaB-dependent cytokine production.
Neoplasms
Conjugated polyhydroxybenzene derivatives block tumor necrosis factor-alpha-mediated nuclear factor-kappaB activation and cyclooxygenase-2 gene transcription by targeting IkappaB kinase activity.
Neoplasms
Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice.
Neoplasms
Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth.
Neoplasms
Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB.
Neoplasms
Cowpox virus and other members of the orthopoxvirus genus interfere with the regulation of NF-kappaB activation.
Neoplasms
Critical role of IkappaB kinase alpha in embryonic skin development and skin carcinogenesis.
Neoplasms
Crosstalk between keratinocytes and adaptive immune cells in an IkappaBalpha protein-mediated inflammatory disease of the skin.
Neoplasms
Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation.
Neoplasms
Curcumin Alleviates Lipopolysaccharide (LPS)-Activated Neuroinflammation via Modulation of miR-199b-5p/I?B Kinase ? (IKK?)/Nuclear Factor Kappa B (NF-?B) Pathway in Microglia.
Neoplasms
Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation.
Neoplasms
Current topics in pharmacological research on bone metabolism: osteoclast differentiation regulated by glycosphingolipids.
Neoplasms
Cystatin cures visceral leishmaniasis by NF-?B-mediated proinflammatory response through co-ordination of TLR/MyD88 signaling with p105-Tpl2-ERK pathway.
Neoplasms
Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers.
Neoplasms
Defective immune responses in mice lacking LUBAC-mediated linear ubiquitination in B cells.
Neoplasms
Defective NF-kappaB activation in virus-infected neuronal cells is restored by genetic complementation.
Neoplasms
Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma.
Neoplasms
Deguelin inhibits expression of IkappaBalpha protein in Raji and U937 cells.
Neoplasms
Depletion of histone deacetylase protein: a common consequence of inflammatory cytokine signaling?
Neoplasms
Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer.
Neoplasms
Different modes of NF-kappaB/Rel activation in pancreatic lobules.
Neoplasms
Differential activation of the IkappaBalpha and mouse mammary tumor virus promoters by progesterone and glucocorticoid receptors.
Neoplasms
Differential effects of lipopolysaccharide and tumor necrosis factor on monocytic IkappaB kinase signalsome activation and IkappaB proteolysis.
Neoplasms
Differential effects of Ras signaling through NFkappaB on skeletal myogenesis.
Neoplasms
Differential effects of tumor necrosis factor-alpha and CD40L on NF-kappaB inhibitory proteins IkappaBalpha, beta and epsilon and on the induction of the Jun amino-terminal kinase pathway in Ramos Burkitt lymphoma cells.
Neoplasms
Differential IkappaB kinase activation and IkappaBalpha degradation by interleukin-1beta and tumor necrosis factor-alpha in human U937 monocytic cells. Evidence for additional regulatory steps in kappaB-dependent transcription.
Neoplasms
Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt.
Neoplasms
Differential regulation of c-Jun N-terminal kinase and NF-kappaB pathway by caffeic acid phenethyl ester in astroglial and monocytic cells.
Neoplasms
Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3.
Neoplasms
Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha.
Neoplasms
Discovery of novel potent nuclear factor kappa-B inhibitors (IKK-?) via extensive ligand-based modeling and virtual screening.
Neoplasms
Divergent effect of proteasome inhibition on interleukin-1beta and tumor necrosis factor alpha signaling in human astroglial cells.
Neoplasms
Dynein light chain LC8 negatively regulates NF-kappaB through the redox-dependent interaction with IkappaBalpha.
Neoplasms
E1A inhibition of radiation-induced NF-kappaB activity through suppression of IKK activity and IkappaB degradation, independent of Akt activation.
Neoplasms
Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors.
Neoplasms
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Neoplasms
Effectiveness of IkappaB kinase inhibitors in murine colitis-associated tumorigenesis.
Neoplasms
Effects of NFKB1 and NFKBIA gene polymorphisms on susceptibility to environmental factors and the clinicopathologic development of oral cancer.
Neoplasms
Effects of the NIK aly mutation on NF-kappaB activation by the Epstein-Barr virus latent infection membrane protein, lymphotoxin beta receptor, and CD40.
Neoplasms
Effects of three superoxide dismutase genes delivered with an adenovirus on graft function after transplantation of fatty livers in the rat.
Neoplasms
Efferent vagal fibre stimulation blunts nuclear factor-kappaB activation and protects against hypovolemic hemorrhagic shock.
Neoplasms
Enhanced IkappaB kinase activity is responsible for the augmented activity of NF-kappaB in human head and neck carcinoma cells.
Neoplasms
Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation.
Neoplasms
Epigenetic inactivation of IkappaB Kinase-alpha in oral carcinomas and tumor progression.
Neoplasms
Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6.
Neoplasms
Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex.
Neoplasms
Essential role for verotoxin in sustained stress-activated protein kinase and nuclear factor kappa B signaling, stimulated by Escherichia coli O157:H7 in Vero cells.
Neoplasms
Essential role of human leukocyte antigen-encoded proteasome subunits in NF-kappaB activation and prevention of tumor necrosis factor-alpha-induced apoptosis.
Neoplasms
Essential role of nuclear factor (NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lymphotoxin beta receptor, but not through tumor necrosis factor receptor I.
Neoplasms
Eugenol inhibits cell proliferation via NF-kappaB suppression in a rat model of gastric carcinogenesis induced by MNNG.
Neoplasms
Experimental study on early protective effect of ischemic preconditioning on rat kidney graft.
Neoplasms
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.
Neoplasms
Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue.
Neoplasms
Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients.
Neoplasms
FAF1 suppresses IkappaB kinase (IKK) activation by disrupting the IKK complex assembly.
Neoplasms
Feed-forward Signaling of TNF{alpha} and NF{kappa}B via IKK{beta} Pathway contributes to Insulin Resistance and Coronary Arteriolar Dysfunction in Type 2 Diabetic Mice.
Neoplasms
Fludarabine induces growth arrest and apoptosis of cytokine- or alloantigen-stimulated peripheral blood mononuclear cells, and decreases production of Th1 cytokines via inhibition of nuclear factor kappaB.
Neoplasms
FoxO: linking new signaling pathways.
Neoplasms
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Neoplasms
Functional isoforms of IkappaB kinase alpha (IKKalpha) lacking leucine zipper and helix-loop-helix domains reveal that IKKalpha and IKKbeta have different activation requirements.
Neoplasms
G2019s LRRK2 promotes mitochondrial fission and increases TNF?-mediated neuroinflammation responses.
Neoplasms
Gabexate mesilate, a synthetic anticoagulant, inhibits the expression of endothelial leukocyte adhesion molecules in vitro.
Neoplasms
Gain-of-Function Mutations in the Toll-Like Receptor Pathway: TPL2-Mediated ERK1/ERK2 MAPK Activation, a Path to Tumorigenesis in Lymphoid Neoplasms?
Neoplasms
Gastrin activates nuclear factor kappaB (NFkappaB) through a protein kinase C dependent pathway involving NFkappaB inducing kinase, inhibitor kappaB (IkappaB) kinase, and tumour necrosis factor receptor associated factor 6 (TRAF6) in MKN-28 cells transfected with gastrin receptor.
Neoplasms
Gene transfer of inhibitor kappaB in human lung cancer cell line NCI-H460 inhibits tumorigenesis and angiogenesis in vivo.
Neoplasms
Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor.
Neoplasms
Genetic instability in Hodgkin's lymphoma.
Neoplasms
Glucocorticoid suppression of CX3CL1 (fractalkine) by reduced gene promoter recruitment of NF-kappaB.
Neoplasms
Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis.
Neoplasms
Growth Inhibition and Apoptosis Induction by Tumor Necrosis Factor-alpha in Human Urethral Rhabdosphincter Satellite Cells.
Neoplasms
Hepatitis B Virus Polymerase Suppresses NF-?B Signaling by Inhibiting the Activity of IKKs via Interaction with Hsp90?.
Neoplasms
Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta.
Neoplasms
Hepatitis C virus nonstructural 5B protein regulates tumor necrosis factor alpha signaling through effects on cellular IkappaB kinase.
Neoplasms
Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.
Neoplasms
Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
Neoplasms
Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha.
Neoplasms
Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects.
Neoplasms
Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy.
Neoplasms
HFE inhibits type I IFNs signaling by targeting the SQSTM1-mediated MAVS autophagic degradation.
Neoplasms
High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer.
Neoplasms
High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity.
Neoplasms
Histone deacetylase inhibitor trichostatin A sustains sodium pervanadate-induced NF-kappaB activation by delaying IkappaBalpha mRNA resynthesis: comparison with tumor necrosis factor alpha.
Neoplasms
Homo-oligomerization is essential for Toll/interleukin-1 receptor domain-containing adaptor molecule-1-mediated NF-kappaB and interferon regulatory factor-3 activation.
Neoplasms
Homodimer of two F-box proteins betaTrCP1 or betaTrCP2 binds to IkappaBalpha for signal-dependent ubiquitination.
Neoplasms
HSP72 protects against obesity-induced insulin resistance.
Neoplasms
HTLV-1 Tax-associated hTid-1, a human DnaJ protein, is a repressor of Ikappa B kinase beta subunit.
Neoplasms
Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro and in vivo.
Neoplasms
Human chorionic gonadotropin decreases proliferation and invasion of breast cancer MCF-7 cells by inhibiting NF-kappaB and AP-1 activation.
Neoplasms
Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response.
Neoplasms
Human T-cell leukemia virus type 1 Tax induction of NF-kappaB involves activation of the IkappaB kinase alpha (IKKalpha) and IKKbeta cellular kinases.
Neoplasms
Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase.
Neoplasms
Hydrogen peroxide has opposing effects on IKK activity and IkappaBalpha breakdown in airway epithelial cells.
Neoplasms
Hydrogen peroxide signaling through tumor necrosis factor receptor 1 leads to selective activation of c-Jun N-terminal kinase.
Neoplasms
Hyperoxia prolongs tumor necrosis factor-alpha-mediated activation of NF-kappaB: role of IkappaB kinase.
Neoplasms
I kappa B overexpression in cardiomyocytes prevents NF-kappa B translocation and provides cardioprotection in trauma.
Neoplasms
Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively.
Neoplasms
Identification by in vivo genomic footprinting of a transcriptional switch containing NF-kappaB and Sp1 that regulates the IkappaBalpha promoter.
Neoplasms
Identification of a Ligand-induced Transient Refractory Period in Nuclear Factor-{kappa}B Signaling.
Neoplasms
Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling.
Neoplasms
Identification of NF-kappaB-dependent gene networks in respiratory syncytial virus-infected cells.
Neoplasms
Identification of sites subjected to serine/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)/Cap43-dependent suppression of angiogenic CXC chemokine expression in human pancreatic cancer cells.
Neoplasms
Ikappa B kinase alpha involvement in the development of nasopharyngeal carcinoma through a NF-?B-independent and ERK-dependent pathway.
Neoplasms
IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines.
Neoplasms
IkappaB kinase alpha (IKKalpha) regulation of IKKbeta kinase activity.
Neoplasms
IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300.
Neoplasms
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
Neoplasms
IkappaB kinase complex is an intracellular target for endotoxic lipopolysaccharide in human monocytic cells.
Neoplasms
IkappaB kinase is an essential component of the Tpl2 signaling pathway.
Neoplasms
IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a.
Neoplasms
IkappaB kinase-alpha regulates endothelial cell motility and tumor angiogenesis.
Neoplasms
IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK.
Neoplasms
IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy.
Neoplasms
IkappaB-kinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium.
Neoplasms
IkappaBalpha degradation and nuclear factor-kappaB DNA binding are insufficient for interleukin-1beta and tumor necrosis factor-alpha-induced kappaB-dependent transcription. Requirement for an additional activation pathway.
Neoplasms
IkappaBalpha gene therapy in tumor necrosis factor-alpha- and chemotherapy-mediated apoptosis of hepatocellular carcinomas.
Neoplasms
IkappaBalpha gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-alpha-mediated cell death.
Neoplasms
IkappaBalpha is essential for maintaining basal c-Jun N-terminal kinase (JNK) activation and regulating JNK-mediated resistance to tumor necrosis factor cytotoxicity in L929 cells.
Neoplasms
IkappaBalpha kinase inhibitor IKI-1 conferred tumor necrosis factor alpha sensitivity to pancreatic cancer cells and a xenograft tumor model.
Neoplasms
IkappaBalpha overexpression delays tumor formation in v-rel transgenic mice.
Neoplasms
IkappaBalpha ubiquitination is catalyzed by an SCF-like complex containing Skp1, cullin-1, and two F-box/WD40-repeat proteins, betaTrCP1 and betaTrCP2.
Neoplasms
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway.
Neoplasms
IKK-beta inhibitors: an analysis of drug-receptor interaction by using Molecular Docking and Pharmacophore 3D-QSAR approaches.
Neoplasms
IKK1/2 protect human cells from TNF-mediated RIPK1-dependent apoptosis in an NF-?B-independent manner.
Neoplasms
IKK? inibition by a glucosamine derivative enhances Maspin expression in osteosarcoma cell line.
Neoplasms
IKKalpha and IKKbeta each function to regulate NF-kappaB activation in the TNF-induced/canonical pathway.
Neoplasms
IKKalpha at the crossroads of inflammation and metastasis.
Neoplasms
IKKalpha controls formation of the epidermis independently of NF-kappaB.
Neoplasms
IKKalpha enhances human keratinocyte differentiation and determines the histological variant of epidermal squamous cell carcinomas.
Neoplasms
IKKalpha is required to maintain skin homeostasis and prevent skin cancer.
Neoplasms
IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program.
Neoplasms
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.
Neoplasms
IKKbeta mediates cell shape-induced aromatase expression and estrogen biosynthesis in adipose stromal cells.
Neoplasms
IKKbeta programs to turn on the GADD45alpha-MKK4-JNK apoptotic cascade specifically via p50 NF-kappaB in arsenite response.
Neoplasms
IKKbeta suppression of TSC1 function links the mTOR pathway with insulin resistance.
Neoplasms
IKKbeta-dependent NF-kappaB pathway controls vascular inflammation and intimal hyperplasia.
Neoplasms
IKKbeta-mediated nuclear factor-kappaB activation attenuates smac mimetic-induced apoptosis in cancer cells.
Neoplasms
IKKgamma /NEMO facilitates the recruitment of the IkappaB proteins into the IkappaB kinase complex.
Neoplasms
Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6.
Neoplasms
Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers.
Neoplasms
Immunohistochemical study of the ubiquitin-nuclear factor-kB pathway in the endometrium of the baboon (Papio anubis) with and without endometriosis.
Neoplasms
In adenovirus type 12 tumorigenic cells, major histocompatibility complex class I transcription shutoff is overcome by induction of NF-kappaB and relief of COUP-TFII repression.
Neoplasms
In vivo and in vitro recruitment of an IkappaBalpha-ubiquitin ligase to IkappaBalpha phosphorylated by IKK, leading to ubiquitination.
Neoplasms
In vivo and in vitro sensitization of leukemic cells to adriamycin-induced apoptosis by pentoxifylline Involvement of caspase cascades and IkappaBalpha phosphorylation.
Neoplasms
Incomplete regulation of NF-kappaB by IkappaBalpha during respiratory syncytial virus infection in A549 cells.
Neoplasms
Increase in IkappaB kinase alpha expression suppresses the tumor progression and improves the prognosis for nasopharyngeal carcinoma.
Neoplasms
Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Neoplasms
Induction of IkappaBalpha mRNA expression in the brain by glucocorticoids: a negative feedback mechanism for immune-to-brain signaling.
Neoplasms
Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation.
Neoplasms
Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1beta in neurodegeneration.
Neoplasms
Inflammation-activated protein kinases as targets for drug development.
Neoplasms
Inflammatory mechanisms contributing to pancreatic cancer development.
Neoplasms
Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IkappaBalpha.
Neoplasms
Inhibition of human immunodeficiency virus type 1 replication by blocking IkappaB kinase with noraristeromycin.
Neoplasms
Inhibition of human immunodeficiency virus type 1 replication in latently infected cells by a novel IkappaB kinase inhibitor.
Neoplasms
Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: molecular and functional study of novel alpha-methylene-gamma-butyrolactone derivatives.
Neoplasms
Inhibition of IkappaB kinase activity by sodium salicylate in vitro does not reflect its inhibitory mechanism in intact cells.
Neoplasms
Inhibition of IkappaB kinase by a new class of retinoid-related anticancer agents that induce apoptosis.
Neoplasms
Inhibition of IkappaB kinase-beta and anticancer activities of novel chalcone adamantyl arotinoids.
Neoplasms
Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury.
Neoplasms
Inhibition of IkappaBalpha nuclear export as an approach to abrogate nuclear factor-kappaB-dependent cancer cell survival.
Neoplasms
Inhibition of NF-kappaB activation by merlin.
Neoplasms
Inhibition of NF-kappaB signaling interferes with phorbol ester-induced growth arrest of keratinocytes in a TNFR1-independent manner.
Neoplasms
Inhibition of nuclear factor kappaB by direct modification in whole cells--mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers.
Neoplasms
Inhibition of nuclear factor-kappaB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells.
Neoplasms
Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.
Neoplasms
Inhibition of TBK1 reduces choroidal neovascularization in vitro and in vivo.
Neoplasms
Inhibition of the NF-kappaB pathway by varicella-zoster virus in vitro and in human epidermal cells in vivo.
Neoplasms
Inhibitor of nuclear factor kappaB kinase deficiency enhances oxidative stress and prolongs c-Jun NH2-terminal kinase activation induced by arsenic.
Neoplasms
Inhibitors of protein kinase C (PKC) prevent activated transcription: role of events downstream of NF-kappaB DNA binding.
Neoplasms
Innate immunity meets with cellular stress at the IKK complex: Regulation of the IKK complex by HSP70 and HSP90.
Neoplasms
Insulin-like growth factor-I stimulates dephosphorylation of ikappa B through the serine phosphatase calcineurin (protein phosphatase 2B).
Neoplasms
Integrative genomic approaches identify IKBKE as a breast cancer oncogene.
Neoplasms
Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta.
Neoplasms
Interleukin-1-induced nuclear factor-kappaB-IkappaBalpha autoregulatory feedback loop in hepatocytes. A role for protein kinase calpha in post-transcriptional regulation of ikappabalpha resynthesis.
Neoplasms
Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding.
Neoplasms
Intestinal antiviral signaling is controlled by autophagy gene Epg5 independent of the microbiota.
Neoplasms
Intracellular prooxidant activity of melatonin induces a survival pathway involving NF-kappaB activation.
Neoplasms
Iodinated N-acylvanillamines: potential "multiple-target" anti-inflammatory agents acting via the inhibition of t-cell activation and antagonism at vanilloid TRPV1 channels.
Neoplasms
Iron-mediated H2O2 production as a mechanism for cell type-specific inhibition of tumor necrosis factor alpha-induced but not interleukin-1beta-induced IkappaB kinase complex/nuclear factor-kappaB activation.
Neoplasms
Ischemic preconditioning improves rat kidney allograft function after ischemia/reperfusion injury: the role of tumor necrosis factor-alpha.
Neoplasms
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss.
Neoplasms
JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes.
Neoplasms
Kaposi's sarcoma-associated herpesvirus (KSHV) oncoprotein K13 bypasses TRAFs and directly interacts with the IkappaB kinase complex to selectively activate NF-kappaB without JNK activation.
Neoplasms
KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta.
Neoplasms
Licochalcone A potently inhibits tumor necrosis factor alpha-induced nuclear factor-kappaB activation through the direct inhibition of IkappaB kinase complex activation.
Neoplasms
Limb and skin abnormalities in mice lacking IKKalpha.
Neoplasms
Lipid peroxidation is involved in the activation of NF-kappaB by tumor necrosis factor but not interleukin-1 in the human endothelial cell line ECV304. Lack of involvement of H2O2 in NF-kappaB activation by either cytokine in both primary and transformed endothelial cells.
Neoplasms
Lipopolysaccharide-primed heterotolerant dendritic cells suppress experimental autoimmune uveoretinitis by multiple mechanisms.
Neoplasms
Liposomal delivery of heat shock protein 72 into renal tubular cells blocks nuclear factor-kappaB activation, tumor necrosis factor-alpha production, and subsequent ischemia-induced apoptosis.
Neoplasms
Loss of IKKbeta activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis.
Neoplasms
Lymphotoxin-beta receptor activation by lymphotoxin-alpha(1)beta(2) and LIGHT promotes tumor growth in an NFkappaB-dependent manner.
Neoplasms
Lymphotoxin-beta receptor mediates NEMO-independent NF-kappaB activation.
Neoplasms
Lysine 63-linked polyubiquitination of TAK1 at lysine 158 is required for tumor necrosis factor alpha- and interleukin-1beta-induced IKK/NF-kappaB and JNK/AP-1 activation.
Neoplasms
Mathematical model of NF-kappaB regulatory module.
Neoplasms
Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes.
Neoplasms
Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells.
Neoplasms
MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta.
Neoplasms
Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK/p38 and inhibiting IkappaBalpha kinase-NFkappaB.
Neoplasms
Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells.
Neoplasms
MicroRNA-429 inhibits neuroblastoma cell proliferation, migration and invasion via the NF-?B pathway.
Neoplasms
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Neoplasms
Modification of cysteine-179 of IkappaBalpha kinase by Nimbolide leads to downregulation of NF-kappaB-regulated cell survival and proliferative proteins and sensitization of tumor cells to chemotherapeutic agents.
Neoplasms
Modification of IkappaBalpha by taurine bromamine inhibits tumor necrosis factor alpha-induced NF-kappaB activation.
Neoplasms
Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells.
Neoplasms
MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling.
Neoplasms
Mutational analysis of IkappaBalpha in hematologic malignancies.
Neoplasms
Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha.
Neoplasms
Mutations of NFKBIA in biopsy specimens from Hodgkin lymphoma.
Neoplasms
Myosin motor Myo1c and its receptor NEMO/IKK-gamma promote TNF-alpha-induced serine307 phosphorylation of IRS-1.
Neoplasms
N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of kappaB kinase beta expression.
Neoplasms
NEMO-binding domains of both IKKalpha and IKKbeta regulate IkappaB kinase complex assembly and classical NF-kappaB activation.
Neoplasms
NF-?B inhibition protects against tumor-induced cardiac atrophy in vivo.
Neoplasms
NF-kappaB activation in premalignant mouse tal-1/scl thymocytes and tumors.
Neoplasms
NF-kappaB activation: nondegradative ubiquitination implicates NEMO.
Neoplasms
NF-kappaB and IKK as therapeutic targets in cancer.
Neoplasms
NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia.
Neoplasms
NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway.
Neoplasms
NF-kappaB overrides the apoptotic program of TNF receptor 1 but not CD40 in carcinoma cells.
Neoplasms
NF-kappaB signalling proteins p50/p105, p52/p100, RelA, and IKKepsilon are over-expressed in oesophageal squamous cell carcinomas.
Neoplasms
NF-kappaB-dependent regulation of matrix metalloproteinase-9 gene expression by lipopolysaccharide in a macrophage cell line RAW 264.7.
Neoplasms
NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176.
Neoplasms
NF-kappaB: a stress-regulated switch for cell survival.
Neoplasms
NF-kappaB: linking inflammation and immunity to cancer development and progression.
Neoplasms
NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-(kappa)B activation.
Neoplasms
Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-kappaB signaling pathway.
Neoplasms
Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells.
Neoplasms
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin.
Neoplasms
Nuclear factor kappa B signaling either stimulates or inhibits neurite growth depending on the phosphorylation status of p65/RelA.
Neoplasms
Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.
Neoplasms
Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression.
Neoplasms
Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone.
Neoplasms
Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression.
Neoplasms
Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer.
Neoplasms
Olanzapine Induces Inflammation and Immune Response via Activating ER Stress in the Rat Prefrontal Cortex.
Neoplasms
Ostreolysin induces browning of adipocytes and ameliorates hepatic steatosis.
Neoplasms
Overexpression of Tissue Transglutaminase Leads to Constitutive Activation of Nuclear Factor-{kappa}B in Cancer Cells: Delineation of a Novel Pathway.
Neoplasms
Oxidative stress induces NF-kappaB nuclear translocation without degradation of IkappaBalpha.
Neoplasms
Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition.
Neoplasms
Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis.
Neoplasms
Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide.
Neoplasms
Peroxynitrite is a potent inhibitor of NF-{kappa}B activation triggered by inflammatory stimuli in cardiac and endothelial cell lines.
Neoplasms
Pervanadate-induced nuclear factor-kappaB activation requires tyrosine phosphorylation and degradation of IkappaBalpha. Comparison with tumor necrosis factor-alpha.
Neoplasms
Phosphorylation and stabilization of TAp63gamma by IkappaB kinase-beta.
Neoplasms
Phosphorylation of ARD1 by IKKbeta contributes to its destabilization and degradation.
Neoplasms
Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB.
Neoplasms
Phosphorylation of IkappaBalpha in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability.
Neoplasms
Phosphorylation of serine 68 in the IkappaB kinase (IKK)-binding domain of NEMO interferes with the structure of the IKK complex and tumor necrosis factor-alpha-induced NF-kappaB activity.
Neoplasms
Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.
Neoplasms
Phosphorylation of TRAF2 within its RING domain inhibits stress-induced cell death by promoting IKK and suppressing JNK activation.
Neoplasms
Pinitol targets nuclear factor-kappaB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis.
Neoplasms
Platelet-activating factor: a role in preterm delivery and an essential interaction with Toll-like receptor signaling in mice.
Neoplasms
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents.
Neoplasms
Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation.
Neoplasms
Potential utility of natural polyphenols for reversing fat-induced insulin resistance.
Neoplasms
Preventive effect of a proteasome inhibitor on the formation of accelerated atherosclerosis in rabbits with uremia.
Neoplasms
Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells.
Neoplasms
Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity.
Neoplasms
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Neoplasms
Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IkappaBalpha.
Neoplasms
Protein kinase C delta activates IkappaB-kinase alpha to induce the p53 tumor suppressor in response to oxidative stress.
Neoplasms
Protein kinase C-alpha is an upstream activator of the IkappaB kinase complex in the TPA signal transduction pathway to NF-kappaB in U2OS cells.
Neoplasms
Protein kinase Cdelta activates RelA/p65 and nuclear factor-kappaB signaling in response to tumor necrosis factor-alpha.
Neoplasms
Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-kappaB, degradation of IkappaBalpha, nuclear translocation of p65, and subsequent gene expression.
Neoplasms
Purified human plasma glycosaminoglycans reduced NF-kappaB activation, pro-inflammatory cytokine production and apoptosis in LPS-treated chondrocytes.
Neoplasms
Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta.
Neoplasms
Ras-related GTPase Rhob represses NF-kappaB signaling.
Neoplasms
Reactive oxygen species from NAD(P)H:quinone oxidoreductase constitutively activate NF-kappaB in malignant melanoma cells.
Neoplasms
Reduced Skeletal Muscle Inhibitor of {kappa}B{beta} Content Is Associated With Insulin Resistance in Subjects With Type 2 Diabetes: Reversal by Exercise Training.
Neoplasms
Reduction in IkappaB kinase alpha expression promotes the development of skin papillomas and carcinomas.
Neoplasms
Regulation and function of IKK and IKK-related kinases.
Neoplasms
Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB.
Neoplasms
Regulation of I(kappa)B kinase complex by phosphorylation of (gamma)-binding domain of I(kappa)B kinase (beta) by Polo-like kinase 1.
Neoplasms
Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer.
Neoplasms
Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells.
Neoplasms
Regulation of NF-{kappa}B responses by epigenetic suppression of I{kappa}B{alpha} expression in HCT116 intestinal epithelial cells.
Neoplasms
Regulation of Vinca alkaloid-induced apoptosis by NF-kappaB/IkappaB pathway in human tumor cells.
Neoplasms
RelA Ser276 phosphorylation is required for activation of a subset of NF-kappaB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes.
Neoplasms
RelB modulation of IkappaBalpha stability as a mechanism of transcription suppression of interleukin-1alpha (IL-1alpha), IL-1beta, and tumor necrosis factor alpha in fibroblasts.
Neoplasms
Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors.
Neoplasms
Repression of MHC class I transcription by HPV16E7 through interaction with a putative RXRbeta motif and NF-kappaB cytoplasmic sequestration.
Neoplasms
Requirement of NEMO/IKK? for effective expansion of KRAS-induced precancerous lesions in the pancreas.
Neoplasms
Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation.
Neoplasms
RKIP inhibits NF-kappaB in cancer cells by regulating upstream signaling components of the IkappaB kinase complex.
Neoplasms
Role of IkappaBalpha and IkappaBbeta in the biphasic nuclear translocation of NF-kappaB in TNFalpha-stimulated astrocytes and in neuroblastoma cells.
Neoplasms
Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo.
Neoplasms
Role of IKKgamma/nemo in assembly of the Ikappa B kinase complex.
Neoplasms
Role of K63-linked polyubiquitination in NF-?B signalling: which ligase catalyzes and what molecule is targeted?
Neoplasms
Roles for homotypic interactions and transautophosphorylation in IkappaB kinase beta IKKbeta) activation [corrected].
Neoplasms
Roles for the IKK-Related Kinases TBK1 and IKK? in Cancer.
Neoplasms
RSK2 mediates NF-{kappa}B activity through the phosphorylation of I{kappa}B{alpha} in the TNF-R1 pathway.
Neoplasms
Salicylic acid reverses phorbol 12-myristate-13-acetate (PMA)- and tumor necrosis factor alpha (TNFalpha)-induced insulin receptor substrate 1 (IRS1) serine 307 phosphorylation and insulin resistance in human embryonic kidney 293 (HEK293) cells.
Neoplasms
Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-kappaB activation, IkappaBalpha phosphorylation, and degradation.
Neoplasms
Sesquiterpene lactone parthenolide ameliorates bladder inflammation and bladder overactivity in cyclophosphamide induced rat cystitis model by inhibiting nuclear factor-kappaB phosphorylation.
Neoplasms
Short-term modulation of interleukin-1beta signaling by hyperoxia: uncoupling of IkappaB kinase activation and NF-kappaB-dependent gene expression.
Neoplasms
Signal-dependent degradation of IkappaBalpha is mediated by an inducible destruction box that can be transferred to NF-kappaB, bcl-3 or p53.
Neoplasms
Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain.
Neoplasms
Signaling by the Mpl receptor involves IKK and NF-kappaB.
Neoplasms
Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus.
Neoplasms
Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1.
Neoplasms
Single injection of naked plasmid encoding alpha-melanocyte-stimulating hormone protects against thioacetamide-induced acute liver failure in mice.
Neoplasms
Site-specific monoubiquitination of IkappaB kinase IKKbeta regulates its phosphorylation and persistent activation.
Neoplasms
Site-specific tyrosine phosphorylation of IkappaBalpha negatively regulates its inducible phosphorylation and degradation.
Neoplasms
Specific IKKbeta inhibitor IV blocks streptonigrin-induced NF-kappaB activity and potentiates its cytotoxic effect on cancer cells.
Neoplasms
Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs.
Neoplasms
Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation.
Neoplasms
Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta.
Neoplasms
Suppression of NF-kappaB signaling by KEAP1 regulation of IKKbeta activity through autophagic degradation and inhibition of phosphorylation.
Neoplasms
Suppression of NFkappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model.
Neoplasms
Suppression of tumour necrosis factor-alpha by Schizonepeta tenuifolia water extract via inhibition of IkappaBalpha degradation and Jun N-terminal kinase/stress-activated protein kinase activation.
Neoplasms
Sustained activation of protein kinase C downregulates nuclear factor-kappaB signaling by dissociation of IKK-gamma and Hsp90 complex in human colonic epithelial cells.
Neoplasms
Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth.
Neoplasms
TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappaB activation.
Neoplasms
TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration.
Neoplasms
TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery.
Neoplasms
Targeted repression of overexpressed CD30 downregulates NF-kappaB and ERK1/2 pathway in Hodgkin lymphoma cell lines.
Neoplasms
Targeting Autophagic Regulation of NFkappaB in HTLV-I Transformed Cells by Geldanamycin: Implications for Therapeutic Interventions.
Neoplasms
Targeting DNA damage response pathways to activate the STING innate immune signaling pathway in human cancer cells.
Neoplasms
Targeting TANK-binding kinase 1 (TBK1) in cancer.
Neoplasms
Targeting the PIAS1 SUMO ligase pathway to control inflammation.
Neoplasms
Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis.
Neoplasms
TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer.
Neoplasms
The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.
Neoplasms
The alpha and beta subunits of IkappaB kinase (IKK) mediate TRAF2-dependent IKK recruitment to tumor necrosis factor (TNF) receptor 1 in response to TNF.
Neoplasms
The ankyrin repeats but not the PEST-like sequences are required for signal-dependent degradation of IkappaBalpha.
Neoplasms
The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B).
Neoplasms
The carboxyl-terminal region of IkappaB kinase gamma (IKKgamma) is required for full IKK activation.
Neoplasms
The deubiquitinating enzyme USP11 controls an IkappaB kinase alpha (IKKalpha)-p53 signaling pathway in response to tumor necrosis factor alpha (TNFalpha).
Neoplasms
The Ectodysplasin and NFkappaB signalling pathways in odontogenesis.
Neoplasms
The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
Neoplasms
The IkappaB kinase - a bridge between inflammation and cancer.
Neoplasms
The IKK inhibitor BMS-345541 affects multiple mitotic cell cycle transitions.
Neoplasms
The IKK-2/Ikappa Balpha /NF-kappa B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in Ikappa Balpha -deficient mice.
Neoplasms
The interleukin-1 receptor-associated kinase is degraded by proteasomes following its phosphorylation.
Neoplasms
The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2.
Neoplasms
The Npro product of classical swine fever virus interacts with IkappaBalpha, the NF-kappaB inhibitor.
Neoplasms
The possible correlation between activation of NF-kappaB/IkappaB pathway and the susceptibility of tumor cells to paclitaxel-induced apoptosis.
Neoplasms
The Prosurvival IKK-Related Kinase IKK? Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine.
Neoplasms
The protein kinase IKKepsilon contributes to tumour growth and tumour pain in a melanoma model.
Neoplasms
The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity.
Neoplasms
The RING domain of TRAF2 plays an essential role in the inhibition of TNFalpha-induced cell death but not in the activation of NF-kappaB.
Neoplasms
The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis.
Neoplasms
The Specific IKK?/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-?B and MAP Kinase Pathways.
Neoplasms
The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta.
Neoplasms
The transcription factor nuclear factor-kappa B and cancer.
Neoplasms
The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance.
Neoplasms
The tumor suppressor activity of IKKalpha in stratified epithelia is exerted in part via the TGF-beta antiproliferative pathway.
Neoplasms
Theaflavin, a black tea extract, is a novel anti-inflammatory compound.
Neoplasms
Thiopental inhibits tumor necrosis factor alpha-induced activation of nuclear factor kappaB through suppression of kappaB kinase activity.
Neoplasms
Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation.
Neoplasms
Tracking the road from inflammation to cancer: the critical role of IkappaB kinase (IKK).
Neoplasms
TRAF2 phosphorylation modulates tumor necrosis factor alpha-induced gene expression and cell resistance to apoptosis.
Neoplasms
Transactivation of CCL20 gene by Epstein-Barr virus latent membrane protein 1.
Neoplasms
Transfer of IkappaBalpha gene increase the sensitivity of paclitaxel mediated with caspase 3 activation in human lung cancer cell.
Neoplasms
Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation.
Neoplasms
Transient IkappaB kinase activity mediates temporal NF-kappaB dynamics in response to a wide range of tumor necrosis factor-alpha doses.
Neoplasms
Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179.
Neoplasms
Tumor necrosis factor receptor-associated factor-6 and ribosomal S6 kinase intracellular pathways link the angiotensin II AT1 receptor to the phosphorylation and activation of the IkappaB kinase complex in vascular smooth muscle cells.
Neoplasms
Tumor necrosis factor-alpha activation of NF-kappa B requires the phosphorylation of Ser-471 in the transactivation domain of c-Rel.
Neoplasms
Tumor necrosis factor-alpha triggers mucus production in airway epithelium through an IkappaB kinase beta-dependent mechanism.
Neoplasms
Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor".
Neoplasms
Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and IkappaB kinase 1/2 in human alveolar epithelial cells.
Neoplasms
Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation.
Neoplasms
Tumor necrosis factor-induced nuclear factor kappaB activation is impaired in focal adhesion kinase-deficient fibroblasts.
Neoplasms
Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways.
Neoplasms
Tumor suppressor SMAR1 represses IkappaBalpha expression and inhibits p65 transactivation through matrix attachment regions.
Neoplasms
Ubiquitin activated tumor necrosis factor receptor associated factor-6 (TRAF6) is recycled via deubiquitination.
Neoplasms
Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells.
Neoplasms
Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells.
Neoplasms
Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle.
Neoplasms
Viral immune surveillance: Toward a TH17/TH9 gate to the central nervous system.
Neoplasms
Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity.
Neoplasms
Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-kappa B activation.
Neoplasms
ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth.
Neoplasms
[Effect and significance of anisodamine on IkappaB kinase-beta in Kupffer cells following hemorrhagic shock]
Neoplasms
[Effect of Berberine on the Insulin Resistance and TLR4/IKKbeta/NF-kappaB Signaling Pathways in Skeletal Muscle of Obese Rats with Insulin Resistance].
Neoplasms
[Expression of nuclear transcription factor kappaB in hamster buccal pouch carcinogenesis]
Neoplasms
[Human pathologies associated with NF-kappaB defects]
Neoplasms
[Lipopolysaccaride influenced peritoneal mesothelial cells on the growth and expression of tumor necrosis factor through nuclear factor kappaB pathway]
Neoplasms
[The alternative NF-kB activation pathway and cancer: friend or foe?]
Neoplasms
[The role of NF-kappaB in colon cancer].
Nephritis
T-lymphocyte-specific knockout of IKK-2 or NEMO induces Th17 cells in an experimental nephrotoxic nephritis mouse model.
Nephrotic Syndrome
Transcriptional and post-transcriptional alterations of IkappaBalpha in active minimal-change nephrotic syndrome.
Nephrotic Syndrome
[Regulatory effect of IkappaBalpha on NF-kappaB activity during viral gene transactivation in patients with steroid responsive simple nephrotic syndrome]
Neuralgia
Inhibition of the protein kinase IKKepsilon attenuates neuropathic pain in mice.
Neuralgia
Specific Inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats.
Neuralgia
The role of spinal nuclear factor-kappa B in spinal hyperexcitability.
Neuroblastoma
Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells.
Neuroblastoma
Mu-opioid receptor-mediated phosphorylation of IkappaB kinase in human neuroblastoma SH-SY5Y cells.
Neuroblastoma
Participation of type II protein kinase A in the retinoic acid-induced growth inhibition of SH-SY5Y human neuroblastoma cells.
Neuroblastoma
Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1.
Neuroblastoma
Phosphorylation of endogenous proteins by adenosine 3':5'-monophosphate-dependent protein kinase in mouse neuroblastoma cells.
Neuroblastoma
Role of IkappaBalpha and IkappaBbeta in the biphasic nuclear translocation of NF-kappaB in TNFalpha-stimulated astrocytes and in neuroblastoma cells.
Neurodegenerative Diseases
alpha-melanocyte-stimulating hormone inhibits NF-kappaB activation and IkappaBalpha degradation in human glioma cells and in experimental brain inflammation.
Neurodegenerative Diseases
IKKalpha and IKKbeta regulation of DNA damage-induced cleavage of huntingtin.
Neurodegenerative Diseases
LRRK2 Kinase Inhibitors as Possible Therapy for Parkinson's Disease and Other Neurodegenerative Disorders.
Neurodegenerative Diseases
Specific correction of a splice defect in brain by nutritional supplementation.
Neuroinflammatory Diseases
G2019s LRRK2 promotes mitochondrial fission and increases TNF?-mediated neuroinflammation responses.
Neuroinflammatory Diseases
Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates ?-Synuclein Gene-induced Neurodegeneration.
Neuroinflammatory Diseases
LRRK2 Kinase Activity Induces Mitochondrial Fission in Microglia via Drp1 and Modulates Neuroinflammation.
Neuroinflammatory Diseases
Phosphorylation of p53 by LRRK2 induces microglial tumor necrosis factor ?-mediated neurotoxicity.
Newcastle Disease
Promoter Organization of the Interferon-A Genes Differentially Affects Virus-induced Expression and Responsiveness to TBK1 and IKK{epsilon}
Non-alcoholic Fatty Liver Disease
Animal models of steatohepatitis.
Non-alcoholic Fatty Liver Disease
IkappaB kinase epsilon: a potential therapeutic target for obesity (and nonalcoholic fatty liver disease)?
Non-alcoholic Fatty Liver Disease
Lipotoxicity reduces DDX58/Rig-1 expression and activity leading to impaired autophagy and cell death.
Obesity
Activated Ask1-MKK4-p38MAPK/JNK stress signaling pathway in human omental fat tissue may link macrophage infiltration to whole-body insulin sensitivity.
Obesity
Defective hypothalamic autophagy directs the central pathogenesis of obesity via IKK-beta/NF-kappaB pathway.
Obesity
Design, synthesis, and biological activity of substituted 2-amino-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid derivatives as inhibitors of the inflammatory kinases TBK1 and IKK? for the treatment of obesity.
Obesity
Diet-induced obesity and acute hyperlipidemia reduce IkappaBalpha levels in rat skeletal muscle in a fiber-type dependent manner.
Obesity
Genetic obesity alters recruitment of TANK-binding kinase 1 and AKT into hypothalamic lipid rafts domains.
Obesity
High-fat diet induces Ikkbeta and reduces insulin sensitivity in rats with low running capacity.
Obesity
Human Protein Kinases and Obesity.
Obesity
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity.
Obesity
IkappaB kinase epsilon: a potential therapeutic target for obesity (and nonalcoholic fatty liver disease)?
Obesity
IKKepsilon: a bridge between obesity and inflammation.
Obesity
Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor.
Obesity
JNK1 and IKK{beta}: molecular links between obesity and metabolic dysfunction.
Obesity
Mechanisms of obesity and related pathology: linking immune responses to metabolic stress.
Obesity
Molecular mechanism of interactions between Chrysin and I-kappa-B kinase epsilon (IKKe)/Tank Binding Kinase-1(TBK1): Cell based assay and insilico molecular docking studies.
Obesity
Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta.
Obesity
The protein kinase IKKepsilon regulates energy balance in obese mice.
Osteoarthritis
Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IkappaBalpha reveals that most, but not all, inflammatory and destructive mediators are NFkappaB dependent.
Osteoarthritis
Adenoviral gene transfer of the endogenous inhibitor IkappaBalpha into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kappaB-dependent.
Osteoarthritis
Antiviral gene expression in rheumatoid arthritis: role of IKKepsilon and interferon regulatory factor 3.
Osteoarthritis
Biochemical and Computational Studies of the Interaction between a Glucosamine Derivative, NAPA, and the IKK? Kinase.
Osteoarthritis
Expression and regulation of inducible IkappaB kinase (IKK-i) in human fibroblast-like synoviocytes.
Osteoarthritis
Regulation of c-Jun phosphorylation by the I kappa B kinase-epsilon complex in fibroblast-like synoviocytes.
Osteolysis
IKKbeta activation is sufficient for RANK-independent osteoclast differentiation and osteolysis.
Osteolysis
Impediment of NEMO oligomerization inhibits osteoclastogenesis and osteolysis.
Osteolysis
Lysine392, a K63-linked ubiquitination site in NEMO, mediates inflammatory osteoclastogenesis and osteolysis.
Osteolysis
The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis.
Osteosarcoma
Okadaic acid induces tyrosine phosphorylation of IkappaBalpha that mediated by PKR pathway in human osteoblastic MG63 cells.
Ovarian Neoplasms
Activation of NF-{kappa}B Signaling by Inhibitor of NF-{kappa}B Kinase {beta} Increases Aggressiveness of Ovarian Cancer.
Ovarian Neoplasms
Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8.
Ovarian Neoplasms
Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer.
Ovarian Neoplasms
IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines.
Ovarian Neoplasms
MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma.
Ovarian Neoplasms
Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis.
Ovarian Neoplasms
Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells.
Ovarian Neoplasms
[Effect of topotecan on expression of aquaporin protein 5 and nuclear factor-kappaB in ovarian cancer SKOV3 cells.]
Overnutrition
IL-6 and IL-10 anti-inflammatory activity links exercise to hypothalamic insulin and leptin sensitivity through IKKbeta and ER stress inhibition.
Overnutrition
NFkappaB-mediated metabolic inflammation in peripheral tissues versus central nervous system.
Pancreatic Neoplasms
Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model.
Pancreatic Neoplasms
Chemosensitivity of human pancreatic carcinoma cells is enhanced by IkappaBalpha super-repressor.
Pancreatic Neoplasms
Identification of sites subjected to serine/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)/Cap43-dependent suppression of angiogenic CXC chemokine expression in human pancreatic cancer cells.
Pancreatic Neoplasms
IkappaBalpha kinase inhibitor IKI-1 conferred tumor necrosis factor alpha sensitivity to pancreatic cancer cells and a xenograft tumor model.
Pancreatic Neoplasms
IKKalpha controls p52/RelB at the skp2 gene promoter to regulate G1- to S-phase progression.
Pancreatic Neoplasms
Inhibition of IkappaB kinase beta restrains oncogenic proliferation of pancreatic cancer cells.
Pancreatic Neoplasms
Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer.
Pancreatic Neoplasms
N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of kappaB kinase beta expression.
Pancreatic Neoplasms
NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells.
Pancreatic Neoplasms
Overexpression of Tissue Transglutaminase Leads to Constitutive Activation of Nuclear Factor-{kappa}B in Cancer Cells: Delineation of a Novel Pathway.
Pancreatic Neoplasms
The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis.
Pancreatitis
Hyperbaric oxygen reduces inflammatory response in acute pancreatitis by inhibiting NF-kappaB activation.
Pancreatitis
Protein kinase C-zeta is critical in pancreatitis-induced apoptosis of Kupffer cells.
Papilloma
Reduction in IkappaB kinase alpha expression promotes the development of skin papillomas and carcinomas.
Parasitic Diseases
Neuronal activity and transcription of proinflammatory cytokines, IkappaBalpha, and iNOS in the mouse brain during acute endotoxemia and chronic infection with Trypanosoma brucei brucei.
Parkinson Disease
A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.
Parkinson Disease
A pathway for Parkinson's Disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain.
Parkinson Disease
Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.
Parkinson Disease
Analysis of ?-synuclein levels related to LRRK2 kinase activity: from substantia nigra to urine of patients with Parkinson's disease.
Parkinson Disease
Autophagy and innate immunity: Insights from invertebrate model organisms.
Parkinson Disease
Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients.
Parkinson Disease
Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity.
Parkinson Disease
Clinical heterogeneity of the LRRK2 G2019S mutation.
Parkinson Disease
Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
Parkinson Disease
Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors.
Parkinson Disease
Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor.
Parkinson Disease
Discovery of Highly Potent, Selective and Brain Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors.
Parkinson Disease
Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.
Parkinson Disease
From structure to ætiology: a new window on the biology of leucine-rich repeat kinase 2 and Parkinson's disease.
Parkinson Disease
Hyperactive LRRK2 kinase impairs the trafficking of axonal autophagosomes.
Parkinson Disease
Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes.
Parkinson Disease
Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.
Parkinson Disease
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.
Parkinson Disease
Inhibitors of LRRK2 kinase activity to probe the treatment option in Parkinson's disease.
Parkinson Disease
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.
Parkinson Disease
Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils.
Parkinson Disease
Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs.
Parkinson Disease
LRRK2 Ablation Attenuates ?lpha-Synuclein-Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo.
Parkinson Disease
Lrrk2 and Lewy body disease.
Parkinson Disease
LRRK2 and the Endolysosomal System in Parkinson's Disease.
Parkinson Disease
LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
Parkinson Disease
LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
Parkinson Disease
LRRK2 kinase in Parkinson's disease.
Parkinson Disease
LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?
Parkinson Disease
LRRK2 Kinase Inhibitors as Possible Therapy for Parkinson's Disease and Other Neurodegenerative Disorders.
Parkinson Disease
LRRK2-phosphorylated Rab10 sequesters Myosin Va with RILPL2 during ciliogenesis blockade.
Parkinson Disease
Membrane association but not identity is required for LRRK2 activation and phosphorylation of Rab GTPases.
Parkinson Disease
Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease.
Parkinson Disease
Molecular insights of the G2019S substitution in LRRK2 kinase domain associated with Parkinson's disease: A molecular dynamics simulation approach.
Parkinson Disease
Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.
Parkinson Disease
Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1.
Parkinson Disease
Phosphorylated IkappaBalpha is a component of Lewy body of Parkinson's disease.
Parkinson Disease
PINK1-dependent phosphorylation of Serine111 within the SF3 motif of Rab GTPases impairs effector interactions and LRRK2-mediated phosphorylation at Threonine72.
Parkinson Disease
Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756).
Parkinson Disease
Rab29 activation of the Parkinson's disease-associated LRRK2 kinase.
Parkinson Disease
RAB8, RAB10 and RILPL1 contribute to both LRRK2 kinase-mediated centrosomal cohesion and ciliogenesis deficits.
Parkinson Disease
Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
Parkinson Disease
Role of LRRK2 kinase dysfunction in Parkinson disease.
Parkinson Disease
Small-Molecule Inhibitors of LRRK2.
Parkinson Disease
The development of CNS-active LRRK2 inhibitors using property-directed optimisation.
Parkinson Disease
The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.
Parkinson Disease
The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.
Parkinson Disease
The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease.
Parkinson Disease
Vitamin B12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection.
Parkinson Disease
X Caps the Phosphate for Phospho-Rab GTPase Recognition in Ciliogenesis and Parkinson's Disease.
Parkinsonian Disorders
Lrrk2 and Lewy body disease.
Parkinsonian Disorders
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease.
Persistent Infection
Neuronal activity and transcription of proinflammatory cytokines, IkappaBalpha, and iNOS in the mouse brain during acute endotoxemia and chronic infection with Trypanosoma brucei brucei.
Photosensitivity Disorders
Nuclear factor-kappaB activation by the photochemotherapeutic agent verteporfin.
Pituitary Neoplasms
Inhibition of NFkappaB reduces cellular viability in GH3 pituitary adenoma cells.
Plasmacytoma
Resolution and general properties of different types of ribosomal protein kinases in mouse plasmocytoma.
Pneumonia
A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice.
Pneumonia
A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity.
Pneumonia
Airway epithelium controls lung inflammation and injury through the NF-kappa B pathway.
Pneumonia
Functions and regulation of NF-kappaB RelA during pneumococcal pneumonia.
Pneumonia
Glutaredoxin 1 regulates cigarette smoke-mediated lung inflammation through differential modulation of I{kappa}B kinases in mice: impact on histone acetylation.
Pneumonia
Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma.
Pneumonia
IkappaB kinase is a critical regulator of chemokine expression and lung inflammation in respiratory syncytial virus infection.
Pneumonia
Resveratrol ameliorates Serratia marcescens-induced acute pneumonia in rats.
Pneumonia
Selective I kappa B kinase expression in airway epithelium generates neutrophilic lung inflammation.
Porcine Reproductive and Respiratory Syndrome
Autophagy and innate immunity: Insights from invertebrate model organisms.
Porcine Reproductive and Respiratory Syndrome
TBK1, a central kinase in innate immune sensing of nucleic acids and beyond.
Porcine Reproductive and Respiratory Syndrome
Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation.
Pre-Eclampsia
Pregnancy is associated with suppression of the nuclear factor kappaB/IkappaB activation pathway in peripheral blood mononuclear cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively.
Premature Birth
Inhibition of choriodecidual cytokine production and inflammatory gene expression by selective I-kappaB kinase (IKK) inhibitors.
Prion Diseases
Prion propagation in mice lacking central nervous system NF-kappaB signalling.
Prostatic Neoplasms
A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells.
Prostatic Neoplasms
Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis.
Prostatic Neoplasms
Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis.
Prostatic Neoplasms
Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen.
Prostatic Neoplasms
Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IkappaBalpha, c-Jun and androgen receptor.
Prostatic Neoplasms
Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation.
Prostatic Neoplasms
Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers.
Prostatic Neoplasms
Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo.
Prostatic Neoplasms
Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells.
Prostatic Neoplasms
NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?
Prostatic Neoplasms
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin.
Prostatic Neoplasms
Over-expression of IkappaB-kinase-epsilon (IKKepsilon/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines.
Prostatic Neoplasms
Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IkappaBalpha.
Prostatic Neoplasms
Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer.
Prostatic Neoplasms
Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha.
Prostatic Neoplasms
Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells.
Prostatic Neoplasms
Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor".
Prostatic Neoplasms
[Curcumin-induced the expression of inhibitor kappaBalpha protein in human prostate cancer cells]
Proteinuria
Inhibition of NF-kappaB-dependent Bcl-xL expression by clusterin promotes albumin-induced tubular cell apoptosis.
Pterygium
The Nuclear-Factor Kappa B Pathway is Activated in Pterygium.
Pulmonary Disease, Chronic Obstructive
Activation of nuclear factor-kappaB in airway epithelial cells in patients with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure-activity relationship.
Pulmonary Disease, Chronic Obstructive
Anti-inflammatory inhibitors of IkappaB kinase in asthma and COPD.
Pulmonary Disease, Chronic Obstructive
Atrophy and hypertrophy signaling in the diaphragm of patients with COPD.
Pulmonary Disease, Chronic Obstructive
Cellular Markers of Muscle Atrophy in Chronic Obstructive Pulmonary Disease (COPD).
Pulmonary Disease, Chronic Obstructive
Decreased exercise-induced expression of NF-{kappa}B regulated genes in muscle of COPD patients.
Pulmonary Disease, Chronic Obstructive
IkappaB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic.
Pulmonary Disease, Chronic Obstructive
Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation.
Pulmonary Disease, Chronic Obstructive
[The function of nuclear factor-erythroid 2-related factor 2 and its association with I-kappa B kinases alpha/beta in a rat model of chronic obstructive pulmonary disease.]
Pulmonary Edema
Airway epithelium controls lung inflammation and injury through the NF-kappa B pathway.
Pulmonary Fibrosis
A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice.
Pulmonary Fibrosis
[Perindopril and losartan attenuate bleomycin A5-induced pulmonary fibrosis in rats]
Reoviridae Infections
Identification of an NF-kappaB-dependent gene network in cells infected by mammalian reovirus.
Reperfusion Injury
Gene transfer of IkappaBalpha limits infarct size in a mouse model of myocardial ischemia-reperfusion injury.
Reperfusion Injury
IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury.
Reperfusion Injury
Ischemic preconditioning attenuates renal ischemia-reperfusion injury by inhibiting activation of IKKbeta and inflammatory response.
Respiratory Distress Syndrome
Enhanced heat shock protein 70 expression alters proteasomal degradation of IkappaB kinase in experimental acute respiratory distress syndrome.
Respiratory Syncytial Virus Infections
IkappaB kinase is a critical regulator of chemokine expression and lung inflammation in respiratory syncytial virus infection.
Respiratory Syncytial Virus Infections
Incomplete regulation of NF-kappaB by IkappaBalpha during respiratory syncytial virus infection in A549 cells.
Retinoblastoma
Mechanisms by Which S-Albuterol Induces Human Bronchial Smooth Muscle Cell Proliferation.
Retinoblastoma
Redox-mediated gene therapies for environmental injury: approaches and concepts.
Rhinitis, Allergic
Amlexanox ameliorates acetaminophen-induced acute liver injury by reducing oxidative stress in mice.
Rocky Mountain Spotted Fever
NF-kappaB activation during Rickettsia rickettsii infection of endothelial cells involves the activation of catalytic IkappaB kinases IKKalpha and IKKbeta and phosphorylation-proteolysis of the inhibitor protein IkappaBalpha.
Rotavirus Infections
Interleukin-8 gene regulation in intestinal epithelial cells infected with rotavirus: role of viral-induced IkappaB kinase activation.
Salivary Gland Neoplasms
5-Fluorouracil suppression of NF-KappaB is mediated by the inhibition of IKappab kinase activity in human salivary gland cancer cells.
Salmonella Infections
beta-Catenin activity negatively regulates bacteria-induced inflammation.
Salmonella Infections
Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor.
Sarcoma
Delayed radioprotection by NFkappaB-mediated induction of Sod2 (MnSOD) in SA-NH tumor cells after exposure to clinically used thiol-containing drugs.
Sarcoma
Viral src gene products are related to the catalytic chain of mammalian cAMP-dependent protein kinase.
Sarcoma, Avian
Cytosolic malic dehydrogenase activity is associated with a putative substrate for the transforming gene product of Rous sarcoma virus.
Sarcoma, Avian
Protein kinase and its regulatory effect on reverse transcriptase activity of Rous sarcoma virus.
Sarcoma, Kaposi
Crystal structure of a vFlip-IKKgamma complex: insights into viral activation of the IKK signalosome.
Seizures
Nuclear factor-kappaB regulates seizure threshold and gene transcription following convulsant stimulation.
Sepsis
Drug repositioning of TANK-binding kinase 1 inhibitor CYT387 as an alternative for the treatment of Gram-negative bacterial sepsis.
Sepsis
Inhibition of LPS-induced NFkappaB activation by a glucan ligand involves down-regulation of IKKbeta kinase activity and altered phosphorylation and degradation of IkappaBalpha.
Sepsis
NF-kappaB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance.
Sepsis
Paeoniflorin Inhibits Systemic Inflammation and Improves Survival in Experimental Sepsis.
Sepsis
Protein kinase C-zeta (PKC-zeta) regulates Kupffer cell apoptosis during experimental sepsis.
Severe Fever with Thrombocytopenia Syndrome
Two Conserved Amino Acids within the NSs of Severe Fever with Thrombocytopenia Syndrome Phlebovirus Are Essential for Anti-interferon Activity.
Shock, Septic
Attenuation of NF-kappaB signalling in rat cardiomyocytes at birth restricts the induction of inflammatory genes.
Shock, Septic
Defective feedback regulation of NF-kappaB underlies Sjogren's syndrome in mice with mutated kappaB enhancers of the IkappaBalpha promoter.
Shock, Septic
IkappaB kinase complex is an intracellular target for endotoxic lipopolysaccharide in human monocytic cells.
Sjogren's Syndrome
Defective feedback regulation of NF-kappaB underlies Sjogren's syndrome in mice with mutated kappaB enhancers of the IkappaBalpha promoter.
Skin Abnormalities
Limb and skin abnormalities in mice lacking IKKalpha.
Skin Diseases
A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas.
Skin Diseases
IKKbeta Leads to an Inflammatory Skin Disease Resembling Interface Dermatitis.
Skin Neoplasms
A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas.
Skin Neoplasms
IKKalpha is required to maintain skin homeostasis and prevent skin cancer.
Skin Neoplasms
IKKalpha, a critical regulator of epidermal differentiation and a suppressor of skin cancer.
Spinal Cord Injuries
Inhibition of peripheral NF-kappaB activation by central action of alpha-melanocyte-stimulating hormone.
Spondylitis, Ankylosing
Down-Regulation of LOC645166 in T Cells of Ankylosing Spondylitis Patients Promotes the NF-?B Signaling via Decreasingly Blocking Recruitment of the IKK Complex to K63-Linked Polyubiquitin Chains.
Spondylitis, Ankylosing
IkBalpha promoter polymorphisms in patients with ankylosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
Curcumin Treatment Suppresses IKK{beta} Kinase Activity of Salivary Cells of Patients with Head and Neck Cancer: A Pilot Study.
Squamous Cell Carcinoma of Head and Neck
CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex.
Squamous Cell Carcinoma of Head and Neck
Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling.
Squamous Cell Carcinoma of Head and Neck
Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling.
Squamous Cell Carcinoma of Head and Neck
LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB.
Squamous Cell Carcinoma of Head and Neck
Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
SDF-1alpha promotes invasion of head and neck squamous cell carcinoma by activating NF-kappaB.
Starvation
Pathogenic LRRK2 regulates ciliation probability upstream of tau tubulin kinase 2 via Rab10 and RILPL1 proteins.
Status Epilepticus
Nuclear factor-kappaB regulates seizure threshold and gene transcription following convulsant stimulation.
Stomach Neoplasms
5-Fluorouracil inhibits nitric oxide production through the inactivation of IkappaB kinase in stomach cancer cells.
Stomach Neoplasms
Expression of apurinic/apyrimidinic endonuclease-1 (APE-1) in H. pylori-associated gastritis, gastric adenoma, and gastric cancer.
Stomach Neoplasms
H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells.
Stomach Neoplasms
Helicobacter pylori Induces I{kappa}B Kinase {alpha} Nuclear Translocation and Chemokine Production in Gastric Epithelial Cells.
Stomach Neoplasms
IkappaBalpha polymorphism at promoter region (rs2233408) influences the susceptibility of gastric cancer in Chinese.
Stomach Neoplasms
Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer.
Stomach Neoplasms
Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells.
Stomach Neoplasms
Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer.
Superinfection
Efficient replication by herpes simplex virus type 1 involves activation of the IkappaB kinase-IkappaB-p65 pathway.
Synucleinopathies
LRRK2 kinase regulates ?-synuclein propagation via RAB35 phosphorylation.
Thrombocytopenia
Two Conserved Amino Acids within the NSs of Severe Fever with Thrombocytopenia Syndrome Phlebovirus Are Essential for Anti-interferon Activity.
Thyroid Neoplasms
Inhibition of nuclear factor-kappaB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells.
Trichuriasis
Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis.
Tuberculosis
Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation.
Tuberculosis
LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages.
Urinary Bladder Neoplasms
Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IkappaBalpha overexpression.
Urinary Bladder Neoplasms
TBK1 Promote Bladder Cancer Cell Proliferation and Migration via Akt Signaling.
Uterine Cervical Neoplasms
Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells.
Vaccinia
Induction of apoptosis by double-stranded-RNA-dependent protein kinase (PKR) involves the alpha subunit of eukaryotic translation initiation factor 2 and NF-kappaB.
Vaccinia
Inhibition of IkappaB Kinase by Vaccinia Virus Virulence Factor B14.
Vaccinia
Mapping the i{kappa}B kinase beta (ikk{beta})-binding interface of B14, a vaccinia virus inhibitor of IKK{beta}-mediated activation of nuclear factor kappa B.
Vaccinia
Modified vaccinia virus Ankara can activate NF-kappaB transcription factors through a double-stranded RNA-activated protein kinase (PKR)-dependent pathway during the early phase of virus replication.
Vaccinia
Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear factor kappa B activation.
Vaccinia
The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation.
Vaccinia
Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells.
Vascular Diseases
Feed-forward Signaling of TNF{alpha} and NF{kappa}B via IKK{beta} Pathway contributes to Insulin Resistance and Coronary Arteriolar Dysfunction in Type 2 Diabetic Mice.
Vascular Diseases
Overexpression of mutated IkappaBalpha inhibits vascular smooth muscle cell proliferation and intimal hyperplasia formation.
Vascular System Injuries
Peptide-based inhibition of I?B kinase/nuclear factor-?B pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes.
Vascular System Injuries
The NFkappaB inhibitory peptide, IkappaBalpha, prevents human vascular smooth muscle proliferation.
Vasculitis
I kappa B alpha promoter polymorphisms in patients with systemic lupus erythematosus.
Vesicular Stomatitis
Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity.
Vesicular Stomatitis
Autophagy and innate immunity: Insights from invertebrate model organisms.
Vesicular Stomatitis
FOSL1 Inhibits Type I Interferon Responses to Malaria and Viral Infections by Blocking TBK1 and TRAF3/TRIF Interactions.
Vesicular Stomatitis
HERP Binds TBK1 To Activate Innate Immunity and Repress Virus Replication in Response to Endoplasmic Reticulum Stress.
Viremia
The P Protein of Spring Viremia of Carp Virus Negatively Regulates the Fish Interferon Response by Inhibiting the Kinase Activity of TANK-Binding Kinase 1.
Viremia
Zebrafish FGFR3 is a negative regulator of RLR pathway to decrease IFN expression.
Virus Diseases
Activation of NF-kappa B in virus-infected macrophages is dependent on mitochondrial oxidative stress and intracellular calcium: downstream involvement of the kinases TGF-beta-activated kinase 1, mitogen-activated kinase/extracellular signal-regulated kinase kinase 1, and I kappa B kinase.
Virus Diseases
Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity.
Virus Diseases
Binding of Kaposi's sarcoma-associated herpesvirus K-bZIP to interferon-responsive factor 3 elements modulates antiviral gene expression.
Virus Diseases
Co-regulation of NF-kappaB and inflammasome-mediated inflammatory responses by myxoma virus pyrin domain-containing protein m013.
Virus Diseases
Differential activation of IFN regulatory factor (IRF)-3 and IRF-5 transcription factors during viral infection.
Virus Diseases
IkappaB kinase beta (IKKbeta/IKK2/IKBKB)-A key molecule in signaling to the transcription factor NF-kappaB.
Virus Diseases
IkappaB kinase is a critical regulator of chemokine expression and lung inflammation in respiratory syncytial virus infection.
Virus Diseases
IkappaB-mediated inhibition of virus-induced beta interferon transcription.
Virus Diseases
Incomplete regulation of NF-kappaB by IkappaBalpha during respiratory syncytial virus infection in A549 cells.
Virus Diseases
Inducible ATP1B1 Upregulates Antiviral Innate Immune Responses by the Ubiquitination of TRAF3 and TRAF6.
Virus Diseases
Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factor-kappaB pathway.
Virus Diseases
Inhibition of transcription of the beta interferon gene by the human herpesvirus 6 immediate-early 1 protein.
Virus Diseases
Inhibitor of NF kappa B alpha is a host sensor of coxsackievirus infection.
Virus Diseases
Involvement of TBK1 and IKKepsilon in lipopolysaccharide-induced activation of the interferon response in primary human macrophages.
Virus Diseases
Involvement of the ubiquitin-like domain of TBK1/IKK-i kinases in regulation of IFN-inducible genes.
Virus Diseases
JNK2 and IKKbeta are required for activating the innate response to viral infection.
Virus Diseases
KRAB-Zinc Finger Protein ZNF268a Deficiency Attenuates the Virus-Induced Pro-Inflammatory Response by Preventing IKK Complex Assembly.
Virus Diseases
Molecular cloning of IKKbeta from the mandarin fish Siniperca chuatsi and its up-regulation in cells by ISKNV infection.
Virus Diseases
MOV10 Provides Antiviral Activity against RNA Viruses by Enhancing RIG-I-MAVS-Independent IFN Induction.
Virus Diseases
Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity.
Virus Diseases
Predicting and validating a model of suppressor of IKKepsilon through biophysical characterization.
Virus Diseases
Promoter Organization of the Interferon-A Genes Differentially Affects Virus-induced Expression and Responsiveness to TBK1 and IKK{epsilon}
Virus Diseases
Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD.
Virus Diseases
Role of cyclophilin B in activation of interferon regulatory factor-3.
Virus Diseases
TANK-binding kinase 1 as a novel therapeutic target for viral diseases.
Virus Diseases
The Role of Herpes Simplex Virus Type 1 ?34.5 in the Regulation of IRF3 Signaling.
Virus Diseases
The Role of Optineurin in Antiviral Type I Interferon Production.
Virus Diseases
The role of the IKK complex in viral infections.
Virus Diseases
The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection.
Virus Diseases
The transcription factor nuclear factor-kappa B and cancer.
Virus Diseases
Triggering the interferon antiviral response through an IKK-related pathway.
Virus Diseases
Ubiquitin-regulated recruitment of IKK{epsilon} to MAVS interferon signaling adapter.
Virus Diseases
USE OF THE PHARMACOLOGICAL INHIBITOR BX795 TO STUDY THE REGULATION AND PHYSIOLOGICAL ROLES OF TBK1 AND IKK{varepsilon}: A DISTINCT UPSTREAM KINASE MEDIATES SER172 PHOSPHORYLATION AND ACTIVATION.
Virus Diseases
Viral protease cleavage of inhibitor of kappaBalpha triggers host cell apoptosis.
Virus Diseases
Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation.
Virus Diseases
Zebrafish FGFR3 is a negative regulator of RLR pathway to decrease IFN expression.
Virus Diseases
[Research progress on the role of TANK-binding kinase 1 in anti-virus innate immune response].
Whooping Cough
Influence of lipoxin A(4) and other lipoxygenase-derived eicosanoids on tissue factor expression.
Whooping Cough
Lipopolysaccharides from Bordetella pertussis and Bordetella parapertussis differently modulate human dendritic cell functions resulting in divergent prevalence of Th17-polarized responses.
Yellow Fever
Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.000041
BX795
Homo sapiens
-
0.03
(1R,4R)-4-(2-amino-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-cyclohexanol
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.0022
(4-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)phenyl)acetic acid
Homo sapiens
-
IC50 for the IKKbeta is 0.0022 mM
0.0025 - 0.03
(R)-2-amino-4-(2-(hydroximethyl)pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.006 - 0.03
(R)-2-amino-4-(3-hydroxypyrrolidin-1-yl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
0.0031 - 0.03
(S)-2-amino-4-(2-(hydroximethyl)pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.00052 - 0.0043
1,4-dimethyl-7-methylamino-2-phenyl-4H-imidazo[4,5-d]imidazo[5,4-b]pyridine
0.0053 - 0.0059
1-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-sulfonamide
0.02
1-(6-chloro-9H-beta-carbolin-8-yl)-3-methylurea
Homo sapiens
-
inhibits IKK with IC50 of 0.02 mM
0.0008 - 0.0126
1-[3-[7-(piperidin-4-yloxy)isoquinolin-6-yl]phenyl]methanamine
0.0001 - 0.0063
1-[4-[7-(piperidin-4-yloxy)isoquinolin-6-yl]phenyl]methanamine
0.0004 - 0.004
1-[4-[7-(piperidin-4-yloxy)isoquinolin-6-yl]phenyl]methanesulfonamide
0.0003
17-acetoxyjolkinolide B
Homo sapiens
-
0.03
2,4-diamino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.03
2-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-benzenesulfonamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.03
2-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.000056 - 0.0083
2-(4-fluorophenyl)-8-methyl-N-[2-(piperidin-1-yl)ethyl]-8H-imidazo[4,5-d][1,3]thiazolo[5,4-b]pyridin-5-amine
0.1
2-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)benzoic acid
Homo sapiens
-
IC50 for the IKK complex is above 0.1 mM
0.0008 - 0.0036
2-amino-4-((1R,2S,3R,4S)-2,3,4-trihydroxycyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.002 - 0.03
2-amino-4-((1R,4R)-4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.03
2-amino-4-((1R,4R)-4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.001 - 0.03
2-amino-4-((1RS,2SR,3RS)-2,3-dihydroxycyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.016 - 0.03
2-amino-4-((cyclopropylmethyl)amino)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
0.03
2-amino-4-(2-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]- pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.002 - 0.03
2-amino-4-(2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.0016 - 0.03
2-amino-4-(2-hydroxyethylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.015 - 0.03
2-amino-4-(2-hydroxyphenyl)-77H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.03
2-amino-4-(2-morpholinoethylamino)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.004 - 0.0098
2-amino-4-(3-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
0.0077 - 0.03
2-amino-4-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.0121 - 0.03
2-amino-4-(3-hydroxypropylamino)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
0.0024 - 0.0038
2-amino-4-(3-hydroyphenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.03
2-amino-4-(4-(2-hydroxyethyl)piperazin-1-yl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.0003 - 0.0024
2-amino-4-(4-(methylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
0.01 - 0.03
2-amino-4-(4-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.00065 - 0.0023
2-amino-4-(4-hydroxymethyl)phenyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
0.0016 - 0.02
2-amino-4-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimdine-5-carbonitrile
0.03
2-amino-4-(4-methylpiperazin-1-yl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.03
2-amino-4-(4-phenylpiperazin-1-yl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.0053 - 0.03
2-amino-4-(benzylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.03
2-amino-4-(cyclohexyl(2-hydroxyethyl)amino)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.0018 - 0.03
2-amino-4-(cyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.03
2-amino-4-(cyclohexylmethylamino)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.013 - 0.03
2-amino-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.013 - 0.03
2-amino-4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.0053 - 0.03
2-amino-4-(piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.004 - 0.03
2-amino-4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.02 - 0.03
2-amino-4-morpholino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.0017 - 0.03
2-amino-4-phenyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
0.000025
2-hydroxy-N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]acetamide
Homo sapiens
-
0.000081 - 0.0076
2-methanesulfonyl-4-methyl-7-methylamino-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
0.000009 - 0.00496
2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7yl)pyridin-2-yl)methyl)acetamide
0.03
3-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimdin-4-yl)benzamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.0053 - 0.0059
3-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-benzenesulfonamide
0.001
3-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)benzoic acid
Homo sapiens
-
IC50 for the IKKbeta is 0.001 mM
0.0027
3-amino-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0169
3-amino-4-(1-benzofuran-2-yl)-6-methylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0108
3-amino-4-(2-methoxyethoxy)thieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.014
3-amino-4-(4-chlorophenyl)-6-methylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.02
3-amino-4-(4-hydroxyphenyl)-6-methylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta, larger than 0.0200
0.002
3-amino-4-ethoxythieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0011
3-amino-4-furan-2-yl-6-methylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0047
3-amino-4-methoxythieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0025
3-amino-4-methyl-6-morpholin-4-ylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.00068
3-amino-4-methyl-6-piperazin-1-ylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0024
3-amino-4-methyl-6-piperidin-1-ylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0022
3-amino-4-propoxythieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.000072
3-amino-6-(1,4-diazepan-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0029
3-amino-6-(2-aminoethoxy)-4-methylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0066
3-amino-6-(2-hydroxyethoxy)-4-methylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.00063
3-amino-6-(3-aminoazepan-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.05
3-amino-6-(3-aminopropoxy)-4-methylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta, larger than 0.0500
0.0024
3-amino-6-(3-hydroxypiperidin-1-yl)-4-methylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.00057 - 0.0133
3-amino-6-(3-hydroxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
0.0051
3-amino-6-(3-hydroxypropoxy)-4-methylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.00014
3-amino-6-(3-oxo-1,4-diazepan-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.002
3-amino-6-(3-oxopiperazin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.000041 - 0.0016
3-amino-6-(4-aminopiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
0.00015
3-amino-6-(4-carbamoylpiperazin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0013
3-amino-6-(4-carbamoylpiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.00075
3-amino-6-(4-hydroxypiperidin-1-yl)-4-methylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.00028 - 0.0112
3-amino-6-(4-hydroxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
0.00068
3-amino-6-(4-methoxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.00052
3-amino-6-(4-methylpiperazin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0025
3-amino-6-methyl-4-(2-methylpropyl)thieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0085
3-amino-6-methyl-4-(4-methylphenyl)thieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0074
3-amino-6-methyl-4-phenylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0013
3-amino-6-methyl-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.006
3-amino-6-methyl-4-pyridin-2-ylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.002
3-amino-6-methyl-4-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0013
3-amino-6-methyl-4-[4-(methylsulfonyl)phenyl]thieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0127
3-amino-6-methylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.00012 - 0.0034
3-amino-6-piperazin-1-yl-4-propylthieno[2,3-b]pyridine-2-carboxamide
0.0058
3-amino-6-[(2-hydroxyethyl)amino]-4-methylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0005
3-amino-6-[(3R)-3-aminopyrrolidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.00195
3-amino-6-[(3R)-3-hydroxypyrrolidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.00059
3-amino-6-[(3S)-3-aminopyrrolidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.00145
3-amino-6-[(3S)-3-hydroxypyrrolidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.00068
3-amino-6-[4-(dimethylamino)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.00012
3-amino-6-[4-(methylamino)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.000098
3-amino-6-[4-[(methylsulfonyl)amino]piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.000012 - 0.00262
3-methoxy-N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]propanamide
0.000007
3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzonitrile
Homo sapiens
-
0.0079 - 0.0251
3-[7-(benzyloxy)isoquinolin-6-yl]benzenesulfonamide
0.0013 - 0.0079
3-[7-(piperidin-4-yloxy)isoquinolin-6-yl]benzenesulfonamide
0.01 - 0.03
4-((2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-benzenesulfonamide
0.03
4-((2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-benzoic acid
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.00025
4-(1-benzothiophen-2-yl)-N-[3-chloro-4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
Homo sapiens
-
IC50 for the IKK complex is 250 nM
0.00015
4-(1-benzothiophen-2-yl)-N-[3-methoxy-4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
Homo sapiens
-
IC50 for the IKK complex is 150 nM
0.0085
4-(1-benzothiophen-2-yl)-N-[4-(pyrrolidin-1-ylcarbonyl)phenyl]pyrimidin-2-amine
Homo sapiens
-
IC50 for the IKK complex is 0.0085 mM, cellular profile
0.00008
4-(1-benzothiophen-2-yl)-N-[4-([4-(dimethyl-amino)piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
Homo sapiens
-
IC50 for the IKK complex is 80 nM, cellular profile
0.00007
4-(1-benzothiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
Homo sapiens
-
IC50 for the IKK complex is 70 nM, cellular profile
0.016 - 0.03
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimdin-4-yl)benzamide
0.00008 - 0.001
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-benzenesulfonamide
0.0014 - 0.016
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(p-tolyl)-benzenesulfonamide
0.0001 - 0.0014
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methylbenzenesulfonamide
0.00061 - 0.0029
4-(2-amino-7H-pyrrol[2,3-d]pyrimidin-4-yl)benzenesulfonamide
0.0008
4-(5-(3-acetamino-3-methylbutyl)thiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
Homo sapiens
-
IC50 for the IKK complex is 800 nM
0.00003
4-(5-(3-amino-3-ethylpentyl)thiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
Homo sapiens
-
IC50 for the IKK complex is 30 nM
0.0002
4-(5-(3-amino-3-methyl-but-1-ynyl)thiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
Homo sapiens
-
IC50 for the IKK complex is 200 nM
0.00004
4-(5-(3-amino-3-methyl-butyl)thiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
Homo sapiens
-
IC50 for the IKK complex is 40 nM
0.00005
4-(5-(3-hydroxy-3-methylbutyl)thiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amin
Homo sapiens
-
IC50 for the IKK complex is 50 nM, cellular profile
0.0001
4-(5-(3-methoxypropyl)thiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
Homo sapiens
-
IC50 for the IKK complex is 100 nM, cellular profile
0.00004
4-(5-(4-hydroxybutyl)thiophen-2-yl)-N-[4-([4-pyrrolidin-1-yl-piperidin-1-yl]carbonyl)phenyl]pyrimidin-2-amine
Homo sapiens
-
IC50 for the IKK complex is 40 nM, cellular profile
0.0021 - 0.03
4-(5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzenesulfonamide
0.001 - 0.0251
4-(7-[[1-(ethylsulfonyl)piperidin-4-yl]oxy]isoquinolin-6-yl)benzenesulfonamide
0.0015 - 0.0025
4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzenesulfonamide
0.03
4-(piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.018
4-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)benzoic acid
Homo sapiens
-
IC50 for the IKK complex is 0.018 mM, cellular profile
0.03
4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.00013
4-methyl-7-methylamino-2-(azepan-1-yl)-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.000028 - 0.0026
4-methyl-7-methylamino-2-(methylthio)-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
0.0015
4-methyl-7-methylamino-2-benzylamino-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.00016
4-methyl-7-methylamino-2-cyclopentylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.0025 - 0.02
4-methyl-7-methylamino-2-diethylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
0.000015 - 0.0011
4-methyl-7-methylamino-2-ethylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
0.0003
4-methyl-7-methylamino-2-hydroxyethylamino-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.000015 - 0.00084
4-methyl-7-methylamino-2-methylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
0.00092 - 0.0034
4-methyl-7-methylamino-2-methylamino-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
0.000011 - 0.00027
4-methyl-7-methylamino-2-phenyl-4H-imidazo[4,5-d]oxazolo[5,4-b]pyridine
0.000006 - 0.0035
4-methyl-7-methylamino-2-phenyl-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
0.00021 - 0.0061
4-methyl-7-methylamino-2-piperidine-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
0.000015
4-methyl-7-methylamino-2-thienylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.000033 - 0.0081
4-methyl-7-methylamino-2-[1,2,3,6-tetrahydropyridine]-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
0.0032 - 0.0251
4-[7-(benzyloxy)isoquinolin-6-yl]benzenesulfonamide
0.0008 - 0.005
4-[7-(piperidin-3-ylmethoxy)isoquinolin-6-yl]benzenesulfonamide
0.0008 - 0.0126
4-[7-(piperidin-3-yloxy)isoquinolin-6-yl]benzenesulfonamide
0.0006 - 0.0016
4-[7-(piperidin-4-ylmethoxy)isoquinolin-6-yl]benzenesulfonamide
0.0001 - 0.0079
4-[7-(piperidin-4-yloxy)isoquinolin-6-yl]benzenesulfonamide
0.0013 - 0.0251
4-[7-[(1-acetylpiperidin-4-yl)oxy]isoquinolin-6-yl]benzenesulfonamide
0.000011
4-[N'-(4,6-dimethylpyrimidin-2-yl)carbamimidamido]-N-(phenylcarbamoyl)benzene-1-sulfonamide
Homo sapiens
at 37°C, pH not specified in the publication
0.0006
5,6-dibromo-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 600 nM
0.0006
5-bromo-6-chloro-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 600 nM
0.0011
5-bromo-6-cyano-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 0.0011 mM
0.002
5-bromo-6-fluoro-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 0.002 mM
0.004
5-bromo-6-methoxy-beta-carboline
Homo sapiens
-
nonspecific inhibitor of IKK, inhibits IKK with IC50 of 0.004 mM
0.0011
5-bromo-6-trifluoromethyl-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 0.0011 mM
0.015
5-bromo-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 0.015 mM
0.003
6,8-dichloro-7-(cyclohexylmethoxy)-9H-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 0.003 mM
0.00014
6,8-dichloro-7-ethoxy-9H-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 140 nM
0.00017
6,8-dichloro-7-methoxy-9H-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 170 nM
0.0032
6,8-dichloro-9H-beta-carbolin-7-yl morpholine-4-carboxylate
Homo sapiens
-
inhibits IKK with IC50 of 0.0032 mM
0.0002
6,8-dichloro-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 200 nM
0.0004 - 0.01
6-bromo-7-(piperidin-4-yloxy)isoquinoline
0.005 - 0.0251
6-bromo-7-[[1-(ethylsulfonyl)piperidin-4-yl]oxy]isoquinoline
0.0002 - 0.0032
6-phenyl-7-(piperidin-3-ylmethoxy)isoquinoline
0.0006 - 0.004
6-phenyl-7-(piperidin-3-yloxy)isoquinoline
0.0013 - 0.01
6-phenyl-7-(piperidin-4-ylmethoxy)isoquinoline
0.0001 - 0.0025
6-phenyl-7-(piperidin-4-yloxy)isoquinoline
0.004 - 0.0251
6-phenyl-7-(pyridin-3-ylmethoxy)isoquinoline
0.005 - 0.0251
6-phenyl-7-(pyridin-4-ylmethoxy)isoquinoline
0.000044
7-(2-fluorophenyl)-N,1-dimethyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
Homo sapiens
-
0.000007
7-(3-fluorophenyl)-N,1-dimethyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
Homo sapiens
-
0.000008
7-(3-methoxyphenyl)-N,1-dimethyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
Homo sapiens
-
0.000043 - 0.00173
7-(4-fluorophenyl)-N,1-dimethyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
0.00008
7-(OCH2CH(CH2CH2))-6,8-dichloro-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 80 nM
0.005 - 0.0251
7-(piperidin-4-yloxy)isoquinoline
0.011
7-hydroxy-6,8-dichloro-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 0.011 mM
0.0126 - 0.0251
7-[(1-acetylpiperidin-4-yl)oxy]-6-bromoisoquinoline
0.0016 - 0.0032
7-[(1-acetylpiperidin-4-yl)oxy]-6-phenylisoquinoline
0.000011
7-[3-(aminomethyl)phenyl]-N,1-dimethyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
Homo sapiens
-
0.0025 - 0.02
7-[[1-(ethylsulfonyl)piperidin-4-yl]methoxy]-6-phenylisoquinoline
0.002 - 0.0126
7-[[1-(ethylsulfonyl)piperidin-4-yl]oxy]-6-phenylisoquinoline
0.00004 - 0.0141
8-(5-chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
0.0013
8-amino-6-chloro-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 0.0013 mM
0.0018
8-dimethylamino-6-chloro-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 0.0018 mM
0.00018 - 0.02
8-methyl-2-(4-fluorophenyl)-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-amine
0.0018
8-methylamino-6-chloro-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 0.0018 mM
0.004
8-nitro-6-chloro-beta-carboline
Homo sapiens
-
inhibits IKK with IC50 of 0.004 mM
0.000033 - 0.005
acetamide,N-[2-[[2-(4-fluorophenyl)-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-yl]amino]ethyl]
0.007
chalcone
Homo sapiens
-
0.000075 - 0.0086
ethanol,N-[2-[[2-(4-fluorophenyl)-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-yl]amino]ethyl]
0.01681
lysyl-N-(4-methoxynaphthalen-2-yl)alaninamide
Homo sapiens
at 37°C, pH not specified in the publication
0.0007
methyl (6-chloro-9H-beta-carbolin-8-yl)carbamate
Homo sapiens
-
inhibits IKK with IC50 of 700 nM
0.0078
methyl 1-(3-amino-2-carbamoyl-4-propylthieno[2,3-b]pyridin-6-yl)piperidine-4-carboxylate
Homo sapiens
-
IKKbeta
0.00004 - 0.00167
N,1-dimethyl-7-phenyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
0.000034 - 0.00099
N,1-dimethyl-7-phenyl-1H-pyrazolo[5,1-b]purin-4-amine
0.00052 - 0.00428
N,3,8-trimethyl-2-phenyl-3,8-dihydrodiimidazo[4,5-b:4',5'-d]pyridin-5-amine
0.000011 - 0.00027
N,8-dimethyl-2-phenyl-8H-imidazo[4,5-d][1,3]oxazolo[5,4-b]pyridin-5-amine
0.000006 - 0.0035
N,8-dimethyl-2-phenyl-8H-imidazo[4,5-d][1,3]thiazolo[5,4-b]pyridin-5-amine
0.0013 - 0.01
N,N-dimethyl-3-[(4-[[(6-phenylisoquinolin-7-yl)oxy]methyl]piperidin-1-yl)sulfonyl]propan-1-amine
0.0003 - 0.004
N-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine
0.0044
N-(2-aminoethyl)-4-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)benzamide
Homo sapiens
-
IC50 for the IKK complex is 0.0044 mM
0.0003
N-(2-dimethyl-aminoethyl)-4-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)benzamide
Homo sapiens
-
IC50 300 nM for the IK cellular profile
0.0005
N-(2-pyrrolidin-1-yl-ethyl)-4-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)benzamide
Homo sapiens
-
IC50 for the IKK complex is 500 nM
0.1
N-(3-methyl-butyl)-4-([4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino)benzamide
Homo sapiens
-
IC50 for the IKKbeta is above 0.1 mM
0.00326
N-(3-[2-imino-6-methyl-3-[(3-nitrophenyl)methyl]-4-oxo-1,2,3,4-tetrahydropyrimidin-5-yl]propyl)-4-methylbenzene-1-sulfonamide
Homo sapiens
at 37°C, pH not specified in the publication
0.0004 - 0.0017
N-(4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)-methanesulfonamide
0.003
N-(6-chloro-9H-beta-carbolin-8-yl)-2-(pyridin-2-yl)acetamide
Homo sapiens
-
inhibits IKK with IC50 of 0.003 mM
0.02
N-(6-chloro-9H-beta-carbolin-8-yl)-2-methoxybenzamide
Homo sapiens
-
inhibits IKK with IC50 of 0.02 mM
0.0006
N-(6-chloro-9H-beta-carbolin-8-yl)-3-methoxybenzamide
Homo sapiens
-
inhibits IKK with IC50 of 600 nM
0.02
N-(6-chloro-9H-beta-carbolin-8-yl)-4-hydroxybutanamide
Homo sapiens
-
inhibits IKK with IC50 of 0.02 mM
0.0013
N-(6-chloro-9H-beta-carbolin-8-yl)-4-methoxybenzamide
Homo sapiens
-
inhibits IKK with IC50 of 0.0013 mM
0.0006
N-(6-chloro-9H-beta-carbolin-8-yl)acetamide
Homo sapiens
-
inhibits IKK with IC50 of 600 nM
0.0007
N-(6-chloro-9H-beta-carbolin-8-yl)benzamide
Homo sapiens
-
inhibits IKK with IC50 of 700 nM
0.02
N-(6-chloro-9H-beta-carbolin-8-yl)benzenesulfonamide
Homo sapiens
-
inhibits IKK with IC50 of 0.02 mM
0.0083
N-(6-chloro-9H-beta-carbolin-8-yl)methanesulfonamide
Homo sapiens
-
inhibits IKK with IC50 of 0.0083 mM
0.02
N-(6-chloro-9H-beta-carbolin-8-yl)morpholine-4-carboxamide
Homo sapiens
-
inhibits IKK with IC50 of 0.02 mM
0.001
N-(6-chloro-9H-beta-carbolin-8-yl)pyridine-2-carboxamide
Homo sapiens
-
inhibits IKK with IC50 of 0.001 mM
0.0003
N-(6-chloro-9H-beta-carbolin-8-yl)pyridine-4-carboxamide
Homo sapiens
-
inhibits IKK with IC50 of 300 nM
0.000019 - 0.0004
N-(8-methyl-2-phenylimidazo[1,2-a]thieno[3,2-e]pyrazin-5-yl)ethane-1,2-diamine
0.02
N-benzyl-6-chloro-9H-beta-carbolin-8-amine
Homo sapiens
-
inhibits IKK with IC50 of 0.02 mM
0.000039 - 0.0034
N-ethyl-2-(4-fluorophenyl)-N-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-amine
0.000026 - 0.0031
N-methyl-2-(4-fluorophenyl)-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-amine
0.000039 - 0.00015
N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]-1,2,3-thiadiazole-4-carboxamide
0.000014 - 0.000633
N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]acetamide
0.000022
N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]butanediamide
Homo sapiens
-
0.00028 - 0.0097
N-[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorobenzyl]acetamide
0.000053 - 0.0035
N-[[2-fluoro-5-[8-methyl-5-methylamino-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]acetamide
0.000032 - 0.0042
N-[[2-fluoro-5-[8-methyl-5-methylamino-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]methanesulfonamide
0.000016 - 0.001
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]-1,2,3-thiadiazole-5-amide
0.000022 - 0.0019
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]acetamide
0.000025 - 0.0014
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]isoxazole-5-amide
0.000005 - 0.001
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]methanesulfonamide
0.000079
N2,N2-dimethyl-N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]glycinamide
Homo sapiens
-
0.03
N4-cyclohexyl-5-(trifluoromethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.03
N4-cyclohexyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.00037 - 0.00064
noraristeromycin
0.0001
PS-1145
Homo sapiens
-
i.e. 8-(NHC(O)-3'-pyridyl)-6-chloro-beta-carboline, inhibits IKK with IC50 of 100 nM in vitro, blocks phosphorylation of IkappaBalpha and subsequent activation of NFkappaB in vivo
0.02
S1627
Homo sapiens
-
specific for the IKK complex, inhibits purified IKK in vitro with IC50 of 0.02 mM, inhibits IKK and NFkappaB nuclear translocation in vivo in umbilical vein endothelial cells and in rats, overview
-
0.0025
(R)-2-amino-4-(2-(hydroximethyl)pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
(R)-2-amino-4-(2-(hydroximethyl)pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.006
(R)-2-amino-4-(3-hydroxypyrrolidin-1-yl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
(R)-2-amino-4-(3-hydroxypyrrolidin-1-yl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.0031
(S)-2-amino-4-(2-(hydroximethyl)pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
(S)-2-amino-4-(2-(hydroximethyl)pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.00052
1,4-dimethyl-7-methylamino-2-phenyl-4H-imidazo[4,5-d]imidazo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.0043
1,4-dimethyl-7-methylamino-2-phenyl-4H-imidazo[4,5-d]imidazo[5,4-b]pyridine
Homo sapiens
-
IKK-1
0.0053
1-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-sulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.0059
1-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-sulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.0008
1-[3-[7-(piperidin-4-yloxy)isoquinolin-6-yl]phenyl]methanamine
Homo sapiens
-
IKK-beta
0.0126
1-[3-[7-(piperidin-4-yloxy)isoquinolin-6-yl]phenyl]methanamine
Homo sapiens
-
IKK-alpha
0.0001
1-[4-[7-(piperidin-4-yloxy)isoquinolin-6-yl]phenyl]methanamine
Homo sapiens
-
IKK-beta
0.0063
1-[4-[7-(piperidin-4-yloxy)isoquinolin-6-yl]phenyl]methanamine
Homo sapiens
-
IKK-alpha
0.0004
1-[4-[7-(piperidin-4-yloxy)isoquinolin-6-yl]phenyl]methanesulfonamide
Homo sapiens
-
IKK-beta
0.004
1-[4-[7-(piperidin-4-yloxy)isoquinolin-6-yl]phenyl]methanesulfonamide
Homo sapiens
-
IKK-alpha
0.000056
2-(4-fluorophenyl)-8-methyl-N-[2-(piperidin-1-yl)ethyl]-8H-imidazo[4,5-d][1,3]thiazolo[5,4-b]pyridin-5-amine
Homo sapiens
-
IKK-2
0.0083
2-(4-fluorophenyl)-8-methyl-N-[2-(piperidin-1-yl)ethyl]-8H-imidazo[4,5-d][1,3]thiazolo[5,4-b]pyridin-5-amine
Homo sapiens
-
IKK-1
0.0008
2-amino-4-((1R,2S,3R,4S)-2,3,4-trihydroxycyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.0036
2-amino-4-((1R,2S,3R,4S)-2,3,4-trihydroxycyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.002
2-amino-4-((1R,4R)-4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-((1R,4R)-4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.001
2-amino-4-((1RS,2SR,3RS)-2,3-dihydroxycyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-((1RS,2SR,3RS)-2,3-dihydroxycyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.016
2-amino-4-((cyclopropylmethyl)amino)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-((cyclopropylmethyl)amino)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.002
2-amino-4-(2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-(2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.0016
2-amino-4-(2-hydroxyethylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-(2-hydroxyethylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.015
2-amino-4-(2-hydroxyphenyl)-77H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-(2-hydroxyphenyl)-77H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.004
2-amino-4-(3-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.0098
2-amino-4-(3-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.0077
2-amino-4-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.0121
2-amino-4-(3-hydroxypropylamino)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-(3-hydroxypropylamino)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.0024
2-amino-4-(3-hydroyphenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.0038
2-amino-4-(3-hydroyphenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.0003
2-amino-4-(4-(methylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.0024
2-amino-4-(4-(methylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.01
2-amino-4-(4-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-(4-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.00065
2-amino-4-(4-hydroxymethyl)phenyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.0023
2-amino-4-(4-hydroxymethyl)phenyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.0016
2-amino-4-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimdine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.02
2-amino-4-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimdine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.0053
2-amino-4-(benzylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-(benzylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.0018
2-amino-4-(cyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-(cyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.013
2-amino-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.013
2-amino-4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.0053
2-amino-4-(piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-(piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.004
2-amino-4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.02
2-amino-4-morpholino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.03
2-amino-4-morpholino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.0017
2-amino-4-phenyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
at pH 7.5 and 30°C
0.03
2-amino-4-phenyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.000081
2-methanesulfonyl-4-methyl-7-methylamino-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.0076
2-methanesulfonyl-4-methyl-7-methylamino-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-1
0.000009
2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7yl)pyridin-2-yl)methyl)acetamide
Homo sapiens
-
IKKbeta catalyzed phosphorylation of IkappaBalpha
0.00029
2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7yl)pyridin-2-yl)methyl)acetamide
Homo sapiens
-
IkappaBalpha phosphorylation in peripheral blood mononuclear cell
0.00496
2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7yl)pyridin-2-yl)methyl)acetamide
Homo sapiens
-
IKKalpha catalyzed phosphorylation of IkappaBalpha
0.0053
3-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-benzenesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.0059
3-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-benzenesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.00057
3-amino-6-(3-hydroxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.013
3-amino-6-(3-hydroxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
whole blood assay
0.0133
3-amino-6-(3-hydroxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKalpha
0.000041
3-amino-6-(4-aminopiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.00009
3-amino-6-(4-aminopiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKalpha
0.0016
3-amino-6-(4-aminopiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
whole blood assay
0.00028
3-amino-6-(4-hydroxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0098
3-amino-6-(4-hydroxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
whole blood assay
0.0112
3-amino-6-(4-hydroxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKalpha
0.00012
3-amino-6-piperazin-1-yl-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKbeta
0.0032
3-amino-6-piperazin-1-yl-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
whole blood assay
0.0034
3-amino-6-piperazin-1-yl-4-propylthieno[2,3-b]pyridine-2-carboxamide
Homo sapiens
-
IKKalpha
0.000012
3-methoxy-N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]propanamide
Homo sapiens
-
0.00262
3-methoxy-N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]propanamide
Homo sapiens
-
0.0079
3-[7-(benzyloxy)isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-beta
0.0251
3-[7-(benzyloxy)isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-alpha, less than 0.0251
0.0013
3-[7-(piperidin-4-yloxy)isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-beta
0.0079
3-[7-(piperidin-4-yloxy)isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-alpha
0.01
4-((2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-benzenesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.03
4-((2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-benzenesulfonamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.016
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimdin-4-yl)benzamide
Homo sapiens
at pH 7.5 and 30°C
0.03
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimdin-4-yl)benzamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.00008
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-benzenesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.001
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-benzenesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.0014
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(p-tolyl)-benzenesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.016
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(p-tolyl)-benzenesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.0001
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methylbenzenesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.0014
4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methylbenzenesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.00061
4-(2-amino-7H-pyrrol[2,3-d]pyrimidin-4-yl)benzenesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.0029
4-(2-amino-7H-pyrrol[2,3-d]pyrimidin-4-yl)benzenesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.0021
4-(5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzenesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.03
4-(5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzenesulfonamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.5 and 30°C
0.001
4-(7-[[1-(ethylsulfonyl)piperidin-4-yl]oxy]isoquinolin-6-yl)benzenesulfonamide
Homo sapiens
-
IKK-beta
0.0251
4-(7-[[1-(ethylsulfonyl)piperidin-4-yl]oxy]isoquinolin-6-yl)benzenesulfonamide
Homo sapiens
-
-
0.0015
4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzenesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.0025
4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzenesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.000028
4-methyl-7-methylamino-2-(methylthio)-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.0026
4-methyl-7-methylamino-2-(methylthio)-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-1
0.0025
4-methyl-7-methylamino-2-diethylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.02
4-methyl-7-methylamino-2-diethylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-1
0.000015
4-methyl-7-methylamino-2-ethylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.0011
4-methyl-7-methylamino-2-ethylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-1
0.000015
4-methyl-7-methylamino-2-methylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.00084
4-methyl-7-methylamino-2-methylamido-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-1
0.00092
4-methyl-7-methylamino-2-methylamino-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.0034
4-methyl-7-methylamino-2-methylamino-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-1
0.000011
4-methyl-7-methylamino-2-phenyl-4H-imidazo[4,5-d]oxazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.00027
4-methyl-7-methylamino-2-phenyl-4H-imidazo[4,5-d]oxazolo[5,4-b]pyridine
Homo sapiens
-
IKK-1
0.000006
4-methyl-7-methylamino-2-phenyl-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.0035
4-methyl-7-methylamino-2-phenyl-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-1
0.00021
4-methyl-7-methylamino-2-piperidine-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.0061
4-methyl-7-methylamino-2-piperidine-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-1
0.000033
4-methyl-7-methylamino-2-[1,2,3,6-tetrahydropyridine]-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-2
0.0081
4-methyl-7-methylamino-2-[1,2,3,6-tetrahydropyridine]-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
Homo sapiens
-
IKK-1
0.0032
4-[7-(benzyloxy)isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-beta
0.0251
4-[7-(benzyloxy)isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-alpha, less than 0.0251
0.0008
4-[7-(piperidin-3-ylmethoxy)isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-beta
0.005
4-[7-(piperidin-3-ylmethoxy)isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-alpha
0.0008
4-[7-(piperidin-3-yloxy)isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-beta
0.0126
4-[7-(piperidin-3-yloxy)isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-alpha
0.0006
4-[7-(piperidin-4-ylmethoxy)isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-beta
0.0016
4-[7-(piperidin-4-ylmethoxy)isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-alpha
0.0001
4-[7-(piperidin-4-yloxy)isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-beta
0.0079
4-[7-(piperidin-4-yloxy)isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-alpha
0.0013
4-[7-[(1-acetylpiperidin-4-yl)oxy]isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-beta
0.0251
4-[7-[(1-acetylpiperidin-4-yl)oxy]isoquinolin-6-yl]benzenesulfonamide
Homo sapiens
-
IKK-alpha, less than 0.0251
0.0004
6-bromo-7-(piperidin-4-yloxy)isoquinoline
Homo sapiens
-
IKK-beta
0.01
6-bromo-7-(piperidin-4-yloxy)isoquinoline
Homo sapiens
-
IKK-alpha
0.005
6-bromo-7-[[1-(ethylsulfonyl)piperidin-4-yl]oxy]isoquinoline
Homo sapiens
-
IKK-beta
0.0251
6-bromo-7-[[1-(ethylsulfonyl)piperidin-4-yl]oxy]isoquinoline
Homo sapiens
-
IKK-alpha, less than 0.0251
0.0002
6-phenyl-7-(piperidin-3-ylmethoxy)isoquinoline
Homo sapiens
-
IKK-beta
0.0032
6-phenyl-7-(piperidin-3-ylmethoxy)isoquinoline
Homo sapiens
-
IKK-alpha
0.0006
6-phenyl-7-(piperidin-3-yloxy)isoquinoline
Homo sapiens
-
IKK-beta
0.004
6-phenyl-7-(piperidin-3-yloxy)isoquinoline
Homo sapiens
-
IKK-alpha
0.0013
6-phenyl-7-(piperidin-4-ylmethoxy)isoquinoline
Homo sapiens
-
IKK-beta
0.01
6-phenyl-7-(piperidin-4-ylmethoxy)isoquinoline
Homo sapiens
-
IKK-alpha
0.0001
6-phenyl-7-(piperidin-4-yloxy)isoquinoline
Homo sapiens
-
IKK-beta
0.0025
6-phenyl-7-(piperidin-4-yloxy)isoquinoline
Homo sapiens
-
IKK-alpha
0.004
6-phenyl-7-(pyridin-3-ylmethoxy)isoquinoline
Homo sapiens
-
IKK-beta
0.0251
6-phenyl-7-(pyridin-3-ylmethoxy)isoquinoline
Homo sapiens
-
IKK-alpha, less than 0.0251
0.005
6-phenyl-7-(pyridin-4-ylmethoxy)isoquinoline
Homo sapiens
-
IKK-beta
0.0251
6-phenyl-7-(pyridin-4-ylmethoxy)isoquinoline
Homo sapiens
-
IKK-alpha, less than 0.0251
0.000043
7-(4-fluorophenyl)-N,1-dimethyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
Homo sapiens
-
0.00173
7-(4-fluorophenyl)-N,1-dimethyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
Homo sapiens
-
0.005
7-(piperidin-4-yloxy)isoquinoline
Homo sapiens
-
IKK-beta
0.0251
7-(piperidin-4-yloxy)isoquinoline
Homo sapiens
-
IKK-alpha, less than 0.0251
0.0126
7-[(1-acetylpiperidin-4-yl)oxy]-6-bromoisoquinoline
Homo sapiens
-
IKK-beta
0.0251
7-[(1-acetylpiperidin-4-yl)oxy]-6-bromoisoquinoline
Homo sapiens
-
IKK-alpha, less than 0.0251
0.0016
7-[(1-acetylpiperidin-4-yl)oxy]-6-phenylisoquinoline
Homo sapiens
-
IKK-alpha
0.0032
7-[(1-acetylpiperidin-4-yl)oxy]-6-phenylisoquinoline
Homo sapiens
-
IKK-beta
0.0025
7-[[1-(ethylsulfonyl)piperidin-4-yl]methoxy]-6-phenylisoquinoline
Homo sapiens
-
IKK-beta
0.02
7-[[1-(ethylsulfonyl)piperidin-4-yl]methoxy]-6-phenylisoquinoline
Homo sapiens
-
IKK-alpha
0.002
7-[[1-(ethylsulfonyl)piperidin-4-yl]oxy]-6-phenylisoquinoline
Homo sapiens
-
IKK-beta
0.0126
7-[[1-(ethylsulfonyl)piperidin-4-yl]oxy]-6-phenylisoquinoline
Homo sapiens
-
IKK-alpha
0.00004
8-(5-chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
Homo sapiens
-
0.0141
8-(5-chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
Homo sapiens
-
0.00018
8-methyl-2-(4-fluorophenyl)-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-amine
Homo sapiens
-
IKK-2
0.02
8-methyl-2-(4-fluorophenyl)-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-amine
Homo sapiens
-
IKK-1, larger than 0.020
0.000033
acetamide,N-[2-[[2-(4-fluorophenyl)-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-yl]amino]ethyl]
Homo sapiens
-
IKK-2
0.005
acetamide,N-[2-[[2-(4-fluorophenyl)-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-yl]amino]ethyl]
Homo sapiens
-
IKK-1
0.000075
ethanol,N-[2-[[2-(4-fluorophenyl)-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-yl]amino]ethyl]
Homo sapiens
-
IKK-2
0.0086
ethanol,N-[2-[[2-(4-fluorophenyl)-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-yl]amino]ethyl]
Homo sapiens
-
IKK-1
0.00004
N,1-dimethyl-7-phenyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
Homo sapiens
-
0.00167
N,1-dimethyl-7-phenyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine
Homo sapiens
-
0.000034
N,1-dimethyl-7-phenyl-1H-pyrazolo[5,1-b]purin-4-amine
Homo sapiens
-
IKK-2
0.00099
N,1-dimethyl-7-phenyl-1H-pyrazolo[5,1-b]purin-4-amine
Homo sapiens
-
IKK-1
0.00052
N,3,8-trimethyl-2-phenyl-3,8-dihydrodiimidazo[4,5-b:4',5'-d]pyridin-5-amine
Homo sapiens
-
0.00428
N,3,8-trimethyl-2-phenyl-3,8-dihydrodiimidazo[4,5-b:4',5'-d]pyridin-5-amine
Homo sapiens
-
0.000011
N,8-dimethyl-2-phenyl-8H-imidazo[4,5-d][1,3]oxazolo[5,4-b]pyridin-5-amine
Homo sapiens
-
0.00027
N,8-dimethyl-2-phenyl-8H-imidazo[4,5-d][1,3]oxazolo[5,4-b]pyridin-5-amine
Homo sapiens
-
0.000006
N,8-dimethyl-2-phenyl-8H-imidazo[4,5-d][1,3]thiazolo[5,4-b]pyridin-5-amine
Homo sapiens
-
0.0035
N,8-dimethyl-2-phenyl-8H-imidazo[4,5-d][1,3]thiazolo[5,4-b]pyridin-5-amine
Homo sapiens
-
0.0013
N,N-dimethyl-3-[(4-[[(6-phenylisoquinolin-7-yl)oxy]methyl]piperidin-1-yl)sulfonyl]propan-1-amine
Homo sapiens
-
IKK-beta
0.01
N,N-dimethyl-3-[(4-[[(6-phenylisoquinolin-7-yl)oxy]methyl]piperidin-1-yl)sulfonyl]propan-1-amine
Homo sapiens
-
IKK-alpha
0.0003
N-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine
Homo sapiens
-
IKK-2
0.004
N-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine
Homo sapiens
-
IKK-1
0.0004
N-(4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)-methanesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.0017
N-(4-(2-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)-methanesulfonamide
Homo sapiens
at pH 7.5 and 30°C
0.000019
N-(8-methyl-2-phenylimidazo[1,2-a]thieno[3,2-e]pyrazin-5-yl)ethane-1,2-diamine
Homo sapiens
-
IKK-2
0.0004
N-(8-methyl-2-phenylimidazo[1,2-a]thieno[3,2-e]pyrazin-5-yl)ethane-1,2-diamine
Homo sapiens
-
IKK-1
0.000039
N-ethyl-2-(4-fluorophenyl)-N-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-amine
Homo sapiens
-
IKK-2
0.0034
N-ethyl-2-(4-fluorophenyl)-N-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-amine
Homo sapiens
-
IKK-1
0.000026
N-methyl-2-(4-fluorophenyl)-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-amine
Homo sapiens
-
IKK-2
0.0031
N-methyl-2-(4-fluorophenyl)-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-5-amine
Homo sapiens
-
IKK-1
0.000039
N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]-1,2,3-thiadiazole-4-carboxamide
Homo sapiens
-
0.00015
N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]-1,2,3-thiadiazole-4-carboxamide
Homo sapiens
-
0.000014
N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]acetamide
Homo sapiens
-
0.000633
N-[3-[1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]benzyl]acetamide
Homo sapiens
-
0.00028
N-[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorobenzyl]acetamide
Homo sapiens
-
IKK-2
0.0097
N-[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorobenzyl]acetamide
Homo sapiens
-
IKK-1
0.000053
N-[[2-fluoro-5-[8-methyl-5-methylamino-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]acetamide
Homo sapiens
-
IKK-2
0.0035
N-[[2-fluoro-5-[8-methyl-5-methylamino-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]acetamide
Homo sapiens
-
IKK-1
0.000032
N-[[2-fluoro-5-[8-methyl-5-methylamino-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]methanesulfonamide
Homo sapiens
-
IKK-2
0.0042
N-[[2-fluoro-5-[8-methyl-5-methylamino-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]methanesulfonamide
Homo sapiens
-
IKK-1
0.000016
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]-1,2,3-thiadiazole-5-amide
Homo sapiens
-
IKK-2
0.001
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]-1,2,3-thiadiazole-5-amide
Homo sapiens
-
IKK-1
0.000022
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]acetamide
Homo sapiens
-
IKK-2
0.0019
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]acetamide
Homo sapiens
-
IKK-1
0.000025
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]isoxazole-5-amide
Homo sapiens
-
IKK-2
0.0014
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]isoxazole-5-amide
Homo sapiens
-
IKK-1
0.000005
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]methanesulfonamide
Homo sapiens
-
IKK-2
0.001
N-[[3-[8-methyl-5-(methylamino)-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]methanesulfonamide
Homo sapiens
-
IKK-1
0.00037
noraristeromycin
Homo sapiens
-
IKKalpha
0.00064
noraristeromycin
Homo sapiens
-
inhibited endogenous IKK activity following TNF-alpha stimulation
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Hu, M.C.; Wang, Y.
IkappaB kinase-alpha and -beta genes are coexpressed in adult and embryonic tissues but localized to different human chromosomes
Gene
222
31-40
1998
Homo sapiens (O14920), Homo sapiens (O15111), Homo sapiens
brenda
Jobin, C.; Sartor, R.B.
The I kappa B/NF-kappa B system: a key determinant of mucosalinflammation and protection
Am. J. Physiol.
278
C451-462
2000
Homo sapiens (O14920), Homo sapiens (O15111), Mus musculus (O88351), Mus musculus (Q60680), Rattus norvegicus (Q9QY78)
brenda
Mercurio, F.; Zhu, H.; Murray, B.W.; Shevchenko, A.; Bennett, B.L.; Li, J.; Young, D.B.; Barbosa, M.; Mann, M.; Manning, A.; Rao, A.
IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation
Science
278
860-866
1997
Homo sapiens (O14920), Homo sapiens (O15111)
brenda
Nemoto, S.; DiDonato, J.A.; Lin, A.
Coordinate regulation of IkappaB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-kappaB-inducing kinase
Mol. Cell. Biol.
18
7336-7343
1998
Homo sapiens (O14920), Homo sapiens (O15111), Mus musculus (O88351), Mus musculus (Q60680), Rattus norvegicus (Q9QY78)
brenda
Shindo, M.; Nakano, H.; Sakon, S.; Yagita, H.; Mihara, M.; Okumura, K.
Assignment of IkappaB kinase beta (IKBKB) to human chromosome band 8p12->p11 by in situ hybridization
Cytogenet. Cell Genet.
82
32-33
1998
Homo sapiens (O14920), Homo sapiens
brenda
Woronicz, J.D.; Gao, X.; Cao, Z.; Rothe, M.; Goeddel, D.V.
IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK
Science
278
866-869
1997
Homo sapiens (O14920)
brenda
Wu, R.C.; Qin, J.; Hashimoto, Y.; Wong, J.; Xu, J.; Tsai, S.Y.; Tsai, M.J.; O'Malley, B.W.
Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase
Mol. Cell. Biol.
22
3549-3561
2002
Homo sapiens (O14920)
brenda
Connelly, M.A.; Marcu, K.B.
CHUK, a new member of the helix-loop-helix and leucine zipper families of interacting proteins, contains a serine-threonine kinase catalytic domain
Cell. Mol. Biol. Res.
41
537-549
1995
Homo sapiens (O15111), Mus musculus (Q60680)
brenda
Delhase, M.; Hayakawa, M.; Chen, Y.; Karin, M.
Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation
Science
284
309-313
1999
Homo sapiens (O15111), Mus musculus (Q60680)
brenda
DiDonato, J.A.; Hayakawa, M.; Rothwarf, D.M.; Zandi, E.; Karin, M.
A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB
Nature
388
548-554
1997
Homo sapiens (O15111)
brenda
Ling, L.; Cao, Z.; Goeddel, D.V.
NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176
Proc. Natl. Acad. Sci. USA
95
3792-3797
1998
Homo sapiens (O15111)
brenda
Ozes, O.N.; Mayo, L.D.; Gustin, J.A.; Pfeffer, S.R.; Pfeffer, L.M.; Donner, D.B.
NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase
Nature
401
82-85
1999
Homo sapiens (O15111)
brenda
Regnier, C.H.; Song, H.Y.; Gao, X.; Goeddel, D.V.; Cao, Z.; Rothe, M.
Identification and characterization of an IkappaB kinase
Cell
90
373-383
1997
Homo sapiens (O15111)
brenda
Nagase, T.; Seki, N.; Tanaka, A.; Ishikawa, K.; Nomura, N.
Prediction of the coding sequences of unidentified human genes. IV. The coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by analysis of cDNA clones from human cell line KG-1
DNA Res.
2; 167-174
199-210
1995
Homo sapiens (Q14164)
-
brenda
Peters, R.T.; Liao, S.M.; Maniatis, T.
IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex
Mol. Cell
5
513-522
2000
Homo sapiens (Q14164)
brenda
Shimada, T.; Kawai, T.; Takeda, K.; Matsumoto, M.; Inoue, J.; Tatsumi, Y.; Kanamaru, A.; Akira, S.
IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases
Int. Immunol.
11
1357-1362
1999
Homo sapiens (Q14164), Mus musculus (Q9R0T8), Mus musculus
brenda
Amici, C.; Belardo, G.; Rozera, C.; Bernasconi, D.; Santoro, M.G.
Inhibition of herpesvirus-induced HIV-1 replication by cyclopentenone prostaglandins: role of IkappaB kinase (IKK)
Aids
18
1271-1280
2004
Homo sapiens
brenda
Castro, A.C.; Dang, L.C.; Soucy, F.; Grenier, L.; Mazdiyasni, H.; Hottelet, M.; Parent, L.; Pien, C.; Palombella, V.; Adams, J.
Novel IKK inhibitors: beta-carbolines
Bioorg. Med. Chem. Lett.
13
2419-2422
2003
Homo sapiens
brenda
Waelchli, R.; Bollbuck, B.; Bruns, C.; Buhl, T.; Eder, J.; Feifel, R.; Hersperger, R.; Janser, P.; Revesz, L.; Zerwes, H.G.; Schlapbach, A.
Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK
Bioorg. Med. Chem. Lett.
16
108-112
2006
Homo sapiens
brenda
Burke, J.R.
Targeting IkB kinase for the treatment of inflammatory and other disorders
Curr. Opin. Drug Discov. Devel.
6
720-728
2003
Homo sapiens
brenda
Carter, R.S.; Pennington, K.N.; Ungurait, B.J.; Ballard, D.W.
In vivo identification of inducible phosphoacceptors in the IKKgamma/NEMO subunit of human IkappaB kinase
J. Biol. Chem.
278
19642-19648
2003
Homo sapiens
brenda
Sakurai, H.; Suzuki, S.; Kawasaki, N.; Nakano, H.; Okazaki, T.; Chino, A.; Doi, T.; Saiki, I.
Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway
J. Biol. Chem.
278
36916-36923
2003
Homo sapiens
brenda
Tang, E.D.; Wang, C.Y.; Xiong, Y.; Guan, K.L.
A role for NF-kappaB essential modifier/IkappaB kinase-gamma (NEMO/IKKgamma) ubiquitination in the activation of the IkappaB kinase complex by tumor necrosis factor-alpha
J. Biol. Chem.
278
37297-37305
2003
Homo sapiens
brenda
Verma, U.N.; Yamamoto, Y.; Prajapati, S.; Gaynor, R.B.
Nuclear role of IkappaB kinase-gamma/NF-kappaB essential modulator (IKK gamma/NEMO) in NF-kappaB-dependent gene expression
J. Biol. Chem.
279
3509-3515
2004
Homo sapiens
brenda
Takada, Y.; Kobayashi, Y.; Aggarwal, B.B.
Evodiamine abolishes constitutive and inducible NF-kB activation by inhibiting IkBalpha kinase Activation, Thereby Suppressing NF-kB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion
J. Biol. Chem.
280
17203-17212
2005
Homo sapiens
brenda
Carter, R.S.; Pennington, K.N.; Arrate, P.; Oltz, E.M.; Ballard, D.W.
Site-specific monoubiquitination of IkappaB kinase IKKbeta regulates its phosphorylation and persistent activation
J. Biol. Chem.
280
43272-43279
2005
Homo sapiens
brenda
Wang, L.C.; Okitsu, C.Y.; Zandi, E.
Tumor necrosis factor alpha-dependent drug resistance to purine and pyrimidine analogues in human colon tumor cells mediated through IKK
J. Biol. Chem.
280
7634-7644
2005
Homo sapiens
brenda
Luo, J.L.; Kamata, H.; Karin, M.
IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy
J. Clin. Invest.
115
2625-2632
2005
Homo sapiens, Mus musculus
brenda
Piccolella, E.; Spadaro, F.; Ramoni, C.; Marinari, B.; Costanzo, A.; Levrero, M.; Thomson, L.; Abraham, R.T.; Tuosto, L.
Vav-1 and the IKKalpha subunit of IkappaB kinase functionally associate to induce NF-kappaB activation in response to CD28 engagement
J. Immunol.
170
2895-2903
2003
Homo sapiens
brenda
Tegeder, I.; Niederberger, E.; Schmidt, R.; Kunz, S.; Guehring, H.; Ritzeler, O.; Michaelis, M.; Geisslinger, G.
Specific inhibition of IkB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats
J. Neurosci.
24
1637-1645
2004
Homo sapiens
brenda
Caposio, P.; Dreano, M.; Garotta, G.; Gribaudo, G.; Landolfo, S.
Human cytomegalovirus stimulates cellular IKK2 activity and requires the enzyme for productive replication
J. Virol.
78
3190-3195
2004
Homo sapiens
brenda
Tegethoff, S.; Behlke, J.; Scheidereit, C.
Tetrameric oligomerization of IkappaB kinase gamma (IKKgamma) is obligatory for IKK complex activity and NF-kappaB activation
Mol. Cell. Biol.
23
2029-2041
2003
Homo sapiens
brenda
Fitzgerald, K.A.; McWhirter, S.M.; Faia, K.L.; Rowe, D.C.; Latz, E.; Golenbock, D.T.; Coyle, A.J.; Liao, S.M.; Maniatis, T.
IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway
Nat. Immunol.
4
491-496
2003
Homo sapiens
brenda
Yamamoto, Y.; Verma, U.N.; Prajapati, S.; Kwak, Y.T.; Gaynor, R.B.
Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression
Nature
423
655-659
2003
Homo sapiens, Mus musculus
brenda
Yamamoto, Y.; Gaynor, R.B.
IkB kinases: key regulators of the NF-kB pathway
Trends Biochem. Sci.
29
72-79
2004
Homo sapiens, Mus musculus
brenda
Byun, M.S.; Choi, J.; Jue, D.M.
Cysteine-179 of IkappaB kinase beta plays a critical role in enzyme activation by promoting phosphorylation of activation loop serines
Exp. Mol. Med.
38
546-552
2006
Homo sapiens
brenda
Ha, U.; Lim, J.H.; Jono, H.; Koga, T.; Srivastava, A.; Malley, R.; Pages, G.; Pouyssegur, J.; Li, J.D.
A novel role for IkappaB kinase (IKK) alpha and IKKbeta in ERK-dependent up-regulation of MUC5AC mucin transcription by Streptococcus pneumoniae
J. Immunol.
178
1736-1747
2007
Homo sapiens, Mus musculus, Mus musculus BALB/c
brenda
Ahn, K.S.; Sethi, G.; Aggarwal, B.B.
Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1
J. Immunol.
178
2507-2516
2007
Homo sapiens
brenda
Hansberger, M.W.; Campbell, J.A.; Danthi, P.; Arrate, P.; Pennington, K.N.; Marcu, K.B.; Ballard, D.W.; Dermody, T.S.
IkappaB kinase subunits alpha and gamma are required for activation of NF-kappaB and induction of apoptosis by mammalian reovirus
J. Virol.
81
1360-1371
2007
Homo sapiens
brenda
Wegener, E.; Oeckinghaus, A.; Papadopoulou, N.; Lavitas, L.; Schmidt-Supprian, M.; Ferch, U.; Mak, T.W.; Ruland, J.; Heissmeyer, V.; Krappmann, D.
Essential role for IkappaB kinase beta in remodeling Carma1-Bcl10-Malt1 complexes upon T cell activation
Mol. Cell
23
13-23
2006
Homo sapiens, Mus musculus
brenda
Edwards, M.R.; Hewson, C.A.; Laza-Stanca, V.; Lau, H.T.; Mukaida, N.; Hershenson, M.B.; Johnston, S.L.
Protein kinase R, IkappaB kinase-beta and NF-kappaB are required for human rhinovirus induced pro-inflammatory cytokine production in bronchial epithelial cells
Mol. Immunol.
44
1587-1597
2007
Homo sapiens
brenda
Cummins, E.P.; Berra, E.; Comerford, K.M.; Ginouves, A.; Fitzgerald, K.T.; Seeballuck, F.; Godson, C.; Nielsen, J.E.; Moynagh, P.; Pouyssegur, J.; Taylor, C.T.
Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity
Proc. Natl. Acad. Sci. USA
103
18154-18159
2006
Homo sapiens
brenda
Lobry, C.; Lopez, T.; Israel, A.; Weil, R.
Negative feedback loop in T cell activation through IkappaB kinase-induced phosphorylation and degradation of Bcl10
Proc. Natl. Acad. Sci. USA
104
908-913
2007
Homo sapiens
brenda
Olivotto, E.; Borzi, R.M.; Vitellozzi, R.; Pagani, S.; Facchini, A.; Battistelli, M.; Penzo, M.; Li, X.; Flamigni, F.; Li, J.; Falcieri, E.; Facchini, A.; Marcu, K.B.
Differential requirements for IKKalpha and IKKbeta in the differentiation of primary human osteoarthritic chondrocytes
Arthritis Rheum.
58
227-239
2008
Homo sapiens (O14920), Homo sapiens (O15111), Homo sapiens
brenda
Shaul, J.D.; Farina, A.; Huxford, T.
The human IKKbeta subunit kinase domain displays CK2-like phosphorylation specificity
Biochem. Biophys. Res. Commun.
374
592-597
2008
Homo sapiens (O14920), Homo sapiens
brenda
Lo, Y.C.; Maddineni, U.; Chung, J.Y.; Rich, R.L.; Myszka, D.G.; Wu, H.
High-affinity interaction between IKKbeta and NEMO
Biochemistry
47
3109-3116
2008
Homo sapiens (O14920)
brenda
Pandey, M.K.; Sung, B.; Kunnumakkara, A.B.; Sethi, G.; Chaturvedi, M.M.; Aggarwal, B.B.
Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis
Cancer Res.
68
5370-5379
2008
Homo sapiens (O14920)
brenda
Wilson, W.; Baldwin, A.S.
Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer
Cancer Res.
68
8156-8163
2008
Homo sapiens (O14920), Homo sapiens (O15111)
brenda
Moreno-Maldonado, R.; Ramirez, A.; Navarro, M.; Fernandez-Acenero, M.J.; Villanueva, C.; Page, A.; Jorcano, J.L.; Bravo, A.; Llanos Casanova, M.
IKKalpha enhances human keratinocyte differentiation and determines the histological variant of epidermal squamous cell carcinomas
Cell Cycle
7
2021-2029
2008
Homo sapiens (O15111), Homo sapiens, Mus musculus (Q60680), Mus musculus
brenda
Dan, H.C.; Cooper, M.J.; Cogswell, P.C.; Duncan, J.A.; Ting, J.P.; Baldwin, A.S.
Akt-dependent regulation of NF-[kappa]B is controlled by mTOR and Raptor in association with IKK
Genes Dev.
22
1490-1500
2008
Homo sapiens (O14920), Homo sapiens (O15111)
brenda
Solt, L.A.; May, M.J.
The IkappaB kinase complex: master regulator of NF-kappaB signaling
Immunol. Res.
23
362-370
2008
Homo sapiens (O14920)
brenda
Mukherjee, S.; Negi, V.S.; Keitany, G.; Tanaka, Y.; Orth, K.
In vitro activation of the IkappaB kinase complex by human T-cell leukemia virus type-1 Tax
J. Biol. Chem.
283
15127-15133
2008
Homo sapiens
brenda
Cahill, C.M.; Rogers, J.T.
Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1
J. Biol. Chem.
283
25900-25912
2008
Homo sapiens (O15111)
brenda
Dan, H.C.; Baldwin, A.S.
Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt
J. Immunol.
180
7582-7589
2008
Mus musculus, Homo sapiens (O15111)
brenda
Lorenzo, P.; Alvarez, R.; Ortiz, M.A.; Alvarez, S.; Piedrafita, F.J.; de Lera, A.R.
Inhibition of IkappaB kinase-beta and anticancer activities of novel chalcone adamantyl arotinoids
J. Med. Chem.
51
5431-5440
2008
Homo sapiens (O14920)
brenda
Yan, S.S.; Li, Y.; Wang, Y.; Shen, S.S.; Gu, Y.; Wang, H.B.; Qin, G.W.; Yu, Q.
17-Acetoxyjolkinolide B irreversibly inhibits IkappaB kinase and induces apoptosis of tumor cells
Mol. Cancer Ther.
7
1523-1532
2008
Homo sapiens (O14920)
brenda
Ryu, M.J.; Anikin, V.; Hong, S.H.; Jeon, H.; Yu, Y.G.; Yu, M.H.; Chernysh, S.; Lee, C.
Activation of NF-kappaB by alloferon through down-regulation of antioxidant proteins and IkappaBalpha
Mol. Cell. Biochem.
313
91-102
2008
Homo sapiens (O15111), Homo sapiens
brenda
Chen, R.; Alvero, A.B.; Silasi, D.A.; Kelly, M.G.; Fest, S.; Visintin, I.; Leiser, A.; Schwartz, P.E.; Rutherford, T.; Mor, G.
Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells
Oncogene
27
4712-4723
2008
Homo sapiens (O14920), Homo sapiens (O15111), Homo sapiens
brenda
Chen, R.A.; Ryzhakov, G.; Cooray, S.; Randow, F.; Smith, G.L.
Inhibition of IkappaB kinase by vaccinia virus virulence factor B14
PLoS Pathog.
4
e22
2008
Homo sapiens
brenda
Ha, K.H.; Byun, M.S.; Choi, J.; Jeong, J.; Lee, K.J.; Jue, D.M.
N-tosyl-L-phenylalanine chloromethyl ketone inhibits NF-kappaB activation by blocking specific cysteine residues of IkappaB kinase beta and p65/RelA
Biochemistry
48
7271-7278
2009
Homo sapiens
brenda
Kempson, J.; Guo, J.; Das, J.; Moquin, R.V.; Spergel, S.H.; Watterson, S.H.; Langevine, C.M.; Dyckman, A.J.; Pattoli, M.; Burke, J.R.; Yang, X.; Gillooly, K.M.; McIntyre, K.W.; Chen, L.; Dodd, J.H.; McKinnon, M.; Barrish, J.C.; Pitts, W.J.
Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IkappaB kinase
Bioorg. Med. Chem. Lett.
19
2646-2649
2009
Homo sapiens (O14920), Homo sapiens (Q15111)
brenda
Wu, J.P.; Fleck, R.; Brickwood, J.; Capolino, A.; Catron, K.; Chen, Z.; Cywin, C.; Emeigh, J.; Foerst, M.; Ginn, J.; Hrapchak, M.; Hickey, E.; Hao, M.H.; Kashem, M.; Li, J.; Liu, W.; Morwick, T.; Nelson, R.; Marshall, D.; Martin, L.; Nemoto, P.; Potocki, I.; Liuzzi, M.; Peet, G.W.; Scouten, E.; Stefany, D.; Turner, M.; Weldon, S.; Zimmitti, C.; Spero, D.; Kelly, T.A.
The discovery of thienopyridine analogues as potent IkappaB kinase beta inhibitors. Part II
Bioorg. Med. Chem. Lett.
19
5547-5551
2009
Homo sapiens
brenda
Sors, A.; Jean-Louis, F.; Begue, E.; Parmentier, L.; Dubertret, L.; Dreano, M.; Courtois, G.; Bachelez, H.; Michel, L.
Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents
Clin. Cancer Res.
14
901-911
2008
Homo sapiens
brenda
Tang, H.; Park, S.; Sun, S.C.; Trumbly, R.; Ren, G.; Tsung, E.; Yeung, K.C.
RKIP inhibits NF-kappaB in cancer cells by regulating upstream signaling components of the IkappaB kinase complex
FEBS Lett.
584
662-668
2010
Homo sapiens
brenda
Asamitsu, K.; Yamaguchi, T.; Nakata, K.; Hibi, Y.; Victoriano, A.F.; Imai, K.; Onozaki, K.; Kitade, Y.; Okamoto, T.
Inhibition of human immunodeficiency virus type 1 replication by blocking IkappaB kinase with noraristeromycin
J. Biochem.
144
581-589
2008
Homo sapiens
brenda
Clark, K.; Plater, L.; Peggie, M.; Cohen, P.
Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation
J. Biol. Chem.
284
14136-14146
2009
Homo sapiens (Q14164)
brenda
Gan, Q.; Li, T.; Hu, B.; Lian, M.; Zheng, X.
HSCARG inhibits activation of NF-kappaB by interacting with IkappaB kinase-beta
J. Cell Sci.
122
4081-4088
2009
Homo sapiens
brenda
Kempson, J.; Spergel, S.H.; Guo, J.; Quesnelle, C.; Gill, P.; Belanger, D.; Dyckman, A.J.; Li, T.; Watterson, S.H.; Langevine, C.M.; Das, J.; Moquin, R.V.; Furch, J.A.; Marinier, A.; Dodier, M.; Martel, A.; Nirschl, D.; Van Kirk, K.; Burke, J.R.; Pattoli, M.A.; Gillooly, K.; McIntyre, K.W.; Chen, L.; Yang, Z.
Novel tricyclic inhibitors of IkappaB kinase
J. Med. Chem.
52
1994-2005
2009
Homo sapiens
brenda
Christopher, J.A.; Bamborough, P.; Alder, C.; Campbell, A.; Cutler, G.J.; Down, K.; Hamadi, A.M.; Jolly, A.M.; Kerns, J.K.; Lucas, F.S.; Mellor, G.W.; Miller, D.D.; Morse, M.A.; Pancholi, K.D.; Rumsey, W.; Solanke, Y.E.; Williamson, R.
Discovery of 6-aryl-7-alkoxyisoquinoline inhibitors of IkappaB kinase-beta (IKK-beta)
J. Med. Chem.
52
3098-3102
2009
Homo sapiens
brenda
Ochiai, T.; Saito, Y.; Saitoh, T.; Dewan, M.Z.; Shioya, A.; Kobayashi, M.; Kawachi, H.; Muto, S.; Itai, A.; Uota, S.; Eishi, Y.; Yamamoto, N.; Tanaka, S.; Arii, S.; Yamaoka, S.
Inhibition of IkappaB kinase beta restrains oncogenic proliferation of pancreatic cancer cells
J. Med. Dent. Sci.
55
49-59
2008
Homo sapiens, Mus musculus
brenda
Mbalaviele, G.; Sommers, C.D.; Bonar, S.L.; Mathialagan, S.; Schindler, J.F.; Guzova, J.A.; Shaffer, A.F.; Melton, M.A.; Christine, L.J.; Tripp, C.S.; Chiang, P.C.; Thompson, D.C.; Hu, Y.; Kishore, N.
A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models
J. Pharmacol. Exp. Ther.
329
14-25
2009
Rattus norvegicus, Homo sapiens (O14920), Homo sapiens (Q15111)
brenda
Gillooly, K.M.; Pattoli, M.A.; Taylor, T.L.; Chen, L.; Cheng, L.; Gregor, K.R.; Whitney, G.S.; Susulic, V.; Watterson, S.H.; Kempson, J.; Pitts, W.J.; Booth-Lute, H.; Yang, G.; Davies, P.; Kukral, D.W.; Strnad, J.; McIntyre, K.W.; Darienzo, C.J.; Salter-Cid, L.; Yang, Z.; Wang-Iverson, D.B.; Burke, J.R.
Periodic, partial inhibition of IkappaB kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis
J. Pharmacol. Exp. Ther.
331
349-360
2009
Canis lupus familiaris, Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Mancino, A.; Habbeddine, M.; Johnson, E.; Luron, L.; Bebien, M.; Memet, S.; Fong, C.; Bajenoff, M.; Wu, X.; Karin, M.; Caamano, J.; Chi, H.; Seed, M.; Lawrence, T.
I kappa B kinase alpha (IKKalpha) activity is required for functional maturation of dendritic cells and acquired immunity to infection
EMBO J.
32
816-828
2013
Homo sapiens, Mus musculus
brenda
Gupta, S.C.; Prasad, S.; Reuter, S.; Kannappan, R.; Yadav, V.R.; Ravindran, J.; Hema, P.S.; Chaturvedi, M.M.; Nair, M.; Aggarwal, B.B.
Modification of cysteine 179 of IkappaBalpha kinase by nimbolide leads to down-regulation of NF-kappaB-regulated cell survival and proliferative proteins and sensitization of tumor cells to chemotherapeutic agents
J. Biol. Chem.
285
35406-35417
2010
Homo sapiens
brenda
Huang, W.; Hung, M.
Beyond NF-kappaB activation: Nuclear functions of IkappaB kinase alpha
J. Biomed. Sci.
20
3
2013
Homo sapiens, Mus musculus
brenda
Accardi, R.; Scalise, M.; Gheit, T.; Hussain, I.; Yue, J.; Carreira, C.; Collino, A.; Indiveri, C.; Gissmann, L.; Sylla, B.S.; Tommasino, M.
IkappaB kinase beta promotes cell survival by antagonizing p53 functions through DELTANp73alpha phosphorylation and stabilization
Mol. Cell. Biol.
31
2210-2226
2011
Homo sapiens
brenda
Mathialagan, S.; Poda, G.I.; Kurumbail, R.G.; Selness, S.R.; Hall, T.; Reitz, B.A.; Weinberg, R.A.; Kishore, N.; Mbalaviele, G.
Expression, purification and functional characterization of IkappaB kinase-2 (IKK-2) mutants
Protein Expr. Purif.
72
254-261
2010
Homo sapiens (O14920)
brenda
Masatani, T.; Ozawa, M.; Yamada, K.; Ito, N.; Horie, M.; Matsuu, A.; Okuya, K.; Tsukiyama-Kohara, K.; Sugiyama, M.; Nishizono, A.
Contribution of the interaction between the rabies virus P protein and I-kappa B kinase epsilon to the inhibition of type I IFN induction signalling
J. Gen. Virol.
97
316-326
2016
Homo sapiens
brenda
Deng, L.; Li, Y.; Ai, P.; Xie, Y.; Zhu, H.; Chen, N.
Increase in IkappaB kinase alpha expression suppresses the tumor progression and improves the prognosis for nasopharyngeal carcinoma
Mol. Carcinog.
54
156-165
2015
Homo sapiens
brenda
Xie, Y.; Li, Y.; Peng, X.; Peng, X.; Henderson, F.; Deng, L.; Chen, N.
Ikappa B kinase alpha involvement in the development of nasopharyngeal carcinoma through a NF-kappaB-independent and ERK-dependent pathway
Oral Oncol.
49
1113-1120
2013
Homo sapiens
brenda
Gao, S.; Wu, J.; Liang, L.; Xu, R.
RNF8 negatively regulates NF-kappaB signaling by targeting IkappaB kinase implications for the regulation of inflammation signaling
Biochem. Biophys. Res. Commun.
488
189-195
2017
Homo sapiens
brenda
Siddiqui, M.A.; Badruddeen, M.A.; Akhtar, J.; Uddin M S, S.; Irfan Khan, M.; Khalid, M.
Molecular mechanism of interactions between chrysin and I-kappa-B kinase epsilon (IKKe)/tank binding kinase-1(TBK1) Cell-based assay and in silico molecular docking studies
J. Biomol. Struct. Dyn.
38
589-596
2020
Homo sapiens (Q14164)
brenda
Anthony, N.G.; Baiget, J.; Berretta, G.; Boyd, M.; Breen, D.; Edwards, J.; Gamble, C.; Gray, A.I.; Harvey, A.L.; Hatziieremia, S.; Ho, K.H.; Huggan, J.K.; Lang, S.; Llona-Minguez, S.; Luo, J.L.; McIntosh, K.; Paul, A.; Plevin, R.J.; Robertson, M.N.; Scott, R.; Suckling, C.J.; Sutcliffe, O.B.; Young, L.C.; Mackey, S.P.
Inhibitory kappa B kinase alpha (IKKalpha) inhibitors that recapitulate their selectivity in cells against isoform-related biomarkers
J. Med. Chem.
60
7043-7066
2017
Homo sapiens (O14920), Homo sapiens (O15111)
brenda
Al-Shaer, M.A.; Almazari, I.S.; Taha, M.O.
Discovery of novel potent nuclear factor kappa-B inhibitors (IKK-beta) via extensive ligand-based modeling and virtual screening
J. Mol. Recognit.
30
e2604
2017
Homo sapiens (O14920)
brenda
Zheng, J.; Park, M.H.; Lee, H.P.; Hyun, B.K.; Chun, H.O.; Jung, S.H.; Seo, H.O.; Ham, Y.W.; Han, S.B.; Hong, J.T.
A small molecule, (E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) phenol suppresses tumor growth via inhibition of IkappaB kinase beta in colorectal cancer in vivo and in vitro
Oncotarget
8
91258-91269
2017
Homo sapiens (O14920)
brenda
2.7.11.10 IkappaB kinase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
